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Abstract
A large proportion of blood-borne viruses (BBV) are transmitted via inject-
ing drug use. Understanding patterns of risk and monitoring trends over time
in people who inject drugs (PWID) is therefore a crucial part of developing
public health policy.
Risks of infection with hepatitis C and B (HCV, HBV) and HIV in PWID
are investigated using serial cross-sectional surveillance data, in particular
via force of infection (FOI) models. Standard models are extended to in-
clude a wealth of covariate data. Individual variability is considered via bi-
variate shared frailty models and correlations between infections. Gamma,
inverse Gaussian and time-varying frailty models are fitted to investigate
how variability in risk evolves throughout injecting career. Finally, models
are extended to the trivariate case and different forms of component frailty
models are proposed.
Recent initiates were found to be at high risk of infection, in particu-
lar in London and the North West. Subsequently the FOI is broadly con-
stant, and similar across different regions. Frailty models indicate that there
is substantial individual variability in risk, although this declines over the
course of injecting career. Females have higher overall risks of HCV and
HBV, but are less heterogeneous than males. Including covariate data on
demographics and a number of risk factors only resulted in modest reduc-
tions in frailty variance. Correlations between HCV-HBV and HBV-HIV
associations were stronger than for HCV-HIV; trivariate models including
additional pairwise components for HCV-HBV and HBV-HIV provided an
improvement in model fit compared to a shared frailty model.
Many of the results in this thesis point towards greater variation in risk
at initiation, potentially due to the varied circumstances in which individuals
start injecting, followed by more comparable risks in those with established
injecting behaviour. The relative importance of injecting and sexual risk
may explain patterns of risk and correlation in the three infections.
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Chapter 1
Introduction
1.1 Blood-borne viruses and the burden of
disease
The World Health Organization (WHO) estimates that in 2015 around 71
million people were living with chronic hepatitis C virus (HCV) infection
worldwide, and 257 million people with chronic hepatitis B virus (HBV)
infection (World Health Organization, 2017). Hepatitis infection is a ma-
jor cause of chronic liver disease, with an estimated 720,000 deaths due
to hepatitis-related cirrhosis and 470,000 deaths from liver cancer (hepa-
tocellular carcinoma) in 2015 (World Health Organization, 2017). Human
immunodeficiency virus (HIV) remains a persistent problem, with 36.7 mil-
lion people worldwide estimated to be living with HIV in 2015 (UNAIDS,
2016). Nearly half (17 million) are on antiretroviral therapy, which reduces
the risk of developing acquired immunodeficiency syndrome (AIDS) and in-
fectiousness to others. Nevertheless, there were an estimated 2.1 million new
infections and 1.1 million AIDS-related deaths globally in 2015 (UNAIDS,
2016).
Blood-borne viruses (BBV) are a major world challenge, and ambitious
targets have been set by the WHO for reductions in incidence and preva-
lence of HCV, HBV and HIV and associated morbidity by 2030 (United
Nations, 2015; World Health Organization, 2016). Much of the epidemic is
focussed in Asian and African countries (The Polaris Observatory Collab-
orators, 2017, 2018), but remain persistent problems in Europe, the USA,
17
Australia and other higher-income countries, where they predominantly (but
not exclusively) affect specific high-risk groups.
People who inject drugs (PWID) are a major risk group in higher-income
countries. Injecting drug use is associated with various health and social
problems such as crime (Stewart et al., 2000; Reuter and Stevens, 2008),
drug-related overdoses and mortality (Bargagli et al., 2006; Hickman et al.,
2009), bacterial infection and infection from blood-borne viruses, in partic-
ular HCV (The Health Protection Agency, 2012b).
In England, 203,000 individuals were estimated to have antibodies to
HCV in 2005 (Harris et al., 2012b), with over 85% in those that currently
or had previously injected drugs (44% in current and 43% in ex-injectors).
Around 76% of those infected progress to chronic infection (Micallef et al.,
2006), many of whom will go on to develop serious complications of the liver.
A back-calculation approach by Sweeting et al. (2007) indicated that over
10,000 individuals would be living with cirrhosis by 2015, and the burden
of HCV-related liver disease is likely to increase further unless substantial
numbers can be successfully treated (Harris et al., 2014).
HBV prevalence in PWID is also moderately high in England, with
around 16% having past or current infection (The Health Protection Agency,
2012b). National exercises to estimate HBV prevalence have not been car-
ried out in England, but WHO-commissioned research estimated 441,000
individuals living with current HBV infection in 2015 (The Polaris Obser-
vatory Collaborators, 2018), indicating that injecting drug use is a smaller
component than it is for HCV. A substantial portion of positive tests for
acute HBV occur in Asian, black and other/mixed ethnic groups (compared
to white/white British), and of those with a known risk factor, injecting drug
use is 7.3% (although this may be under-reported) (Public Health England,
2017).
HIV prevalence in PWID is relatively low in England, at around 1.2%
(The Health Protection Agency, 2012b,a). There were estimated to be
101,200 people living with HIV in the UK in 2015 (Public Health England,
2016). Nearly half (47,000) were estimated to be among gay, bisexual and
other men who have sex with men, and only 2,500 PWID. However, HIV-
infected PWID have higher mortality and lower proportions of timely linkage
to care than other groups, and rapidly spreading outbreaks of HIV still occur
18
in this population (Public Health England, 2016). HIV is therefore not an
insignificant concern in PWID.
In England, evidence suggests that the risk of HCV in PWID was reduced
throughout the early 1990s by successful harm reduction programmes (Hope
et al., 2001), but there is the suggestion that incidence began to increase
again from 2000 onwards (Sweeting et al., 2009b), with a similar pattern
for HIV (Hope et al., 2005, 2014). Many of those starting to inject drugs
in recent years will be too young to recall the beginning of the epidemic of
HIV and blood-borne viruses in the late 1980s and may therefore be less
aware of, or concerned with, the consequences of infection. Such a view
may be partly due to the dramatic improvement in HIV treatments since
the advent of combined antiretroviral therapy (WHO, 2012c), and there is
the worrying view that HCV infection may be seen as “inevitable” by many
PWID (Rhodes et al., 2004).
New treatments offer the potential to markedly reduce HCV prevalence,
both by reducing the number of people currently living with chronic in-
fection and reducing transmission, known as treatment as prevention. The
potential impact of treatment as prevention has been investigated in math-
ematical models and predicted to dramatically reduce prevalence over 10 to
15-year time-spans, even at modest treatment levels (Martin et al., 2013).
In contrast to high endemic levels of HCV in PWID, HBV appears to be
well-controlled through vaccination (Public Health England et al., 2014),
and HIV transmission is hindered by effective treatment and at a low en-
demic level. Nevertheless, these infections persist in the PWID population,
and show no signs of declining over time. Understanding the risks of blood-
borne infection in PWID and the crucial role that new treatments will play
in the eventual elimination of HCV will require a thorough understanding of
available surveillance data.
1.2 Epidemiology and biology
1.2.1 Hepatitis C virus (HCV)
HCV is most commonly transmitted through exposure to infectious blood,
which can occur through receipt of contaminated blood transfusions, blood
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products and organ transplants; injections given with contaminated syringes
and needle-stick injuries in health-care settings; injection drug use; and being
born to a hepatitis C-infected mother (WHO, 2012b). It is thought that
transmission via sexual contact is rare (Balogun et al., 2003), although there
is increasing concern that certain high-risk sexual practices are leading to
transmission in men who have sex with men, in particular those infected
with HIV (van de Laar et al., 2007). In the UK, most HCV infection occurs
via injecting drug use (De Angelis et al., 2009). Since the introduction of
screening for blood donations in 1991, very few infections occur due to blood
transfusions (McClelland, 2013) and a substantial proportion of infection in
those that have never injected drugs is likely to have been imported from
high-prevalence countries (Harris et al., 2012b).
Six known HCV genotypes exist (with various subtypes), although the
majority of positive tests in England are genotype 1 (47%) or 3 (44%) (Public
Health England, 2015). Outcomes are generally similar for the two types,
although genotype 1 infections respond somewhat differently to treatment
(European Association for the Study of the Liver, 2015), and for practical
purposes the infected population is often dichotomised into genotype 1 and
“non-1” types.
Following infection with HCV (and other blood-borne viruses), the virus
will begin to reproduce and shortly afterwards the body will produce anti-
bodies in response. The strength of the response is initially weak, but in-
creases over time in most individuals and plateaus at around 6 months (see
section 1.2.4). Around 76% of those infected will develop chronic infection
within around 6 months (Micallef et al., 2006) and will remain permanently
infected, and infectious, unless the virus is successfully cleared by treatment.
Chronic infection results in progressive damage to the liver, which in
some individuals will lead to scarring of the liver (cirrhosis). Cirrhosis has
two stages, defined as compensated, in which there is scarring but while main-
taining function; and decompensated cirrhosis, also known as end-stage liver
disease (ESLD), when liver function is compromised. Individuals with cir-
rhosis are also at risk of developing hepatocellular carcinoma (HCC) (Mauss
et al., 2018). Upon developing either of these diseases, mortality is ex-
tremely high, with annual rates of up to 20% and 60% for ESLD and HCC
respectively (Hutchinson et al., 2005). At this stage, the only option is liver
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transplantation, which is expensive, restricted by a limited supply of donors,
and not without risks (Thuluvath et al., 2007).
Interferon-based treatments became available around 20 years ago, but
have had limited success: durations are of 24-48 weeks, individuals experi-
ence unpleasant side-effects and success rates are low (Thomson et al., 2008).
In particular, as individuals age and develop progressive fibrosis of the liver
(the formation of excess fibrous tissue that precedes cirrhosis and severe dis-
ease) the probability of successfully clearing the virus decreases to as low
as 37% in those with genotype non-1 infection, and lower still in those with
genotype 1 (Thomson et al., 2008). This means that previous treatment
has had virtually no impact on HCV-related morbidity, with low uptake and
little possibility of disease prevention in those that need it most urgently
(Harris et al., 2014). New treatments became available from around 2014
with markedly improved efficacy and success rates in excess of 90% in all
groups, including those with cirrhosis (Afdhal et al., 2014; National Insti-
tute for Health and Care Excellence, 2015). It remains to be seen whether
clearance of the virus will result in long-term improvements in liver function
and life expectancy once substantial damage has already occurred, although
studies suggest that risk of further disease progression is greatly reduced
(Singal et al., 2010).
1.2.2 Hepatitis B virus (HBV)
HBV infection can be acquired through similar routes as HCV, but can also
be transmitted sexually and there are risks of vertical transmission from
mother to child. HBV infection carries a lower risk of severe disease, as a high
proportion will clear infection naturally (WHO, 2012a). Chronic infection
causes progressive disease of the liver and cirrhosis in much the same way as
HCV, eventually leading to ESLD and HCC in some individuals (El-Serag,
2012).
HBV has been a major problem in some parts of the world, with much of
the disease burden in children, who have a higher risk of developing chronic
infection and disease progression. Fortunately, substantial progress has been
made in preventing HBV infection through vaccination programmes (Shep-
ard et al., 2006). In the UK vaccination is only offered to specific risk groups,
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which include PWID. A high proportion of PWID in the UK are now vacci-
nated against infection (Hope et al., 2007).
1.2.3 Human immunodeficiency virus (HIV)
The first reported cases of HIV occurred in the 1980s and quickly spread,
rising to an estimated peak of 3.7 million new infections in 1997 (Fettig et al.,
2016). HIV can be transmitted sexually and through blood-to-blood con-
tact, although HIV is less infectious than HCV via blood (de Vos et al., 2012;
Baggaley et al., 2006). Infection causes a fall in CD4 cell count and corre-
sponding immunodeficiency, resulting in the potential to develop a number
of conditions that would be rare in the uninfected population. Such condi-
tions are classified as acquired immunodeficiency syndrome (AIDS), and are
generally associated with high mortality rates (The Antiretroviral Therapy
Cohort Collaboration, 2009).
In the UK, the HIV epidemic is focussed in particular risk groups, in-
cluding men who have sex with men, PWID, and those born in sub-Saharan
Africa (Public Health England, 2016). A large proportion of infected indi-
viduals are now on antiretroviral drugs, especially in industrialised countries
(WHO, 2012c), which greatly reduces infectiousness and the risk of AIDS.
Those on treatment are now estimated to have life expectancy comparable to
the general population (The Antiretroviral Therapy Cohort Collaboration,
2017).
1.2.4 Serological testing
Sero-epidemiology refers to the practice of testing for antibodies to deter-
mine current or past infection with a virus. Such tests are not always perfect:
the test may have imperfect sensitivity, whereby those with antibodies test
negative. The opposite of this is imperfect specificity, where those without
antibodies test positive (Altman and Bland, 1994). In general, test status is
determined by judging whether some continuous quantity is above a certain
threshold, which will be developed to balance sensitivity and specificity in
some way; the value selected for the threshold will depend on the expected
prevalence in the population of interest, and the potential consequences asso-
ciated with the two types of error, called false positives and false negatives.
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An alternative approach, rather than dichotomising infection status, is to
analyse the antibody levels directly in order to answer epidemiological ques-
tions (Bollaerts et al., 2012).
In addition to tests for antibodies, active infection may also be deter-
mined by directly testing for the presence and quantity of the virus in the
blood, usually via Polymerase Chain Reaction (PCR) testing for RNA, the
genetic material of the virus. Both antibody and RNA tests are available
for HCV, although the latter is only recently becoming more commonplace
in surveillance (Public Health England, 2018a).
Testing for HBV is more complicated, with three types of test. Hep-
atitis B surface antigen tests are used to detect the presence of the virus
in the blood; hepatitis B surface antibody tests indicate whether the per-
son is protected against HBV, either through past infection or vaccination;
and hepatitis B core antibody tests indicate current or past infection, but
cannot determine whether this confers protection against HBV. HIV testing
also consists of antibody and antigen tests, often using an enzyme-linked
immunosorbent assay (ELISA) to detect both HIV antibodies and antigens
in the blood. Viral load tests are an integral part of monitoring infected
patients in clinical practice once infection is confirmed.
For some infections, it is possible to assess whether an infection occurred
recently via the stage of the body’s response to the virus. For instance, in
the first few weeks, individuals may test positive for the presence of the virus
(RNA) but still be antibody negative, as the body has not yet mounted a
response. Further, the strength of antibody binding, known as avidity may
be used as a marker: this is weak shortly after infection occurs and increases
over time. However, the process is imperfect: for HCV there is considerable
uncertainty regarding the length of the so-called “window” period between
initial infection and the development of strongly binding antibodies (Klima-
shevskaya et al., 2007; Gaudy-Graffin et al., 2010). Sample sizes are also an
issue, as very large numbers are required to observe a sufficient number of
individuals with markers of recent infection. The period in which an individ-
ual is HCV RNA positive and antibody negative is thought to last for less
than 2 months; even with a rate of infection as high as 12 per 100 person
years this would imply only around 20 such individuals would be expected
to be observed in a sample of 1000 antibody negative individuals, and the
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confidence intervals for resulting calculations tend to be wide (Public Health
England, 2018a).
A number of approaches are used to determine recent HIV infection in
diagnosis data, including “de-tuned” tests that cannot detect antibodies in
samples that have previously been confirmed as antibody positive, propor-
tions of HIV-specific immunoglobulin directed against HIV antigens, and
avidity assays (Murphy and Parry, 2008; Rosenberg et al., 2016). An algo-
rithm to determine recent infection is routinely used in diagnostic testing
by Public Health England (Public Health England, 2016); as test-seeking
often follows an episode of exposure risk, this is more pertinent to testing
behaviour than answering epidemiological questions about incidence of in-
fection.
1.2.5 Opiate and injecting drug use
The use of opiates administered via injection into the blood, and in partic-
ular heroin, has been around since the beginning of the last century when it
was first marketed for medicinal use. It was still relatively uncommon in the
1960s but increased markedly in the 1980s, when the epidemic is reported
to have begun (De Angelis et al., 2004; BMA Board of Science, 2013, Chap-
ter 5). The population is difficult to enumerate, but there is evidence that
injecting drug use in England has fallen in the last decade to below 100,000
people injecting in the last year; however, a far larger number are previous
injectors still at risk, or otherwise still recovering from opiate dependency
(Hay et al., 2012).
The population considered here are people who currently inject drugs.
This population is somewhat difficult to define as the level of usage can
vary, with some people only ever occasionally injecting, and longer-term
users cycling between multiple periods of abstinence and relapse (Xia et al.,
2015). Further, although opiates are the most commonly injected drugs, the
group of people who inject drugs may include those injecting crack cocaine,
amphetamines and other drugs. These groups may have very different risk
patterns in terms of injecting frequency and risk behaviour. Nevertheless, the
bulk of injecting drug use is opiate-based, in particular heroin, the addictive
properties of which mean that most injectors will be dependent and injecting
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on a more or less regular basis. Typically, a “current” injector is taken to
mean someone that has injected in the last year, with those that have ceased
to inject for one year or more being classed as “ex-injectors” (De Angelis
et al., 2009).
Those beginning to inject drugs are often, unsurprisingly, in difficult per-
sonal circumstances; challenges in monitoring and treating this population
are often described as being due to “chaotic” lifestyles (Mravcˇ´ık et al., 2013).
Typically the age at first use is in the early twenties (Kimber et al., 2010),
and the population is characterised by high rates of homelessness and im-
prisonment (Cullen et al., 2015). Nevertheless, detailed studies of PWID
indicate that a large proportion of this population is in contact with some
kind of treatment or harm reduction service (i.e., needle exchange) (Hick-
man et al., 2007), which is promising when considering whether survey data
obtained via these services are representative.
Infection with blood-borne viruses will occur due to sharing of needles,
syringes, or other injecting paraphernalia that has been contaminated with
infected blood. It has been widely reported that risk of infection is far
higher in those that have started injecting recently (Crofts et al., 1997; Sut-
ton et al., 2006, 2008). One reason for this is that new initiates are likely to
be assisted by someone more experienced and not have their own injecting
equipment. Under these circumstances, a significant proportion of initiates
may become infected very early on, potentially within a few weeks of ini-
tiation. Further, there may be a period of stabilisation before the initiate
begins to use needle and syringe exchange services. Once injecting behaviour
is established, PWID may actually be at relatively low risk of infection, pro-
vided their circumstances remain stable. However, intermittent episodes of
upheaval are likely, due to interruptions or changes in drug supply, changing
peer groups, periods of homelessness or imprisonment, or any other factor
that might cause a change in risk behaviour. Although the timings are not
clear, homelessness and imprisonment are strongly associated with the risk
of blood-borne infection (Cullen et al., 2015). Patterns of injecting use and
mixing may also have a seasonal component, although this would be difficult
to assess in practice and no evidence on this is available.
Harm reduction strategies have been in place in England for over two
decades (Hope et al., 2001), consisting of opiate substitution therapy and
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needle and syringe programmes. The former reduces drug dependence and
the frequency of injecting, and the latter aims to reduce unsafe injecting
practices. These measures have been shown to be effective in reducing risks
of HCV (Turner et al., 2011), although mathematical modelling suggests
that other interventions are required to achieve substantial reductions in
prevalence, such as HCV treatment (Vickerman et al., 2012).
1.3 Surveillance systems for monitoring blood-
borne viruses
1.3.1 Study designs
Approaches for investigating the incidence or prevalence of infection (or any
condition of interest) in a population fall under the three main observational
study designs: cohort, case-control and cross-sectional studies. Case-control
studies are useful for determining risk factors, but do not provide any infor-
mation on absolute prevalence or incidence of infection, and are not consid-
ered subsequently.
Cohort studies recruit a group of people and follow them up over time,
allowing direct observation of the rate at which individuals acquire infection
or other event of interest. For “hard” outcomes such as mortality, or condi-
tions that otherwise have a known onset date, this may be known precisely;
but incident infection may only be known to have occurred within some time
interval between repeated tests. Although this should be accounted for in
the analysis of such data, it is not a major concern provided the frequency of
testing relative to the typical exposure duration is sufficient. For example,
many PWID inject for 10 years or more before permanent cessation (Sweet-
ing et al., 2009a) and serological testing for blood-borne viruses every 6-12
months would provide sufficient information to understand broad patterns
of incidence throughout injecting career.
Although cohort studies have the advantage of being able to directly es-
timate incidence, they are time-consuming and costly to conduct. Further,
those agreeing to participate in such studies may not be typical of the pop-
ulation of interest. This may be particularly true of PWID, who are at risk
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of homelessness, imprisonment and other instabilities, and are commonly
described as being “hard to reach” by treatment or other services (Alliance -
CAHR, 2013). PWID who choose to regularly participate in research studies
for extended periods may therefore be somewhat different to the norm.
Cross-sectional studies sample from the population of interest and test
infection status, providing a snapshot of prevalence at a particular time
point. This type of study is often carried out as part of routine surveillance
by public health bodies. In many cases the samples are anonymised, and
may have little in the way of additional data; frequently, only the age of the
individual is considered. Such data are known as age-specific current status
data (Keiding, 1991). Alternatively, other information may be collected, ei-
ther based on patient records, or via a questionnaire. Such data will often
still be anonymous, which makes obtaining ethical approval for conducting
research easier. For example, legislation allows the anonymous testing of
residual sera without consent for specific public health purposes. As with
cohort studies, there are a number of potential issues to consider when mak-
ing inferences from such data, as they may be subject to various forms of
selection bias, whereby the population sampled is systematically different to
the target population.
1.3.2 Studies of people who inject drugs
A number of long-term cohort studies have been set up to study PWID.
The Amsterdam Cohort Study began in 1985, with the aim of investigating
risk factors for blood-borne and sexually transmitted infections, and effects
of interventions. Participants complete a standardised questionnaire every
4-6 months when visiting the Health Service of Amsterdam (van den Berg
et al., 2007). The Edinburgh Addiction Cohort studies patients sampled
from a large primary care facility with a history of injecting drug use, and
examines behaviour and outcomes through a combination of interview-based
questionnaire data and primary care records (Kimber et al., 2010). Again,
there is a strong interest in investigating risk patterns for infections, but also
on behavioural aspects of injecting drug use.
Public Health England (and its predecessors) has conducted monitor-
ing programmes in different risk groups under the umbrella of The Un-
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linked Anonymous Monitoring programme (UAM) (Kessel and Watts, 2001).
This includes monitoring leftover samples from those attending genitouri-
nary medicine (GUM) clinics, pregnant women (via residue samples from
newborn infants), and surveys of PWID attending drug treatment centres
or needle exchange services. The latter is an annual cross-sectional sero-
prevalence survey of PWID in England, Wales and Northern Ireland that
began in 1990, and is the principal data source used in this thesis (Public
Health England, 2014). Briefly, PWID attending treatment and needle ex-
change surveys are invited to participate in the study. Those that consent
complete a questionnaire on risk behaviour and demographics, and provide a
serological sample that is tested for HCV, HBV and HIV (see section 1.2.4).
Data from the study have been used to monitor prevalence of blood-borne
viruses and trends in risk behaviour, and investigate the epidemiology of
blood-borne viruses in PWID. The study provides information on prevalence
according to the duration of injecting and the correlation between different
infections (see section 1.4), which are key themes of this thesis. A more de-
tailed overview of the study and previous research applications is provided
in chapter 2.
The Needle Exchange Surveillance Initiative (NESI) in Scotland is an-
other PWID survey programme (Health Protection Scotland, 2017). Similar
to the UAM survey, the aim of NESI is to measure and monitor the preva-
lence of BBVs and injecting risk behaviours among PWID. The initiative
was funded by the Scottish Government as part of the Hepatitis C Action
Plan, which states that efforts to prevent HCV in Scotland must focus on
preventing transmission of the virus among PWID (NHS Scotland, 2005).
As with the UAM, the purpose of NESI is to provide information to evalu-
ate and better target interventions aimed at reducing the spread of infection
among this population group (Allen et al., 2010). At present, research using
NESI data is particularly focussed on monitoring incidence and the potential
impact of new HCV treatments on transmission (Palmateer et al., 2014).
Numerous analyses of cross-sectional data in PWID have been conducted.
Prior to NESI, a cross-sectional study of PWID in Glasgow was conducted
from 1990-1996, finding high HCV prevalence that increased with injecting
duration. Age, age started injecting and calendar time were considered,
although no force of infection analysis was conducted (Taylor et al., 2000).
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Del Fava et al. (2011b) examined cross-sectional data on HCV and HIV
infection in PWID in Italy and Spain, noting a strong correlation between
the prevalence of infections (odds ratios of 2.56 and 2.42 for Italy and Spain
respectively). They used various approaches to jointly model prevalence,
including the bivariate Dale model, generalised linear mixed models and
shared frailty models. Del Fava et al. (2011a) also examined aggregated
cross-sectional data in 20 regions in Italy, finding an association between
HCV and HIV prevalence and marked variation between regions. Over-
dispersion and other issues are discussed in more detail in the PhD thesis of
Del Fava (2012).
1.3.3 Other surveillance systems and studies of blood-
borne virues
A number of studies have used opportunistic testing to estimate prevalence of
HCV and other blood-borne viruses; for instance, national HCV prevalence
in Australia was estimated using opportunistic testing of residual sera from
pathology laboratories (Amin et al., 2004) and patterns of HCV prevalence in
the UK assessed using antenatal screening data (Balogun et al., 2000). HCV
prevalence has also been examined in blood donors (The Health Protection
Agency, 2009), and those attending GUM clinics (Balogun et al., 2003) and
emergency departments (Orkin et al., 2015).
Other studies have used specific sampling frames to assess HCV preva-
lence, such as The National Health and Nutrition Examination Survey
(NHANES) in the USA (Denniston et al., 2014). The survey collects data on
the health of the non-institutionalized population using a multistage proba-
bility sampling design from approximately 5000 persons annually. By defini-
tion, those that are homeless or incarcerated are excluded from the study. A
cross-sectional study in France was used to estimate prevalence of HCV and
HBV. Again, a complex, stratified, multistage sampling design was required,
the sampling frame covered 80% of the population (beneficiaries of the na-
tional health insurance system) and response rates were low (11%) (Meffre
et al., 2010).
Monitoring HCV in the general population is problematic, due to major
difficulties in obtaining an unbiased sampling frame. In particular, PWID
29
(current or ex) will tend to be under- or over-represented in surveys: they
may be less frequently observed in surveys of the general population due
to an increased likelihood to be homeless, in temporary accommodation or
incarcerated. Conversely they are more likely to use a variety of health
services; for example, around 10% of those in the UAM survey of PWID
report using a GUM clinic in the past year, and over one quarter using an
accident and emergency department. This means that opportunistic testing
will, in many cases, result in higher observed prevalence than that of the
general population. In England, only around one in 50 adults have ever
injected drugs, but the probability of HCV infection in those that have is
over 200 times higher than those that have not (De Angelis et al., 2009). Even
a small degree of under- or over-sampling of those that have ever injected
drugs will therefore have a major impact on observed prevalence.
In England, the lack of a valid sampling frame has led to the development
of a multi-parameter evidence synthesis (MPES) approach, which combines
multiple sources of data on risk group sizes and risk group-specific prevalence
studies (Sweeting et al., 2008; De Angelis et al., 2014). The appeal of this
approach is that specific biases can be accounted for, and the consistency
of evidence assessed. MPES estimates are the basis of official prevalence
figures for HCV and HIV in England. In Scotland, which has better link-
age between surveillance systems (for instance, between HCV diagnoses and
other sources), a more detailed analysis of diagnosed and undiagnosed preva-
lence was undertaken in an MPES framework (Prevost et al., 2015).
Further understanding of the HCV epidemic may be inferred from infor-
mation on the number of people developing severe HCV-related liver disease,
namely HCC and ESLD, or HCV-related mortality. Such data are available
from Hospital Episode Statistics (HES) data, and the ONS mortality data.
Severe liver-related disease is almost certain to result in hospital attendance
and is reliably recorded; however, the fact that it is HCV-related may not
be recorded, and the potential for under-reporting must be borne in mind
(Mann et al., 2009). Examining trends in disease endpoints provides infor-
mation on those with earlier disease stages: compensated cirrhosis is the
precursor to severe liver disease, and will roughly follow the same pattern,
one step removed. In fact, if rates of disease progression are known (or can be
assumed) then earlier disease stages, and the whole course of the historic epi-
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demic, can be reconstructed via the back-calculation approach (Brookmeyer
and Gail, 1988). This approach can be used to make short-term predictions,
and has been much used for HCV to estimate future disease burden and
potential impact of treatment (Sweeting et al., 2007; Deuffic-Burban et al.,
2012; Harris et al., 2014); and for HIV (Sweeting et al., 2005; Birrell et al.,
2013; Brizzi, 2018). However, the approach has limited scope for estimating
incidence and overall prevalence, due to a lack of information on recent inci-
dence of infection and the need for accurate population-level rates of disease
progression, which are difficult to determine (Sweeting et al., 2006).
1.4 Analysis of age-specific prevalence data
This thesis is primarily concerned with the analysis of age-specific prevalence
data obtained from cross-sectional seroprevalence surveys, also known as
current status data. With “age” interpreted more generally as time at risk,
such data provide information on the rate at which prevalence increases with
time at risk and hence the force of infection, the rate at which uninfected
individuals acquire infection. This process was first modelled by Muench
(1934) and described as a “catalytic model”. The basis of the model is given
by
S(a) = exp
[
−
∫ a
0
λ(u) du
]
,
where S(a) is the proportion of uninfected individuals and λ(a) the force of
infection at age a.
A variety of choices are available for defining the functional form of λ(a):
in its simplest case, this may be constant. Parametric models may be de-
fined based on subject-specific knowledge, incorporating known epidemio-
logical characteristics of the infection. For instance, the force of infection
may decrease, increase, or accelerate with age, suggesting the use of Weibull
or Gompertz distributions, which are widely used in epidemiology and hu-
man survival. Childhood diseases may rise to a peak and fall in adulthood:
Farrington (1990) proposed the use of an “exponentially damped” function
to capture such patterns.
Piecewise constant models specify constant hazards within a set of age
intervals, which may be defined according to known epidemiological charac-
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teristics such as infant, school age, adulthood, etc. (Farrington et al., 2001).
Alternatively, a large number of small intervals (such as for each year of age)
allows for arbitrary age patterns, although there may be insufficient data to
obtain precise estimates of the force of infection within each interval.
This has led to the development of different approaches for providing flex-
ible shapes with a comparatively small number of parameters, or providing
some smooth function. Keiding (1991) discussed the use of kernel smooth-
ing of the estimated incidence, and later the use of spline-based smoothing
(Keiding et al., 1996). A similar, local polynomial approach was employed
by Shkedy et al. (2013) to analyse datasets on rubella, mumps and hepatitis
A. Marschner (1996) used piecewise constant incidence models along with
a moving average as part of an expectation-maximisation (EM) algorithm.
Parametric models using fractional polynomials have also been considered
(Shkedy et al., 2006), as have penalised splines and generalised linear mixed
models (Nagelkerke et al., 1999; Namata et al., 2007).
Flexible, parsimonious approaches are particularly useful when the age-
specific pattern is of particular interest, may have an arbitrary shape, and
estimation is restricted by comparatively sparse data. Frequently of interest
in the study of infectious diseases are contact patterns, in terms of who infects
who (Farrington et al., 2001). Detailed examination of age-specific patterns
of infection may reveal features of interest: for instance, a secondary peak in
infections in parent-age adults may suggest transmission from their school-
age children. Such an interpretation was made by Shkedy et al. (2013) with
regard to data on mumps, although resting on assumptions about mixing
patterns.
1.4.1 Models for age and calendar time
A key difficulty with the analysis of cross-sectional data from a single time
point is that the effects of calendar time are completely confounded with
age, and time homogeneity must be assumed. For a great many infections
this is implausible due to improvements in hygiene and awareness, a fact
pointed out by a number of authors (Keiding, 1991; Nagelkerke et al., 1999),
but often not accounted for in practice. An alternative is to estimate the
time-specific force of infection under an assumption of age-homogeneity, as
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argued for by Schenzle et al. (1979) in their analysis of hepatitis A in different
European countries.
It is preferable to consider that the force of infection may vary by both
age and time. Ades and Nokes (1993) proposed an extension to the standard
model that may be used where data from multiple serological surveys at
different points in time are available, which is the case with the dataset used
in this thesis.
Ades and Nokes (1993) treated the effects of age and time as indepen-
dent (and combining additively or multiplicatively) and only considered more
complex functions in terms of testing for the presence of potential age-time
interactions in piecewise constant models to verify the adequacy of this as-
sumption. An alternative to the age-time formulation is to specify the model
in terms of cohorts (birth years, or year first injected for PWID) plus an age
or time dimension; a third effect would be confounded with the other two and
not identifiable. Nagelkerke et al. (1999) considered age and cohort effects,
which were introduced as covariates, rather than age and calendar time. In
any case, interactions between age and time (or cohort effect) can only be
estimated within the time frame of serial data collection; prior to this age
and time effects are confounded.
Age-time models bring (literally) another dimension to the problem of
estimating an underlying process for the force of infection from noisy data
with inherently low informational content. Unless age and time effects com-
bine multiplicatively (or additively), specification of two-dimensional para-
metric forms may be problematic. Smoothing in two dimensions is also not
straightforward. One approach of potential use is the highly flexible class of
generalised additive models and “thin plate” splines (Hastie and Tibshirani,
1986; Wood, 2003). Such models were used to estimate the underlying in-
cidence rate of HIV in UK men who have sex with men (Brizzi, 2018) and
could also be applied to current status data such as those used in this thesis.
1.4.2 Mortality and relative inclusion in sample
The effect of mortality in the analysis of current status data can largely be
ignored if the focus is on the average age-specific force of infection, or inves-
tigation is of an infectious agent that has no, or little, effect on mortality
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and mortality is low until advanced age (Farrington et al., 2001). However,
difficulties can arise if those infected are subject to a higher mortality rate,
and therefore less likely to be observed in the sample, for instance, in the
pre-treatment era of HIV. Differential mortality can be considered more gen-
erally in terms of the relative inclusion rate (RIR), which was considered in
the context of HIV-infected women in ante/neonatal surveys by Ades and
Medley (1994). Due to the sampling frame, the RIR is relevant here in
terms of the relative fertility of those with and without HIV infection. Not
all parameters are fully identifiable from the data; age-specific patterns were
identified (via serial cross-sectional surveys, as in Ades and Nokes (1993))
but overall incidence could only be estimated to within a constant of pro-
portionality. Alternatively, information on infection-specific mortality can
be obtained from external sources and used within the analysis, as in the
study by Keiding et al. (1989) on incidence of diabetes. Marschner (1997)
discussed the potential for identifying patterns of age- and time-specific force
of infection and RIR from cross-sectional data, concluding that an external
data source would be preferable, or exploration of the impact of different
values for the RIR in sensitivity analyses.
It is not clear whether PWID infected with blood-borne viruses would be
more or less likely to take part in surveys, and if so, whether there might be
relative differences in the RIR according to injecting duration. HCV, HBV
and HIV can all lead to early mortality, although generally at low levels for
HBV and HIV in the combined antiretroviral treatment era. Mortality due
to HCV is a potential issue, although disease progression at younger ages
is generally slow (Sweeting et al., 2006) and unlikely to have a substantial
impact on those injecting for less than 20 years, which form the majority of
the UAM sample. Nevertheless, this possibility must be borne in mind when
considering estimates of the force of infection in those injecting for longer
periods.
1.4.3 Contact matrices: who infects whom
The force of infection as described so far represents an average age-specific
rate. A key parameter of interest for planning public health interventions
such as vaccination is R0, the expected number of infections produced by
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the introduction of an “average” infected individual in a population of sus-
ceptible individuals (Farrington et al., 2001). If R0 is less than 1 (or can
be reduced to below 1 via vaccination), the infection will naturally die out
within the population, otherwise the infection will remain endemic.
Central to this question are patterns of infectious contact between indi-
viduals of different ages (or more generally, between groups). This is com-
monly defined in terms of a contact matrix specifying the rate of contact
between individuals of different age classes; again, these may reflect societal
structures of pre-school, school age, adult and so on. Unconstrained, the
contact matrix will generally have more parameters than the available de-
grees of freedom and require reductions in the number of parameters: for
instance, different within-group rates but the same rate of contact between
all groups of different ages. Different assumptions about the structure of
the contact matrix may lead to markedly different estimates of R0, with no
difference in model fit (Farrington et al., 2001).
An alternative to estimating rates of contact from the data under some
assumed structure is to use an external source of information on mixing
patterns and relative intensities. The POLYMOD project, for instance, was
a large-scale study on the frequency of day-to-day contacts between different
ages across several European countries, with the explicit aim of informing
mathematical modelling (Mossong et al., 2008).
In terms of PWID and the sharing of injecting equipment that results
in effective contact, mathematical transmission models have generally been
developed on the basis of homogeneous mixing or an assumed mixing pattern
(see, for instance, de Vos et al. (2012) and Fu et al. (2016)). Rolls et al. (2012)
based mixing patterns on empirical evidence from a social study of PWID,
although, as ever, this population is difficult to study and recall of injecting
partners is generally poor (Brewer and Garrett, 2001). These considerations
are therefore set aside in this thesis, and the analysis restricted to estimation
of the average force of infection, rather than the process of who infects whom.
Of note is that in addition to a better understanding of contact patterns in
PWID, further development of existing methods would likely be required,
which are generally specified for infections with a short infectious period
(Farrington et al., 2001), unlike the blood-borne viruses considered here.
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1.4.4 Individual heterogeneity
Individual heterogeneity can have an important effect when estimating the
force of infection. In particular, if some individuals are more likely to be
infected than others, then there will be an apparently higher force of infection
early on in the period of time at risk than later. This is because those
that are at increased risk of infection will, on average, experience the event
sooner, whereas the rate of infections will be lower at a later time where
those remaining tend to be at lower risk. In this way, heterogeneity has the
effect of decreasing the population hazard relative to the individual hazard
over time, i.e., a time gradient is introduced Aalen et al. (2008, p. 235).
Gamma distributions for the frailty are commonly used, although many other
functions are possible, notably those from the so-called power variance family
(Hougaard, 2000).
Heterogeneity in seroprevalence studies is often considered using multi-
variate data, in which information on frailty comes from the correlation that
occurs between infections that share the same transmission route (Farrington
et al., 2001, 2013). Various extensions to the shared frailty model have been
considered. Hens et al. (2009) describe the use of a correlated frailty model
for multivariate data, which allows for separate, but correlated frailties for
each infection. These models are somewhat limited in that such effects may
only be identified if a specific functional form is assigned to the force of
infection, in much the same way as shared frailty models in the univariate
case.
Frailty may also be allowed to vary by age (or more generally, exposure
time), as described in Farrington et al. (2013). In their example, they found
greater heterogeneity at younger ages, which diminished in adulthood. In the
context of injecting drug use, changes in heterogeneity may be conceivable
over the course of injecting career, with a high degree of heterogeneity in
risk of blood-borne infection early on, possibly dependent on the context in
which initiation occurred, but longer-term users having more homogeneous
risk levels.
The selection effect induced by individual heterogeneity means that the
hazard in survivors decreases over time, but another question is how hetero-
geneous these survivors are. This depends on the choice of frailty distribu-
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tion, which may result in an increasing or decreasing coefficient of variation
over time; in fact, the gamma frailty is the only distribution for which the
coefficient of variation is constant (Aalen et al., 2008, p. 234; Farrington
et al., 2012).
Note that it is not possible to distinguish between temporal and selection
effects (Farrington et al., 2012), i.e., whether increasing or decreasing het-
erogeneity with age is due to a particular underlying frailty distribution that
causes the change via selection, or genuine changes in the frailty distribution
over time. Farrington et al. (2012) recommend that subject-specific knowl-
edge or external data are used to guide the choice of frailty distribution, then
examine potential time variation given the chosen functional form.
1.5 Aims of the thesis
The preceding sections provide some background on blood-borne viruses,
epidemiology and sero-surveillance, and the population at risk. The aim of
this thesis is to apply methods for estimating incidence and prevalence from
current status data to surveillance data on PWID. These data present an op-
portunity to develop methods for the analysis of cross-sectional data, which
in turn may reveal new insights on the epidemiology of blood-borne viruses
in PWID. The focus of analyses is on HCV, which of the three infections
considered is the greatest public health concern in PWID. However, HBV
and HIV are also of interest, and form an integral part of investigation of
variability in risk.
The UAM study is a unique data source, with a long series of sequential
surveys and a wealth of covariate data not typically found in current status
data. This gives the potential to investigate models including risk factors and
their effect on the force of infection. The effects of gender, age (in addition
to injecting duration), sharing injecting equipment, frequency of injecting,
needle exchange use, imprisonment and sexual behaviour are considered.
Models are developed that estimate the overall effect of risk factors on the
force of infection, and also whether the effect of a covariate is modified
according to injecting duration or calendar time (an interaction effect). The
data are sampled at a number of different sites, so geographic differences
can be examined and in particular regional trends in prevalence and the
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underlying force of infection.
Piecewise constant models are employed in order to maintain flexibility
in the baseline force of infection while estimating covariate effects and indi-
vidual variability, which are key points of interest. Parametric models and
smoothing approaches, which might more efficiently model the baseline force
of infection (especially when considering both age and time effects, such as
in Brizzi (2018)) are borne in mind but not used. It is shown later that
patterns of risk according to injecting duration (“age” in this context) are
relatively simple.
A key aim of this thesis is to understand individual variability in risk.
Shared frailty models that make use of bivariate infection data have typically
been used to estimate individual variability, most commonly using a gamma
frailty distribution. This thesis also examines the inverse Gaussian distri-
bution, which results in a different selection effect, and time-varying frailty
(Farrington et al., 2013), a relatively new development that has not been
applied to data on PWID before. Such approaches can help to understand
how variability in risk evolves throughout injecting career.
Bivariate frailty models are extended to include covariate information.
This is seldom considered in practical examples, as frailty models typically
use data aggregated by age and all individual variability is assumed to be
unmeasured. By including covariates, the frailty component is interpreted as
residual variability, which in theory should decrease (compared to a model
without covariates) as more information on risk is introduced. This the-
sis aims to examine this phenomenon and, more practically, whether the
marked variability in risk indicated by previous studies can be reduced us-
ing risk factor information. This would help to better target harm reduction
interventions to those at greatest risk.
The UAM data include infection status for HCV, HBV and HIV, and
bivariate models are considered for each infection pair. In this thesis trivari-
ate models are also investigated. Trivariate models extend the shared frailty
model to include different frailty components, which can be estimated from
the richer correlation structure of the three infections, although there are
restrictions on what can be identified. The information available to estimate
different aspects of frailty is considered, and different formulations proposed,
one of which has a similar form to the correlated frailty model.
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This thesis is organised as follows. In the second chapter the UAM study
is introduced, giving an overview of its history and purpose, available data,
limitations and previous analyses. The third chapter provides an overview
of statistical methods for analysing univariate cross-sectional data, covering
the basics of generalised linear models for binomial data, the force of infec-
tion model, and including covariates. The fourth chapter presents results of
fitting the univariate models described previously to the UAM data for HCV,
HBV and HIV, with a focus on HCV. The fifth chapter provides an overview
of multivariate models, in particular the bivariate shared frailty model, and
different frailty distributions are discussed, including measures of association
and time-varying frailties. Chapter six then presents results on measures of
association in the UAM data and fitting bivariate frailty models, including
models with covariates. In the seventh chapter component frailty models are
introduced, and different model forms are discussed. Trivariate models are
then fitted to the UAM data. The eighth chapter provides overall conclu-
sions on the work conducted in this thesis. R code and other background
information is included in the appendices.
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Chapter 2
The Unlinked Anonymous
Prevalence Monitoring
Programme
Public Health England (PHE, formerly the Health Protection Agency) has
conducted monitoring programmes in various risk groups for the last 20 years
or more under the umbrella of Unlinked Anonymous Monitoring (UAM)
surveys. This includes monitoring leftover samples from those attending
genitourinary medicine (GUM) clinics, pregnant women (via residue samples
from newborn infants), and surveys of people who inject drugs (PWID)
attending drug treatment centres or needle exchange services. The latter
survey on PWID is of principal interest in the following.
The aim of the UAM survey of PWID is to measure the changing preva-
lence of HIV, HBV and HCV, and monitor levels of risk and protective
behaviours among PWID. The data are used to assess and develop appro-
priate preventative and health education campaigns, evaluate the impact of
such interventions, and to assist in the provision of services for PWID in
the UK. Survey data have been collected annually since the programme was
established in 1990. PHE works in partnership with around 50 of 149 spe-
cialist drug agencies in England (data for Wales and Northern Ireland are
also collected, but not considered here). The drug action teams (DATs) that
are sampled from change from year to year: around 80 DATs have been sam-
pled at some point since the survey was established, and many have samples
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for every survey year.
Each year, the agencies are encouraged to ask all eligible clients to par-
ticipate in the survey, an eligible client being a current or former injecting
drug user who has not already participated in the survey in the current cal-
endar year. Each eligible client is asked to complete a short questionnaire,
which includes questions on patterns of drug use, including injecting dura-
tion, frequency in the last month and sharing of drug-taking paraphernalia,
treatment for drug addiction and participation in needle exchange services,
and their sexual behaviour. This information is used to assess the associa-
tion between risky activities (such as needle sharing) and the prevalence of
BBVs among PWID. Descriptions of the most relevant variables are given
subsequently. A copy of the 2015 questionnaire is shown in the appendices
(section 9.1).
Participants also provide a sample for serological testing: in the past,
oral fluid samples were used, but the survey moved over to dried blood spot
samples during 2009-2010. Identifying information is irreversibly unlinked
from all samples before testing, ensuring that both the sample and the ques-
tionnaire are completely anonymous. Samples are tested for the presence of
antibodies to HIV (signalling current infection), and antibodies to hepatitis
C and to the hepatitis B core antigen (which can indicate current or previous
infection).
All testing is conducted by the Virus Reference Department at Public
Health England Colindale, which has strict policies for quality assurance
and maintains all relevant accreditations (Public Health England, 2018c).
Dried blood spots are assigned a unique identifier and labelled upon receipt
and kept at 4◦C for short-term storage and prior to testing and −20◦C for
long-term storage. Samples must be of a sufficient specified size for testing
and are prepared according to the manufacturer specifications of the testing
equipment and Public Health England’s detailed protocols.
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2.1 Available data
2.1.1 Hepatitis C
Hepatitis C testing has been performed regularly on samples since 1998 using
the OraSure device, which has an estimated sensitivity of 91.7% (95% confi-
dence interval (CI): 87.5, 94.8) and specificity of 99.2% (95% CI: 97.8, 99.8)
(Judd et al., 2003). From 2009 to 2010, there was a gradual switch-over to
dried blood spots, which have near-perfect sensitivity and specificity. Both
tests were evaluated by the Public Health Laboratory Service (now Public
Health England) in those with known infection status, to determine optimal
thresholds for maximum sensitivity and specificity (Judd et al., 2003). A
smaller number of samples are available for the years 1992, 1994 and 1996.
These samples were taken using the Salivette device, which has sensitivity of
only 74.1% (95% CI: 68.2, 79.4) and 99.0% (95% CI: 97.4, 99.7) specificity. It
is necessary to account for varying sensitivity over time if HCV prevalence
prior to 2011 is to be estimated, as in Sweeting et al. (2009b). It is also
possible to adjust for the proportion of those infected that naturally clear
infection to obtain estimates of the prevalence of chronic HCV infection, for
example, as in De Angelis et al. (2009).
Since 2011, HCV positive samples have also been tested for avidity, a
measure of how strongly antibodies bind, and a potential marker for recent
infection (Klimashevskaya et al., 2007; Coppola et al., 2009; Gaudy-Graffin
et al., 2010). Samples with weak avidity (and subject to an RNA positive
test) are more likely to be recent infections; although the best value to use
as a cut-off, and the likely “window” period between seroconversion and
development of strong avidity is not well established.
2.1.2 Hepatitis B
Testing for hepatitis B via hepatitis B core antibody (anti-HBc, indicating
past or current infection) has been performed in all survey years. The tests
used had poor sensitivity prior to the introduction of dried blood spot testing
(which has near-100% sensitivity) with 76% sensitivity prior to 1998 and
75% up to 2009-2010; although specificity has always been above 99% (Judd
et al., 2007). Hepatitis B surface antigen tests are also conducted, although
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numbers are low. The UAM study is currently in the process of carrying
out hepatitis B surface antibody tests (see section 1.2.4) on a subset of
data, which could provide more insights into patterns of HBV infection and
validation of vaccination status (which is otherwise self-reported).
2.1.3 HIV
The UAM survey for PWID was originally conceived to monitor HIV and
therefore samples are available for all years (Noone et al., 1993; Hope et al.,
2014). The Salivette device was used until 1998, followed by the OraSure
device before dried blood spots were introduced around 2009-2010; for all
years the test has near-perfect sensitivity and specificity. HIV has been
studied extensively in terms of CD4 cell counts, RNA levels and treatment
with antiretroviral therapy in cohort studies, but only infection status is
available in the UAM data. Prevalence of HIV infection in PWID is low
compared to HCV and HBV, and follows somewhat different patterns with
markedly higher prevalence in London compared to all other regions (The
Health Protection Agency, 2012b).
2.1.4 Injecting behaviour
Participants are asked whether they injected in the last year and in the last
month, as well as frequency of recent behaviour. Many studies that have
used the UAM data have focussed on those that have injected within the
last month, this being seen as the best definition of “current” injectors, who
are a group of principal interest. Some participants have not injected for over
a year, who might viewed as a potentially unusual group of ex-injectors, as
those that have ceased to inject but are still in long-term treatment are likely
to have different characteristics to the general population of ex-injectors.
Despite this, the UAM data have been used to estimate HCV prevalence in
ex-injectors (Sweeting et al., 2008), albeit after careful adjustment for biases
that are likely to be present in so-called snapshot samples (Kaplan, 1997).
Participants are also asked about sharing needles and other parapher-
nalia, including whether they have ever received needles or syringes from
anyone, and the number of people they have passed on to, and received
needles from, in the last 28 days.
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Finally, participants are asked for the age at which they first started
injecting. Combined with their current age, this provides a key piece of
information on understanding the risk of infection: injecting duration. For
infection via injecting drug use this corresponds to time at risk. The typical
“career” of PWID will often involve multiple periods of stopping and start-
ing, rather than a single, uninterrupted period of injecting prior to cessation,
although the simplifying assumption of a continuous period of risk is usually
made.
2.1.5 Sexual behaviour and health
Participants are asked whether they have had sex in the last 12 months, with
how many male and female partners, and whether they have exchanged goods
or money for sex in the last year, or ever. They are also asked whether they
have attended various types of health services in the last year, in particular
GUM or STI clinics. The most recent questionnaire also includes questions
on accident and emergency attendance due to overdose.
Participants are also asked about previous HIV and HCV testing and
treatment for HCV, whether they have ever been in prison or a young of-
fenders institution (and whether injected drugs while in prison), and whether
they have ever been homeless. There is little information on timing and dura-
tion of periods of homelessness or imprisonment, although there is a question
on when last went to prison.
2.2 Previous UAM studies
Data collected from the UAM survey of PWID have been used in various
ways to estimate trends in the prevalence of blood-borne infections, be-
havioural characteristics and demographics of PWID in England and Wales.
One of the earliest studies examined prevalence of HIV and HBV in PWID
in 1990 and 1991, finding a prevalence of 1.2% and 1.8% respectively for
HIV and 33% and 31% for HBV, with high levels of reported sharing of
equipment and risky sexual behaviour (Noone et al., 1993).
A later analysis examined HCV prevalence in 1997 and 1998, a time when
the effectiveness of harm reduction measures for PWID was being assessed,
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and prevalence of BBVs was found to be lower than previously thought
(30% for HCV, 21% for HBV, and 0.9% for HIV) (Hope et al., 2001). The
association between HCV infection and HBV/HIV status was examined, and
found to have odds ratios of 2.3 (95% CI: 1.8, 2.8) and 1.5 (95% CI: 0.6, 3.5)
respectively after adjusting for injecting duration, age, sex, area and previous
testing for HIV.
Between 1991-2000 an increase in needle sharing was reported, which was
thought to be associated with a rise in HBV prevalence (HIV levels were too
low for comparison, and HCV testing only recently introduced (Hope et al.,
2002)). They speculated that needle sharing may have increased due to
changed perceptions of the severity of HIV infection following advances in
treatment, or the perception of no longer being at high risk of infection.
HIV trends between 1990-2003 were examined via the UAM and com-
munity surveys (Hope et al., 2005). Prevalence was found to have decreased
throughout the 1990s, then increased from 2000 onwards, with prevalence far
higher in London compared to other areas. They also used a force of infec-
tion model with piecewise constant time effects, and found higher incidence
between 1998-2002 compared to 1992-1997 in London, but not other areas,
and a far higher force of infection in the first year of injecting compared to
other years.
Age of starting injecting and subsequent cessation were investigated by
Sutton et al. (2005). A gamma distribution for age starting injecting was
used, and a piecewise linear function for rates of removal by age chosen
after a model selection exercise. They estimated that 50% of injectors start
between the ages of 18 to 25, with 15% starting after the age of 30. Annual
removal probabilities rose linearly up to a maximum of around 30% at age
30-35. The authors acknowledge potential under-representation of different
injecting career lengths and attempted to incorporate this in their model.
Sutton et al. (2006) jointly modelled the force of infection of HCV and
HBV between 1998-2003, investigating individual heterogeneity via a shared
frailty model with a gamma distribution. They considered trends over cal-
endar time, but eventually assumed a constant force of infection for each
virus, which was found to fit the data equally well. For injecting duration,
they selected a simple dichotomy of < 1 vs. ≥ 1 years, finding a three-fold
reduction in force of infection after the first year. This was assumed the
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same for both viruses, again based on goodness of fit of the model. They
found substantial individual heterogeneity and concluded that some PWID
are at significantly higher risk of blood-borne infections.
The impact of HBV vaccination has been considered, with levels of uptake
rising from 27% to 59% from 1998 to 2004 (Hope et al., 2007). However,
there was no corresponding decline in prevalence, and the force of infection
was estimated to have increased in 1999-2004 vs. 1993-1998 (Judd et al.,
2007).
Sweeting et al. (2009b) examined HCV prevalence over time while ad-
justing for injecting duration and other covariates. Polynomial functions
were fitted to the logit prevalence, including non-linear trends for time and
injecting duration of up to degree 4, as well as age and region. By doing so,
the underlying temporal trend was estimated while controlling for changing
demographics in the PWID population. Imperfect sensitivity and specificity,
including uncertainty in the estimates used (Judd et al., 2003), was incor-
porated in a Bayesian framework. Previous studies had acknowledged the
limitations of the assays, but the work by Sweeting et al. (2009b) was the
first to explicitly include this as part of the model. They found that after ac-
counting for imperfect testing, prevalence had decreased in the early 1990s,
but increased from the late 1990s until the mid 2000s.
More recent work using these data estimated HCV prevalence in recent
initiates (self-reported injecting duration of three years or less), with this
interpreted as a measure of incidence, which was found to be largely stable
between 2000-2008 (Hope et al., 2012).
Local level differences in HCV prevalence have also been examined (Har-
ris et al., 2012a). Across 152 Drug Action Team (DAT) areas, prevalence was
found to vary substantially, with estimates ranging from 14% to 82%. Spa-
tially correlated random effects models were employed (Besag et al., 1991)
in order to identify spatial patterns, and crucially, to derive prevalence es-
timates for non-sampled areas. The inclusion of area-level covariates, or
auxiliary variables in the spatial mapping terminology, further improved es-
timates in terms of out-of-sample prediction and reducing standard errors of
small samples.
Hope et al. (2014) modelled prevalence of HIV between 1992-2012 using
polynomial functions, similar to the analysis of Sweeting et al. (2009b). Inci-
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dence was also estimated via a joint model for HIV and HCV, using injecting
duration- and time-specific contributions to the force of infection. Both time
and injecting duration components were estimated via a random walk func-
tion in a Bayesian framework, and the effect of injecting duration was shared
by the two infections, based on the assumption that risk of either HIV or
HCV throughout injecting career is proportional. This approach increased
the power to estimate the individual effects, which are difficult to estimate
as rates of HIV are relatively low, but does not account for the possibility of
sexual transmission of HIV or other differing risk patterns between the two
infections. Hope et al. (2014) also constructed a timeline of government pol-
icy changes, broadly ascribing periods of increased risk to policies focussing
on drug-related crime, rather than treatment and harm reduction.
Markers of recent infection for HCV are currently being investigated, with
avidity-based measures and proportions of RNA-positive, antibody-negative
individuals being explored to determine patterns of incidence (Cullen et al.,
2015). With the advent of new HCV treatments and the potential for reduc-
ing incidence via treatment as prevention (Martin et al., 2015), there is great
interest in the potential for monitoring progress via such measures. However,
estimates suffer from substantial statistical uncertainty and the power to de-
tect reductions over time is low (Public Health England, 2018a). Therefore
force of infection models still have a crucial role to play in understanding
changes in the risk of infection over time.
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Chapter 3
Methods for the analysis of
cross-sectional serological
surveillance data
Cross-sectional data on infectious diseases typically consist of binary (0/1)
infection status and a set of covariates, the most important generally being
age, but potentially including other demographic or risk factor information.
The resulting data may be modelled via a generalised linear model (GLM) to
determine the relationship between the covariates and infection status. Data
consisting of age-specific infection status, or current status data, are usually
modelled in a particular way: by relating infection status to time at risk,
estimates of the age-specific rate of infection may be obtained in a framework
that is conceptually similar to survival analysis. In fact, such data are called
interval censored type 1 data in the survival analysis literature.
This chapter is organised as follows: the GLM specification for binary
responses is reviewed, and how such models are fitted to observed data by
maximising the log-likelihood. Assessment of model fit is then discussed,
along with differences between binary data and the aggregated binomial
form. The basics of survival analysis are then reviewed, and how this theory
is related to the analysis of current status data from cross-sectional surveil-
lance data. The basic model for age-specific data is then extended to allow
rates of infection to vary by both age and time, and the inclusion of other
covariates.
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3.1 Models for binary responses
Binary data consist of observations that can take only two possible states,
assigning “failure” as zero and “success” as 1 (generally the diseased state
or a positive test for infection). The interest lies in estimating the mean
probability of success, p, and how this varies according to different covariate
levels. This is achieved via a generalised linear model (GLM), which is spec-
ified by a random component, a systematic component, and a link function
(Nelder and Wedderburn, 1972). For binary (or binomial) data, the random
component is a set of independent observations with a Bernoulli (or bino-
mial) distribution and mean probability of success pi for observation i. The
systematic component relates a vector of parameters to the covariates,
ηi = β0 + β1x1i + ...+ βkxki,
where ηi is known as the linear predictor. Finally, the link function relates
the linear predictor to the mean of the random component, which in most
cases will constrain the values that the transformed linear predictor can take
to between zero and 1. The most widely used link function for binary data
is the logit function, which gives the logistic regression model
pi =
exp(ηi)
1 + exp(ηi)
. (3.1)
The logit is a symmetric, S-shaped function that is bounded by zero and
1. An alternative to this is the probit model, which uses the cumulative
distribution function (CDF) of the standard normal distribution, denoted
Φ:
pi = Φ(ηi). (3.2)
Finally, the complementary log-log (CLL) link gives the model
log(− log(1− pi)) = ηi. (3.3)
These links produce different relationships between the linear predictor and
the probability of success, which are displayed in Figure 3.1. If the link func-
tions are considered to be cumulative distribution functions, the probability
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density function of the logit link has heavier tails than the probit link and
the CLL link is negatively skewed.
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Figure 3.1: Link functions for binary data: linear predictor η and resulting
probability p.
Another possibility is the log link, which is not generally recommended
for binary data as a positive value in the linear predictor will result in p > 1
(Figure 3.1). Nevertheless, a log link might be used to model binary data
when the probabilities of success are low. More pertinently, a GLM with
a log link may be used for the analysis of age-specific current status data.
This is described in section 3.2.2.
Alternative link functions are of course possible. For instance, Aranda-
Ordaz (1981) describes a symmetric family of functions that include the
identity (linear) link and logistic as special cases; and an asymmetric family
that includes the logistic and CLL as special cases. The univariate prevalence
models considered in this thesis use only categorical variables, for which the
specification of the relationship between the linear predictor and the mean
probability may be of lesser importance: in univariable models fit is identical,
although covariate effects may combine in different ways in multivariable
models under different link functions. For multivariable models, some care is
required to distinguish between the need for an alternative link function and
the addition of interaction terms between covariates (Collett, 2002, p. 149).
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3.1.1 Model fitting
In the following it is assumed that a logistic regression model is to be fitted
to binomial data, although the concepts will still hold for binary data and
other link functions. The aim is to obtain the maximum likelihood estimates
(MLE) of the parameters, βj, in the model. Given data where yi is the
number of successes from ni observations in covariate group i, we maximise
the binomial log-likelihood:
n∑
i=1
[
log
(
ni
yi
)
+ yi log(pi) + (ni − yi) log(1− pi)
]
. (3.4)
As the term log
(
ni
yi
)
is constant, this does not need to be calculated in order to
maximise the log-likelihood, and the function can be simplified to the kernel
log-likelihood. However, maximising the kernel log-likelihood still requires
solving a system of nonlinear equations, so numerical optimisation methods
are required to find the set of parameter values that are maximum likelihood
estimates. The Newton-Raphson method is typically used for logistic regres-
sion, which uses first and second derivatives to obtain local approximations
of the function, and converges to the maximum over successive iterations.
3.1.2 Accounting for imperfect sensitivity and speci-
ficity
When modelling the infection status, or any other binary response that may
be imperfectly measured, there is the potential to under- or overestimate
the probability of infection p if the test used to determine infection status
does not always provide a correct classification. The imperfection of a test,
assessed by comparing results against a “gold standard”, is generally defined
in terms of the proportion of true positives with a positive test status, called
sensitivity and the proportion of true negatives with a negative test status,
called specificity (Altman and Bland, 1994) (see section 1.2.4). Imperfect
sensitivity (less than 100%) will therefore lead to underestimates of p, while
imperfect specificity will result in overestimates. Furthermore, if different
tests with varying sensitivity and specificity have been used in the sample,
and the usage of some tests is associated with a covariate of interest, esti-
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mation of the effect of this covariate can be biased due to the systematic
under- or overestimation of p at different covariate levels. For instance, if
test sensitivity improves over the survey period, p would be underestimated
in earlier survey years.
If the sensitivity and specificity of the test are known then the probability
of a positive test can be related to the true probability of infection. The
table below shows the relationship between infection status and test results
given imperfect sensitivity and specificity, where pi is the true probability of
infection and Sens and Spec are the sensitivity and specificity:
True disease Test result
status Negative Positive
Negative (1− pi)Spec (1− pi)(1− Spec)
Positive pi(1− Sens) piSens
Therefore the observed proportions of a positive test p and a negative
test 1− p are given by
p = piSens+ (1− pi)(1− Spec)
1− p = (1− pi)Spec+ pi(1− Sens).
(3.5)
This relationship can then be incorporated into model fitting by substituting
p with pi in the link function. The covariates are then estimated according
to the true probability of infection pi. Provided that Sens and Spec are
known, the kernel likelihood derived from equation 3.4 can therefore be used
to estimate the parameters. Estimates from such a model will then estimate
the true probabilities of infection and give unbiased estimates of covariate
effects. The disadvantage is that the model can no longer be fitted using
standard GLM procedures in most packages and must be implemented using
bespoke code.
3.1.3 Model assessment
An adequately fitted model should predict the probability of success, or the
number of successes for each covariate combination, with a suitable level of
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accuracy. Model fit (or lack of) is easiest to interpret for binomial data, that
is aggregated successes and failures for each covariate combination. “Co-
variate combination” here is taken to mean whatever grouping is used for
the aggregated data. This might not correspond to the covariates that are
used in the model, and instead might be considered as unique data combina-
tions. For instance, data might be aggregated by age in years, but analysed
in terms of broader age groups. In any case, data in the following are as-
sumed to consist of yi successes from ni individuals for each observation. The
deviance provides an assessment of how well the model predicts the probabil-
ity of success, p, based on a comparison between the likelihood of the fitted
model and the likelihood of the saturated model, this being a model with
one parameter for each data point and fitting the data perfectly. Predicted
probabilities from the fitted model are given by
pˆi = g
−1(βˆ0 + βˆ1x1i + ...+ βˆkxki), (3.6)
where βˆj is the maximum likelihood estimate of parameter j. The predicted
number of successes for data point i is then yˆi = nipˆi and the deviance is
defined as
D = 2
n∑
i=1
[
yi log
(
yi
yˆi
)
+ (ni − yi) log
(
ni − yi
ni − yˆi
)]
. (3.7)
See, for instance, Collett (2002, p. 65). Given a sufficient sample size and
non-sparsity in the aggregate data (see below), the deviance has an ap-
proximately χ2 distribution with n − k degrees of freedom under the null
hypothesis that the model is correct, n being the number of data points and
k the number of parameters (Collett, 2002, p. 69). This leads to the rule of
thumb that the deviance should be roughly equal to the degrees of freedom.
Aggregation of the data is required for the deviance to have any meaning-
ful interpretation. For binary data, the yi are all zero or 1, and the deviance
provides no information on the agreement between the observations and
those predicted by the fitted model. This is also the case where aggregated
data are so finely cross-classified that many of the cell counts are very small:
there should be few data points for which ni is 1 and most of reasonable size
(see, e.g., Collett (2002, p. 69)). The deviance should therefore be examined
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at an appropriate level of cross-classification, which may mean aggregating
groups that are relatively sparse, especially where there is cross-classification
with another variable that contains few observations in certain categories. In
fact, where data are purely binary, as is the case when continuous covariates
are analysed, tests for goodness of fit need to be based on a categorisation of
the data, such as the percentiles (often deciles) of the predicted probabilities
for the Hosmer-Lemeshow test (Lemeshow and Hosmer, 1982).
Where data are classified according to a single covariate, a lack of fit may
indicate that the relationship between the covariate and the outcome has
not been captured by the model (provided that the link function is correctly
specified). For instance, a linear relationship between the covariate and the
linear predictor may not be appropriate, or for grouped variables the classes
may be too broad or have inappropriate cut-points. Discrepancies between
the observed and predicted probabilities may be assessed for the individual
data points via deviance residuals, defined as
di = sign(yi − yˆi)
[
2yi log
(
yi
yˆi
)
+ 2(ni − yi) log
(
ni − yi
ni − yˆi
)]1/2
(3.8)
for data point i (Collett, 2002, p. 131). Plotting the residuals against the
values of the covariates can help to answer questions such as whether the
general relationship of a variable has been correctly specified, or whether
there are systematic deviations in the fitted probabilities.
For an adequately fitted model with sufficient observations and successes
for each i, the di can be standardised to have an approximate standard
normal distribution (Collett, 2002, p. 131). Histograms of deviance residuals
can be used to assess this, or the ordered values can be plotted against the
values of a standard normal distribution in a so-called quantile-quantile or
Q-Q plot: if the di have a standard normal distribution, the points will lie on
the line y = x. If plots of the residuals against covariate values do not reveal
any systematic differences, but the standardised deviance residuals are more
variable than would be expected under a standard normal distribution then
there is likely overdispersion.
Where data are classified according to multiple covariates, a lack of fit
may also be due to the presence of interactions between these variables.
This is also known as effect modification, where the effect of one variable
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changes according to the values of another variable. Of course, model fit can
always be improved on by adding interactions. For categorical covariates, the
model including all possible interactions is called the saturated model, that
is, there is a parameter for every observation, and the model fits perfectly.
However, it is generally not desirable to do this. Firstly, it is inefficient and
will result in imprecise parameter estimates. Secondly, because the model is
then not summarising or simplifying the data. Finally, it is often unlikely the
underlying data-generating process really includes high-level interactions,
with 2nd order usually being the limit of what is considered.
Whether the data include multiple covariates or a single covariate, it may
be that the specification of the relationships between the covariates and the
outcome, including interactions, is considered sufficient. Excess variability in
the observed values of the outcome would then be considered as overdisper-
sion. This simply means that prevalence varies more than would be expected
by sampling variability alone, given the structure of the linear predictor in
the model. For instance, a linear effect of age might appear broadly cor-
rect, but observed proportions with the outcome vary substantially between
individual years, which would be an obvious case of overdispersion. More
difficult to ascertain is whether the additional structure of interaction terms
is required, which may require subject-specific knowledge. However, plots of
residuals against covariates, stratified by levels of a second covariate, can still
be informative in identifying the need for interaction terms. Formal tests for
structure in residuals may be carried out, for instance whether there are se-
rial patterns in positive and negative residuals according to age or calendar
year. Such tests are referred to as runs tests, as they assess the observed vs.
expected number of runs of positive and negative values in the data under
the null hypothesis of randomness (Wald and Wolfowitz, 1940; Swed and
Eisenhart, 1943).
3.1.4 Estimates, confidence intervals and predictions
Having obtained a set of parameter values that maximise the log-likelihood,
the uncertainty of these estimates due to sampling variability is also of in-
terest: the less information there is (either in terms of small ni, or a small
number of successes/failures) then the less precise the estimates will be. An
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indication of the uncertainty in the estimate is given by the standard er-
ror, which can then be used to construct confidence intervals. The Hessian
matrix (2nd derivatives of the log-likelihood) may be calculated numerically
by the numerical optimisation routine, and the observed Fisher information
matrix is minus the Hessian matrix. The Hessian matrix is the degree of
curvature in the log-likelihood surface and therefore represents the amount
of information available to estimate the unknown parameters. Thinking of
maximum likelihood estimation as searching for the top of a hill, a sharp
peak indicates that the true value of a parameter is likely to be in a small
region of the parameter space, whereas gentle curvature indicates greater
uncertainty in the location of the MLE. Taking the inverse of the negative
Hessian matrix, calculated at the MLE, provides an estimate of the asymp-
totic covariance matrix, with diagonal elements estimates of the asymptotic
variances of the MLEs of the parameters. Hence under the assumption of
approximate normality 95% confidence intervals for a parameter β may be
obtained from the standard errors (SE) as CI95 = βˆ ± 1.96SE.
The predicted probability of success for a given covariate pattern is given
by equation 3.6, with pˆi obtained by taking the inverse of the link function
g. To obtain 95% confidence intervals for g(pˆi), the variance of the linear
predictor is given by
var(ηˆi) =
k∑
j=0
x2jivar(βˆj) +
k∑
h=0
∑
j 6=h
xhixjicov(βˆh, βˆj) (3.9)
(Collett, 2002, p. 131). The full asymptotic covariance matrix is also ob-
tained from the inverse of the Hessian matrix, but using the whole matrix
rather than just the diagonal elements. Denoting the standard error of the
linear predictor as SE(ηˆi), 95% confidence intervals for the predicted prob-
ability of success are given by CI95 = g
−1(ηˆi ± 1.96SE(ηˆi).
Plots may then be constructed that include observed and fitted prob-
abilities pi and pˆi and the confidence intervals of the fitted probabilities;
if the model fit is satisfactory, then around 95% of the observed probabil-
ities should lie within the 95% confidence intervals, hence this is a useful
diagnostic procedure.
Alternatively, predictions may be obtained for a certain set of parameter
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values that is not necessarily included in the dataset. Continuing with the
example of age, region and sex, predictions may be created with region and
sex at fixed levels so that changes in predicted probabilities according to age
alone may be assessed, which may be preferable to examining a number of
plots for each combination of region and sex. If there are no interactions, the
pattern will be similar across different levels of region and sex. However, if
interactions between age and the other variables are included in the model,
it must be borne in mind that the relationship is conditional on the specified
values of these covariates. A set of fixed values may be selected for the
largest or most representative group(s), or alternatively averaged over the
dataset.
If a model has been fitted accounting for imperfect sensitivity and speci-
ficity as in equation 3.5, then the predicted probabilities from equation 3.6
will be for true infection status, rather than observed test results. This may
be desirable, but plots of observed and predicted probabilities as described in
the above will no longer be interpretable, as the observed probabilities will be
systematically higher or lower according to the sensitivity and specificity of
the test. In this case, it is preferable to adjust the fitted probabilities for the
imperfect sensitivity and specificity according to equation 3.5 so that they
revert to fitted probabilities of a positive test result, rather than infection
status. This procedure may also be used to produce confidence intervals for
a positive test result using equations 3.6 and 3.9, then converting the lower
and upper bounds according to equation 3.5.
3.1.5 Model comparison
The methods outlined in sections 3.1.3 and 3.1.4 may be used to assess the
adequacy of model fit, either overall or in terms of systematic differences
according to covariate levels. However, it may be that there are multiple
candidate models with different sets of covariates or parameterisations (for
instance, inclusion of interactions) that are under consideration, from which
it is not clear whether a more complex model should be preferred. Differ-
ences in deviance may then be used to assess whether one model provides a
substantially better fit than another; for two nested models, where the more
complex model includes all of the parameters of the less complex one, the
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difference in deviance between two models has an approximately χ2 distri-
bution under the null hypothesis that the simpler model is correct (Collett,
2002, p. 73). An appropriate test statistic is constructed with degrees of free-
dom equal to the difference in the number of parameters between the two
models, and the p-value provided by the test gives an indication of whether
the more complex model should be preferred.
An alternative is to use model selection measures such as the Akaike
Information Criterion (Akaike, 1974). This, and other measures like it, gives
a score based on how well a model fits the data, but with a penalty for model
complexity. For nested models, the performance of the AIC is very similar
to deviance-based tests; however, the AIC may also be used to compare
non-nested models. The AIC is defined as:
AIC = −2 log(L(θˆ|y)) + 2k, (3.10)
which is based on the maximised log-likelihood of the estimated parameters,
log(L(θˆ|y)), plus a penalty term 2k, where k is the number of parameters in
the model. The measure is simple but underpinned by information theory,
being based on minimising the information lost when a given model is used to
represent the data compared to the true data-generating process. A variety of
alternative measures have been proposed, such as the Bayesian (or Schwartz)
Information Criterion (BIC), which applies a heavier penalty for complexity.
An overview of various approaches is given in Burnham and Anderson (2002),
who recommend the AIC as their measure of choice. In particular, the BIC
assumes that the correct model is included in the set of candidate models,
which is usually implausible, although the AIC may prefer overly complex
models when datasets are large (Kuha, 2004). In practice the choice may
come down to the consequences of selecting an overly-complex model (AIC)
compared to one that is overly-simple (BIC). Much of the model comparison
in chapter 4 concerns whether interactions between injecting duration and
time are necessary. In the context of then estimating HRs for risk factors,
and subsequent investigation of heterogeneity (chapter 6) a more flexible,
if potentially over-complex, parameterisation of the baseline FOI may be
preferable.
For the AIC (and similar measures) the absolute value has no meaning,
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but differences between scores indicate the relative merits of two or more
models, with lower scores being better. A rough rule of thumb is that dif-
ferences of 2 or less indicate little difference between models, differences of
4-7 indicate a likely difference, and more than 10 a substantial difference.
3.2 Analysis of current status data
In this section some basic theory of survival analysis is reviewed before ap-
plying this theory to current status data. Survival analysis is concerned with
time to event data, consisting of observation times until an event occurred,
or the time of censoring if the event did not occur before observation ended.
Data therefore consist of a time t and a binary event indicator. The aim is to
estimate the hazard rate, which is the instantaneous event rate in survivors
(those who have not yet experienced the event) over time, and differences in
the hazard rate according to covariates, which can be expressed as hazard
ratios (HR). The mathematical relationship between the hazard rate and
the proportion of survivors over time has a direct bearing on the analysis of
current status data, where time at risk is related to the binary outcome of
infection status. In the infectious disease literature the hazard rate is usu-
ally called the force of infection, and survivors called susceptibles (not yet
infected); these terms are exactly equivalent. Models that incorporate this
relationship for binary current status data may be of the form of a GLM as in
section 3.1 and may also incorporate changes over time and other covariates.
3.2.1 Basic theory of survival analysis
The hazard rate and survival function are central to survival theory, and are
derived as follows (see, e.g., Aalen et al. (2008, p. 6)). Let T denote sur-
vival time, and f(t) be its probability density. The cumulative distribution
function of T is then
F (t) = P (T ≤ t) =
∫ t
0
f(u) du.
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Hence F (t) is the probability of failure by time t. The survival function is
defined as
S(t) = P (T > t) = 1− F (t) (3.11)
and is the probability of survival beyond time t. This is an unconditional
probability, whereas the hazard rate, λ(t), is related to the probability of
failure in an infinitesimally small time period between t and t+δt, conditional
on survival up to time t. This is defined as the limit:
λ(t) = lim
δt→0
P (t < T ≤ t+ δt|T > t)
δt
. (3.12)
From equation 3.12:
λ(t) = lim
δt→0
S(t)− S(t+ δt)
δtS(t)
= − 1
S(t)
dS(t)
dt
= − d
dt
log[S(t)],
which leads to the equation
S(t) = exp
[
−
∫ t
0
λ(u) du
]
. (3.13)
3.2.2 Application to serological surveillance data
The type of data commonly collected by routine surveillance tends to be
cross-sectional and does not include the time of the event, only the duration
of exposure and current status (hence interval censored). However, the same
theory from the survival analysis literature applies: the time-specific propor-
tion susceptible is related to the cumulative force of infection, provided the
infection confers life-long immunity and serological tests can reliably deter-
mine past infection. In many applications infection may occur from birth,
and hence the time at risk is the person’s age. Subsequently models are
described in terms of age, but the same concepts hold for any measure of
time since the individual became at risk.
Given data from a serological survey in which rt of nt individuals at age
t are infected, the force of infection λ(t) may be estimated by maximising
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the binomial log-likelihood as in equation 3.4, with S(t) corresponding to
the proportion of successes pi (considering susceptible a “success”); see, e.g.,
Farrington et al. (2001). In the simplest case of a constant force of infection
over time (λ(t) = λ), we have:
S(t) = exp
[
−
∫ t
0
λ du
]
= exp(−λt).
The relationship is that of a GLM for binomial data with a log link
log(S(t)) = −λt (3.14)
and models of this form can therefore be fitted using standard GLM routines
in many statistical software packages (although some will not allow a log link
with binomial data). Although a log link is not generally recommended for
binomial data, given that λ must be positive, the linear predictor will always
be negative, so S(t) cannot exceed 1 (and is equal to 1 at t = 0). Model
fitting routines may be adapted to allow for constraints, which can be used
to ensure that the force of infection takes only non-negative values. However,
this is often not necessary as the function may be parameterised such that the
force of infection is always positive (e.g., by exponentiating). Note that the
linear predictor in equation 3.14 does not include a constant, as this would
imply non-zero prevalence (proportion susceptible 6= 1) at birth. However,
the presence of a constant term would give an indication of imperfect test
sensitivity or specificity (Ades and Nokes, 1993), given the assumption of
constant force of infection.
Equation 3.14 may also be arranged in the form of the complementary
log-log (CLL) link function
log(− log(S(t))) = log(λ) + log(t). (3.15)
This parameterisation may be preferable if a log link is not permitted by
the software package to be used, but otherwise gives the same mathematical
relationship between the parameters and the data.
The model described in equation 3.14 may easily be extended to a piece-
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wise constant model, where the force of infection is constant within age
bands. With cut-points a0 (usually zero), a1, a2...ak, the duration of time
spent within age band i = 1, 2...k is defined as
Ai(t) =

0, if t ≤ ai−1;
t− ai−1, if t > ai−1 and t ≤ ai;
ai − ai−1, if t > ai.
For a set of age bands 1, 2...k with cut-points a0, a1, a2...ak and force of
infection λi in age band i, the survivor function is defined as:
S(t) = exp[−(λ1A1(t) + λ2A2(t) + ...+ λkAk(t))]. (3.16)
This also has the form of a GLM with log link, although unlike the constant
model, cannot be arranged to have a CLL link. Piecewise constant models
may be useful when risk periods are well-defined, such as pre-school, junior
school, secondary school and adulthood; or, if a suitably large number of
groups are used, the piecewise constant approach avoids making assump-
tions of a certain parametric shape. However, the choice of the number and
locations of cut-points may be somewhat arbitrary, and modelling the shape
of the hazard function may require a higher number of parameters than nec-
essary; in which case, a parametric function for λ(t) may be preferred. For
example, a simple choice is an exponential decline model, where risk declines
asymptotically towards zero. With λ0 the force of infection at t = 0 and ρ
the rate of decline:
λ(t) = λ0 exp(−ρt).
Substituting this into the formula for the proportion susceptible gives:
S(t) = exp
[
−
∫ t
0
λ0 exp(−ρu) du
]
= exp
[
λ0
ρ
(exp(−ρt)− 1)
]
.
This cannot be arranged in the form of a linear model, and hence it is not
possible to estimate using standard GLM routines. In this case, the likeli-
hood must be evaluated using non-linear optimisation methods as described
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in section 3.1.1. However, some other specific model forms may be fitted
within the GLM framework, such as the Weibull model, that allows for a
monotonically increasing or decreasing hazard over time and can be fitted
with a CLL link.
No matter what the functional form is used to characterise λ(t), predic-
tions for the proportion susceptible may be estimated as in section 3.1.3, and
the number of susceptibles substituted for the number of successes. Hence all
of the apparatus in section 3.1 is available for checking model fit, producing
predictions and obtaining confidence intervals.
3.2.3 Models for age and time
For many infectious diseases, changes in hygiene, sexual behaviour and other
risk factors over time are likely to result in changes in the force of infection. In
the presence of such temporal effects, older individuals will have experienced
a different force of infection in their earlier years to younger individuals, in
addition to any age-specific effects. When data are collected from a single
serological survey in the form of age-specific disease status the age-specific
risk and any temporal effects are completely confounded. However, when
multiple surveys are undertaken at different time points, it is possible to
estimate these components separately (Ades and Nokes, 1993). For age a
and survey time t, an age- and time-specific hazard λ(a, t) is defined and
S(a, t) = exp
[
−
∫ a
0
λ(u, t− a+ u) du
]
.
In the case of piecewise constant models, the force of infection may consist
of age components µi for age band i and time components φj for time band
j. With A1(a), A2(a)...Ak(a) as the durations of time spent in age band
1, 2...k, indexed by age a, as before, a similar function for calendar time,
indexed by t with cut-points t0, t1, t2...tm is defined as
Tj(a, t) =
0, if t− a > tj or t < tj−1;min(t, tj)−max(t− a, tj−1) if t− a ≤ tj and t ≥ tj−1,
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this being the duration of time spent in time band j. In the framework
of Ades and Nokes (1993) the effects of age and time combine additively to
produce the force of infection as λ(a, t) = µi+φj for age band i corresponding
to age a and time band j for time t. The cumulative hazard is then related to
the survivor function according to the age- and time-specific contributions
of the two functions. For a set of age bands i = 1, 2...k and time bands
j = 1, 2...m,
S(a, t) = exp
[
−
(
k∑
i=1
µiAi(a) +
m∑
j=1
φjTj(a, t)
)]
. (3.17)
This model assumes that the time and age effects combine additively and are
independent, i.e., there is no interaction corresponding to a change in age-
specific force of infection over time. Such an assumption could be relaxed by
the incorporation of interaction terms, or equivalently, by specifying age-time
specific bandings. In either case, the model can be fitted using standard GLM
routines. Alternatively, a model with multiplicative age and time effects for
the force of infection would require λ(a, t) = µiφj, which can no longer be
fitted as a standard GLM. In general such models will require bespoke code.
To illustrate the information contained in age-specific current status col-
lected at different time points, a Lexis diagram is displayed in Figure 3.2.
Clearly, if observations were at a single time point (e.g., the year 2000) there
would be no information to differentiate between age and time effects.
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Figure 3.2: Lexis diagram of individual exposure by age and time. Circles
denote time of observation (between 1991 and 2008), solid are infected, hol-
low uninfected. Age bands with cut-points 0, 5, 15, 30 and 45, and time
bands with cut-points 1960, 1980 and 2000 are shown on the figure.
Using the age and time bands in Figure 3.2, an individual born at the
start of 1958 and observed at the end of 2006 would have the following
piecewise constant age-time contributions (in years):
Time
Age
0-5 5-15 15-
30
30-
45
45+ Total
Pre-1960 2 0 0 0 0 2
1960-1980 3 10 7 0 0 20
1980-2000 0 0 8 12 0 20
2000 onwards 0 0 0 3 4 7
Total 5 10 15 15 4 49
Using a parameter for each individual cell corresponds to an age and time-
specific force of infection, whereas using row and column totals would imply
independence. Note that there is only information available to estimate age
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and time interactions where data are available; for instance, in the example
above no individuals were of age 30-45 or 45+ prior to 1960, nor of age 45+
in 1960-1980; therefore the force of infection in these bandings would have to
be extrapolated from other time periods or age bands. Note that although
no information on the interaction is provided outside the range of the data,
there is however a restriction on the upper bound that the FOI can take,
as the FOI in the pre-survey period must be consistent with the observed
prevalence, which should not decrease with increasing exposure time.
Some thought is required as to whether the temporal effect or the rela-
tive effect of age is assumed constant outside the range of the data. In the
following, models are considered in terms of a time-specific FOI λ0(t) at a
baseline age a0 and a function for age-specific modifications to the baseline
hazard, which may be independent of time, or allow for interactions within
the survey period. Within this framework the age-specific FOI can be esti-
mated along with any changes in this pattern during the survey, and subject
to the assumption of constant age effects outside the survey period, historical
changes in the FOI can be considered. Therefore λ(a, t) = λ0(t) + D(a, t),
where D(a, t) is the time-specific additive difference in the FOI at age a vs.
age a0 (and D(a0, t) = 0), giving
S(a, t) = exp
[
−
∫ a
0
(λ0(t− a+ u) +D(u, t− a+ u)) du
]
, (3.18)
which may be fitted as a piecewise constant model using standard GLM
routines. The general form for multiplicative age- and time-specific differ-
ences in the FOI, with R(a, t) the ratio in the FOI at age a vs. age a0 (and
R(a0, t) = 1) is
S(a, t) = exp
[
−
∫ a
0
λ0(t− a+ u)R(u, t− a+ u) du
]
, (3.19)
the piecewise constant form of which cannot be fitted using standard GLM
packages.
The components of these models may be split further into main effects
for time and age and a separate age-time interaction. This would be math-
ematically equivalent to the models in equations 3.18 and 3.19 (any set of
estimates from one model can be transformed to another) but with a different
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interpretation of the parameters. More importantly, this specification allows
for the necessary constraint that there is no age-time interaction outside the
range of the data.
Careful consideration is needed as to whether age and time effects are
independent, and whether they combine additively or multiplicatively, as
decisions on the latter will produce different estimates for the independent
models. This can of course be assessed by comparing the model fit under
additive and multiplicative assumptions. However, models that include the
full set of estimable age-time interactions are saturated in a sense, as there
is a parameter for every combination of the age and time bands. Estimates
of the proportion susceptible will then be the same for both the additive and
multiplicative model, as will the FOI within the range of the survey.
Another consideration is that the multiplicative model, in which age-time
contributions are exponentiated to obtain the FOI, is constrained to have
a positive FOI, but the additive model is not. Additive models therefore
permit negative values for the FOI where prevalence decreases with time
at risk within an age or age-time banding. The likelihood of this occurring
increases with model complexity, as with a large number of age/time bands
or interactions it becomes more likely that observed prevalence is not strictly
increasing for all age-time combinations. Piecewise constant models for age
alone can be constrained so that the force of infection for each age band
i is non-negative; however, constraining the sum of age-time contribution
parameters in the framework of Ades and Nokes (1993) is not supported by
most statistical software packages or optimisation routines. It can of course
simply be taken that negative estimates of the FOI are equivalent to zero, but
this issue also affects model fit statistics. In particular, allowing violations
of monotonically increasing prevalence with time at risk in additive models
but not multiplicative ones could skew comparisons of the two model types
in favour of additive models.
3.2.4 Parametric models
Parametric forms for the force of infection can be useful in that they require
fewer parameters to model a particular shape compared to the step-wise
changes of a piecewise constant model, particularly if expert knowledge in-
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dicates that a particular pattern in the age- or time-specific FOI is likely.
Some choices of parametric function can provide a certain degree of flexibil-
ity in addition to easily interpretable quantities: the exponentially damped
line rises to a peak before tailing off to some constant level (Farrington,
1990). This is a likely pattern for childhood infections, and the parameter
values determine the size of the peak, how long this period of elevated risk
extends for, and the level of risk that remains in adulthood. A selection of
parametric shapes are shown in Table 3.1 and Figure 3.3.
Table 3.1: A selection of parametric hazard functions discussed in Farrington
(1990) and Ades and Nokes (1993).
Name Function Values in figure 3.3
Exponential exp(−a− bt) a = 0.8, b = 0.2
polynomial (1)
Exponential exp(−a− bt− ct2) a = 0.9, b = 0.1,
polynomial (2) c = 0.05
Exponentially (at− c) exp(−bt) + d, a = 0.5, b = 0.45,
damped line b ≥ 0 c = 0.025, d = 0.025
Gompertz function a exp[− exp(−b(t− c))] + d, a = 0.15, b = 0.5,
a, d > 0 c = 10, d = 0.01
Symmetric logistic a/[1 + exp(−b(t− c))] + d, a = 0.15, b = 0.5,
a, d > 0 c = 10, d = 0.01
These functions may be deemed epidemiologically plausible for certain
applications, but in the absence of such knowledge, or more complex pat-
terns of risk according to age or time, might be too restrictive to capture
the true shape of underlying hazard. Changes over time may be particu-
larly unpredictable: more than one peak may occur, or a peak, then decline,
followed by a later, steady rise, or any other shape. It will then become
increasingly difficult to find a smooth function that will fit the data well and
still have any sensible interpretation. Polynomial or fractional polynomial
models may provide a good fit to the data (Royston, 2000), but the inter-
pretation of parameters beyond a linear trend is difficult. There is also the
difficulty of specifying interactions between age and time; Ades and Nokes
(1993) assume independent parametric functions for age and time, but the
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data may indicate that they do not combine independently, and defining a
suitable parametric function in two dimensions may be challenging.
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Figure 3.3: A selection of parametric hazard functions discussed in Far-
rington (1990) and Ades and Nokes (1993). EP1 and EP2 : exponential
polynomials of order 1 and 2 (no constant), EDL: exponentially damped
line, Gomp: Gompertz, Sym log : symmetric logistic. The latter two may
rise or fall between two asymptotes.
An alternative is the use of spline functions, piecewise polynomial func-
tions (usually cubic) that can provide any level of flexibility, often including
a smoothing component to avoid over-complexity. Such models have been
applied to current status data, providing a smooth function for the hazard
or cumulative hazard (Namata et al., 2007; Nagelkerke et al., 1999). The
flexibility of these models is appealing, but again can be challenging in two
dimensions.
3.2.5 Covariates for force of infection models
Section 3.2.3 shows how the basic model for age-specific force of infection
may be extended to include changes over time, with the combination of age-
and calendar time-specific time at risk acting as a special type of covariate.
Additional covariates may also be included in the model to allow changes
in the FOI due to other factors. The effects may be assumed to modify
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the FOI multiplicatively at all ages and/or times, which would be described
as proportional hazards in survival analysis terminology. Alternatively, the
covariate may have an interaction with age, time, or both, such that the
effect of the covariate on the FOI can vary. Finally, if the covariate itself
changes over time, then the FOI may be modified according to the time-
varying nature of the covariate. An example of this would be the age of
vaccination or uptake of some other intervention or behaviour. In this case
the FOI can change between the pre- and post-intervention periods defined
by the time-varying covariate (TVC). A TVC may also act proportionally
at all times and ages, or have a varying effect.
For a covariate with proportional hazards, the FOI at age a, time t and
covariate level x is defined as
λ(a, t, x) = λ0(a, t) exp(βx), (3.20)
where λ0(a, t) is the force of infection at the baseline level of x, which should
be set to zero for the baseline FOI to have a sensible interpretation. This
will mean centering continuous variables by subtracting the desired baseline
value. For categorical variables standard practice is to treat the baseline as
zero and other groups via 0/1 indicator variables.
As with the age-time models in section 3.2.3, the multiplicative form of
the covariate model cannot be fitted in the GLM framework, but covariates
with additive effects can. In this case
λ(a, t, x) = λ0(a, t) + βx, (3.21)
again, with the baseline value of x being zero. Considering a model with
piecewise constant age-specific FOI and a covariate x with constant, additive
differences, yields an extension to the survivor function in equation 3.16
S(a, x) = exp[−(λ1A1(a) + λ2A2(a) + ...+ λkAk(a) + βxa)]. (3.22)
Therefore the addition of the covariate is achieved by including a variable
that multiplies the individual’s age, a by the covariate x in the GLM, rather
than simply including x in the list of variables for inclusion as one would for
a logistic regression model.
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Interactions between age and the covariate, or age-specific covariate ef-
fects, in which λ(a, x) = λ0(a) + β(a)x can also be included in a GLM form
by multiplying the covariate by the time spent in age band i rather than the
total time at risk. The survivor function for this model would therefore be
S(a) = exp[−((λ1+β(1)x)A1(a)+(λ2+β(2)x)A2(a)+...+(λk+β(k)x)Ak(a))].
(3.23)
Inclusion of covariates in age-time models follows readily from this within
the additive framework, and may be parameterised with fixed differences in
the FOI at all times and ages, or with interactions with age, time or both by
relating covariates to specific ages and times and the duration spent within
each band. The most general form of covariate model with FOI dependent
on age, time and covariate effect λ(a, t, x) is therefore
S(a, t, x) = exp
[
−
(∫ a
0
λ0(u, t− a+ u, x)du
)]
, (3.24)
with any simpler model obtained by specifying independent contributions
of age and time effects in the FOI, either multiplicatively or additively. As
noted in section 3.2.3, increasing complexity of the model can result in neg-
ative FOI estimates in additive models, and this will become increasingly
likely if complex interactions are considered.
Time-varying covariates (TVC) are a further extension of the above
framework in which the covariate itself changes over time. Current sta-
tus data are by definition collected at a single time point and would not
usually include detailed time-varying information in the way that a cohort
study might, where individuals are followed up over time. TVCs in current
status data are therefore likely to consist of dichotomous changes at a sin-
gle age/time point, rather than detailed histories. An age-specific FOI with
multiplicative effect of a covariate x which changes from 0 to 1 at time ax
can be expressed as
λ(a, ax) =
λ0(a), if a < ax;λ0(a) exp(β), if a ≥ ax. (3.25)
The additive model is defined similarly with the parameter β being added to
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the baseline hazard. Again, in a piecewise constant framework the model can
be fitted as a GLM by subdividing the age bands into pre- and post-TVC,
and similarly for age and time models.
3.2.6 Concluding remarks
This chapter has outlined the basic tools for fitting models to binary data,
assessing their adequacy and between-model comparisons. These tools may
be applied to current status data via generalised linear models (GLM) where
age and time effects for the force of infection are modelled as piecewise
constant and combine additively. Some parametric forms are also available
in the GLM framework (such as the Weibull model with complementary
log-log link) but are not considered further. There are a number of reasons
for preferring piecewise constant models here: firstly, parametric models
place restrictions on the assumed shape of the FOI, which would require a
priori knowledge to justify. Secondly, the effect of covariates or age-time
interactions become difficult to parameterise. Thirdly, the focus of later
chapters shifts to heterogeneity; estimates of the FOI are somewhat less
important, but functions for the baseline FOI must be sufficiently flexible so
that they do not distort estimates of the frailty parameters.
It must be borne in mind however that age-time interactions may result
in large numbers of model parameters and model instability where data are
sparse. Resulting standard errors should therefore be checked carefully, and
simpler models considered as required. Another option is Bayesian methods,
under which semi-informative priors could be placed on model parameters to
ensure baseline FOIs or age/time-specific HRs are within a plausible range.
For instance, baseline rates may be low but not effectively zero, HRs within
bounds of 0.1 to 10, and so on; see, for instance Greenland (2001). Of course,
where there is little information to estimate a parameter, results may then
be sensitive to the choice of prior.
GLMs for the force of infection can also include covariates in the piecewise
constant framework, again assuming additivity. Implementation in standard
statistical packages could be advantageous for exploring changes in risk ac-
cording to a number of possible factors, as the inclusion of a candidate
covariate in a model is generally quick to implement. In contrast, multi-
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plicative effects are not possible to parameterise in the form of a GLM, and
must therefore be fitted by maximising the likelihood using bespoke code.
This is not only simply a software limitation: the non-linear combination of
parameters means that a general-purpose specification is difficult to achieve.
Therefore the GLM framework may be used for exploratory purposes, guid-
ing the choice of which covariates to use and how to parameterise them,
before building a multiplicative model if required.
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Chapter 4
Blood-borne viruses in people
who inject drugs: trends and
risk patterns
In this chapter the methods described in chapter 3 for analysing cross-
sectional surveillance data are applied to data collected by the Unlinked
Anonymous Prevalence Monitoring Programme (UAM). These data include
current infection status, time at risk, and a large number of self-reported risk
factors. Careful analysis of the UAM data may help to gain insights into
patterns of risk behaviour, informing public health policy and preventative
interventions. This section also aims to identify key covariates for inclusion
in models of heterogeneity in subsequent chapters.
Prevalence of blood-borne viruses (BBV) according to injecting duration,
the time at risk (analogous to age), calendar time and reported risk factors
is examined via generalised linear models (GLM). Models are then fitted
that incorporate the relationship between prevalence and time at risk via
the force of infection (FOI), as in section 3.2, to understand how the FOI
changes according to injecting duration and calendar time. Finally, models
that incorporate changes in the FOI according to different covariates are
developed.
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4.1 Prevalence and risk patterns of blood-
borne viruses
Between 1990 and 2014, 43,002 participants were sampled with information
on injecting duration and a test result for HCV, HBV or HIV. Of those sam-
pled, 13,383 (31.1%) had participated in the survey before. 32,784 (76.2%)
participants were male. The median age of those taking part in the survey
was 30 (IQR: 25-36, range: 16-68) and the median age at first injecting was
20 (IQR: 17-25, range: 12-63). The median length of injecting duration was
8 years (IQR: 3-14, range: 1-53). The overall mean prevalence of infection
with HCV, HBV and HIV was 42.1%, 20.1% and 1.1% respectively. Ob-
served prevalence was relatively high in those injecting for one year for all
infections, rising from 17.2% for those injecting for 1 year or less to 47.7%
after 10 years for HCV. For HBV, prevalence in first-year injectors was 6.0%,
rising to 22.4% after 10 years; and for HIV prevalence in first-year injectors
was 0.5%, rising to 1.4% after 10 years. 10-year results are for average preva-
lence in those injecting 10-12 years. In the following, all participants were
assumed to have been injecting for at least 1 year, rounding the injecting
duration upwards where the current age is the same as age first injected.
Figure 4.1 shows the prevalence of HCV, HBV and HIV according to
injecting duration in different survey periods. In all periods for HCV and
HBV and more recent periods for HIV, there is a relatively abrupt increase
in prevalence from 0 to 1 year of injecting duration, after which prevalence
increases more slowly. For HCV, prevalence generally decreased over time
from 1990 to 2000 and increased again recently (as noted by Sweeting et al.
(2009b)). After the first year of injecting, HCV prevalence according to
injecting duration has a pattern that is consistent with a constant FOI,
i.e., S(t) = exp(−ct). Conversely, HBV prevalence decreases over the survey
period, and appears less likely to have a constant force of infection, especially
in recent survey years: the flatter trajectory does not seem to suggest a
constant FOI. These observations point to temporal changes in the FOI and
potential interactions between time and injecting duration.
For HIV, patterns of prevalence are more irregular as there are far fewer
infections, although there are some visible patterns. In the earliest 1990-1994
survey period, prevalence was low in those with injecting durations of up to
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7-8 years but increased markedly for longer durations. These individuals
would have been at risk during the peak of the 1980s epidemic, before harm
reduction campaigns were introduced. This peak in infections is evident
in later survey years at longer injecting durations, with prevalence generally
remaining low in those that had not started injecting prior to 1990. However,
prevalence does decrease in this cohort over time, which could potentially
be due to a selection effect from higher mortality rates in those infected
early in the epidemic (see, e.g., Ades and Medley (1994)). Of note is that
prevalence at shorter injecting durations rises somewhat in the surveys from
2005 onwards, indicating an increased risk of infection in newer injectors (as
noted by Hope et al. (2014)).
4.1.1 Generalised linear models for HCV by age and
time
The relationship between injecting duration and calendar time and HCV
prevalence was modelled via a GLM with a logistic link, producing esti-
mated odds ratios (OR) for different covariate levels in comparison to a
baseline category. Injecting duration was categorised with cut-points of 1,
2, 3, 5, 7, 9, 12, 15, 20, 25, 30 and 35. As prevalence is expected to increase
continuously with exposure time, a relatively large number of groups are
required to accurately capture the relationship between injecting duration
and prevalence. The chosen cut-points result in approximately equal-sized
groups up to 15 years (ranging from 3262-5699) but numbers injecting for
longer durations fall rapidly beyond this. Fewer categories were used for
survey year, with a four-year group for the earliest survey years, 1990-1993,
then three-year groups subsequently: 1994-1996, 1997-1999 ... 2012-2014;
again, each group is of roughly equal size (4500-6359).
Table 4.1 shows resulting model coefficients for a GLM with logistic link
fitted to the HCV prevalence data, with main effects for injecting duration
(baseline 5-6 years) and survey period (baseline 2006-2008). The constant
term for log odds in the baseline category is -0.79 (95% CI -0.87, -0.70)
indicating HCV prevalence of around 31% in those injecting for 5-6 years in
survey years 2006-2008. As expected, the ORs show a monotonic increase
in prevalence with injecting duration. Risk in the first year of injecting is
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Figure 4.1: Prevalence of HCV, HBV and HIV by injecting duration in differ-
ent survey periods, point estimates and 95% binomial confidence intervals.
Injecting durations are grouped at longer durations to maintain adequate
size groups, and durations longer than 35 years are omitted for clarity.
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obviously high, with the OR vs. 5-6 years indicating only around half the
odds (0.44) of infection at 1 year. The effect for time is more interesting,
with higher prevalence in 1990-1993 vs. 2006-2008 (OR=1.57), followed by
a possible decline (OR=0.93 for 2000-2002); then a further rise in recent
years (OR=1.27 for 2012-2014). This pattern was noted by Sweeting et al.
(2009b), who found a similar pattern after adjusting for additional covariates
and the imperfect sensitivity of earlier tests. The true prevalence in early
survey years is likely to be higher than indicated by the ORs in Table 4.1
due to imperfect sensitivity.
Table 4.1: Model coefficients for injecting duration and survey period, main
effects model fitted to HCV data, exponentiated to give odds ratios (ORs)
(except constant).
OR 95% CI Z-val p-val
Injecting duration
1 0.44 0.39, 0.49 -15.39 <0.001
2 0.54 0.48, 0.61 -10.25 <0.001
3-4 0.74 0.67, 0.82 -6.10 <0.001
5-6 1 (ref)
7-8 1.28 1.16, 1.41 5.00 <0.001
9-11 1.66 1.52, 1.81 11.22 <0.001
12-14 2.10 1.92, 2.31 15.71 <0.001
15-19 2.89 2.64, 3.16 23.10 <0.001
20-24 4.22 3.79, 4.69 26.40 <0.001
25-29 5.72 4.94, 6.62 23.47 <0.001
30-34 6.76 5.47, 8.36 17.66 <0.001
35+ 9.74 6.83, 13.90 12.56 <0.001
Survey period
1990-1993 1.57 1.40, 1.77 7.56 <0.001
1994-1996 1.04 0.95, 1.14 0.89 0.376
1997-1999 0.99 0.91, 1.08 -0.20 0.845
2000-2002 0.93 0.86, 1.00 -1.86 0.063
2003-2005 1.18 1.09, 1.28 3.94 <0.001
2006-2008 1 (ref)
2009-2011 1.19 1.09, 1.29 4.01 <0.001
2012-2014 1.27 1.16, 1.38 5.49 <0.001
Constant -0.79 -0.87, -0.70 -18.21 <0.001
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The resulting deviance from the main effects model presented in Table
4.1 was 962 on 768 degrees of freedom, which indicates that the model fit
is not quite satisfactory; one would hope for the deviance to be roughly
equal to the degrees of freedom (section 3.1.3). Including interaction terms
for injecting duration category and survey period provides an indication of
whether the lack of fit is due to systematic changes in the relationship be-
tween prevalence and injecting duration according to survey period. The
interaction model gave a deviance of 730 on 692 degrees of freedom, which
is an acceptable fit. However, this model uses 117 parameters and only a
handful of interaction terms are significant, so it is rather inefficient. Figure
4.2 shows the observed data by year and injecting duration and the model
fit of the main effects and interaction models. In some places the interaction
model is clearly performing better, particularly between 1992-1998. How-
ever, the interaction model does not look as if it provides a better fit to
the data for later years. This is further borne out by plots of the residual
deviances, shown in Figure 4.3. There appear to be some patterns to the
residuals between 1990-1998, with something of a downward trend for 1992
for injecting duration between 1-18 years vs. a sharp upward trend in 1998.
A runs test indicated non-randomness of residuals across injecting duration
for the main effects model (p = 0.007), although not for the interaction model
(p = 0.260). In subsequent years both models have a fairly random scatter.
This is of note, as many key covariates are only available from 2000, so the
interaction may not be necessary for covariate models that only use more re-
cent data. Finally, Figure 4.4 shows histograms and quantile-quantile (QQ)
plots of the residuals from main effect and interaction models. Both have
an approximately normal distribution, but the main effects model has vari-
ance greater than 1 and both models exhibit divergence from the theoretical
distribution at the tails.
Re-fitting the models to data from 2000 onwards, the deviance for the
main effects model is 659 on 601 degrees of freedom and the interaction model
555 on 557 degrees of freedom; a moderately good fit for the main effects and
very good for the interaction model. However, both models still show some
visible patterns in the residuals, particularly for those injecting for less than
10 years in the year 2000, and some extreme outliers. Although the overall
fit is better for the interaction model, the most extreme outliers generally
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occur in both models. Figures 4.5, 4.6 and 4.7 show observed/predicted
HCV prevalence, deviance residuals by injecting duration and calendar time
and the distributions of residuals respectively under the main effects and
interaction model for data from 2000 onwards.
81
0
.2
.4
.6
.8
1
0
.2
.4
.6
.8
1
0
.2
.4
.6
.8
1
0
.2
.4
.6
.8
1
0 5 10 15 20 25 30 35 0 5 10 15 20 25 30 35 0 5 10 15 20 25 30 35 0 5 10 15 20 25 30 35 0 5 10 15 20 25 30 35
0 5 10 15 20 25 30 35 0 5 10 15 20 25 30 35 0 5 10 15 20 25 30 35 0 5 10 15 20 25 30 35 0 5 10 15 20 25 30 35
0 5 10 15 20 25 30 35 0 5 10 15 20 25 30 35 0 5 10 15 20 25 30 35 0 5 10 15 20 25 30 35 0 5 10 15 20 25 30 35
0 5 10 15 20 25 30 35 0 5 10 15 20 25 30 35 0 5 10 15 20 25 30 35 0 5 10 15 20 25 30 35 0 5 10 15 20 25 30 35
1992 1994 1996 1998 1999
2000 2001 2002 2003 2004
2005 2006 2007 2008 2009
2010 2011 2012 2013 2014
Main effects Interaction
P
r
e
v
a
l
e
n
c
e
Injecting duration (years)
Figure 4.2: Observed and predicted HCV prevalence by injecting duration and survey year; main effects of injecting duration
and calendar time, and interaction model. 95% binomial confidence intervals are displayed around the observed prevalence.
Note that testing for HCV was only conducted for a subset of participants in 1992, 1994 and 1996 prior to 1998.
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Figure 4.3: Deviance residuals by injecting duration and survey year from main effects and interaction models fitted to
HCV prevalence data. Reference lines are the 2.5/97.5th and 0.1/99.9th percentiles of the standard normal distribution.
Note that testing for HCV was only conducted for a subset of participants in 1992, 1994 and 1996 prior to 1998.
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Figure 4.4: Distributions of deviance residuals from main effects and interac-
tion models fitted to HCV prevalence data. Histograms with normal density
overlaid and quantile-quantile plots.
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Figure 4.5: Observed and predicted HCV prevalence from 2000 onwards by injecting duration and survey year; main effects
of injecting duration and calendar time, and interaction model. 95% binomial confidence intervals are displayed around the
observed prevalence.
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Figure 4.6: Deviance residuals by injecting duration and survey year from main effects and interaction models fitted to
HCV prevalence data from 2000 onwards. Reference lines are the 2.5/97.5th and 0.1/99.9th percentiles of the standard
normal distribution.
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Figure 4.7: Distributions of deviance residuals from main effects and interac-
tion models fitted to HCV prevalence data from 2000 onwards. Histograms
with normal density overlaid and quantile-quantile plots.
4.1.2 Age and time patterns for HBV infection
The age and time models from section 4.1.1 were fitted to the data on HBV
infection. The constant term (-2.44) indicated HBV prevalence of 8% in
those injecting for 5-6 years in survey years 2006-2008. The ORs for inject-
ing duration from the main effects model follow a broadly similar pattern to
HCV, but are more extreme for longer injecting durations, although the con-
stant (logit prevalence at baseline) is lower (Table 4.2. The temporal effect
is very different though, with a much greater risk in 1990-1993 compared
to 2006-2008 (OR=3.94) and subsequently decreasing; instead of the ORs
increasing again for more recent survey years, the ORs continue to decline
(0.63 in 2012-2014). Figure 4.8 shows observed and predicted prevalence
from the main effects and age/time interaction models.
The deviance of the main effects model was 1295 on 919 degrees of free-
dom, which is somewhat inadequate. The interaction model provided a sig-
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nificantly better overall fit than the main effects model (likelihood ratio test
χ2 = 182.4 on 77 degrees of freedom, p < 0.0001), but in terms of absolute
fit was also inadequate, with a deviance of 1113 on 842 degrees of freedom.
Note that the number of observations is larger for the HBV data, which has
been collected every year since the inception of the survey. Similarly to the
HCV data, much of the lack of fit occurs in data from earlier survey peri-
ods, with both models fitting particularly badly for 1990 and 1991, with a
downward trend in residuals according to injecting duration for 1990 and an
upward trend for 1991 (Figure 4.9). Runs tests of deviance residuals across
injecting duration indicated non-randomness in the years 1990 (p < 0.001),
1999 (p = 0.015) and 1999 (p = 0.025) for the main effects model. From
2000 onwards there was less evidence of non-randomness, with an overall
p-value of 0.076 for the main effects model. Figure 4.10 shows histograms
and quantile-quantile (QQ) plots of the residuals from main effect and inter-
action models. Both have an approximately normal distribution, although
there is an apparent spike in the distribution of residuals for the main effects
model that is not present in the interaction model. Further investigation
of the distribution showed no specific pattern in the binomial data (for in-
stance, small counts of 1 or 2) or covariates associated with the spike: the
distribution is simply somewhat lumpy.
Marked differences between one year and the next cannot be captured
by broad categories for temporal effects whether an interaction is included
or not. The only alternative would be to include individual year effects,
although it seems unlikely that underlying prevalence would change so
markedly in successive years; more likely, there are substantial differences
in the sampling frame and survey methodology in the earlier years of the
survey.
Restricting to 2000 onwards as before results in a deviance of 785 on 600
degrees of freedom for the main effects model and 710 on 556 degrees of
freedom for the interaction model; both models providing a somewhat inad-
equate fit to the data. Examination of the residuals reveals some patterns
in specific years of the survey and some extreme outliers, rather than sys-
tematic deviations that persist across different years. These outliers occur
both in the main effects and interaction models, and therefore correspond to
variability in prevalence within a particular time or injecting duration band.
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As the categories are already relatively small, it seems reasonable to consider
this excess variability as overdispersion rather than a failure to adequately
describe the structural part of the model. Such factors could of course be due
to changes in risk factors in those recruited in particular years, and therefore
could be captured if other risk information from the questionnaire data is
included in the model.
Table 4.2: Model coefficients for injecting duration and survey period, main
effects model fitted to HBV data, exponentiated to give odds ratios (ORs)
(except constant)
OR 95% CI Z-val p-val
Injecting duration
1 0.42 0.37, 0.49 -11.71 <0.001
2 0.63 0.55, 0.74 -6.01 <0.001
3-4 0.83 0.73, 0.94 -2.99 0.003
5-6 1 (ref)
7-8 1.33 1.18, 1.50 4.65 <0.001
9-11 1.85 1.66, 2.06 11.18 <0.001
12-14 2.64 2.37, 2.95 17.19 <0.001
15-19 3.99 3.59, 4.44 25.58 <0.001
20-24 5.62 5.00, 6.31 29.15 <0.001
25-29 8.36 7.27, 9.62 29.74 <0.001
30-34 13.31 11.03, 16.07 26.97 <0.001
35+ 19.62 14.78, 26.06 20.56 <0.001
Survey period
1990-1993 3.94 3.57, 4.35 27.14 <0.001
1994-1996 2.06 1.86, 2.27 14.27 <0.001
1997-1999 1.56 1.41, 1.73 8.53 <0.001
2000-2002 1.66 1.50, 1.84 9.79 <0.001
2003-2005 1.43 1.28, 1.59 6.55 <0.001
2006-2008 1 (ref)
2009-2011 0.69 0.61, 0.77 -6.21 <0.001
2012-2014 0.63 0.56, 0.70 -7.91 <0.001
Constant -2.44 -2.55, -2.32 -42.26 <0.001
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Figure 4.8: Observed and predicted HBV prevalence by injecting duration and survey year; main effects of injecting duration
and calendar time, and interaction model. 95% binomial confidence intervals are displayed around the observed prevalence.
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Figure 4.9: Deviance residuals by injecting duration and survey year from main effects and interaction models fitted to
HBV prevalence data. Reference lines are the 2.5/97.5th and 0.1/99.9th percentiles of the standard normal distribution.
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Figure 4.10: Distributions of deviance residuals from main effects and in-
teraction models fitted to HBV prevalence data. Histograms with normal
density overlaid and quantile-quantile plots.
4.1.3 Age and time patterns for HIV infection
Finally, GLMs for age and time were fitted to the HIV data. Prevalence is far
lower than the other two infections, so results were far less precise; further,
the categorisation used previously leads to over-fitting (data not shown).
Broader categories were therefore used, with survey period grouped into 5-
year intervals (1990-1994 etc.) and injecting duration as 1, 2-4, 5-9, 10-14,
15-19, 20-34 and 35+, with 2005-2009 and 5-9 as the baseline groups. Table
4.3 shows that the prevalence in the baseline category of 5-9 years injecting
in survey years 2005-2009 was around 0.7%. The odds of infection with HIV
at 0-1 and 2-4 years injecting were not significantly less than 5-9 years; and
the increase in odds with injecting duration was not quite monotonic, even
with the broader categories.
As with the other infections the OR for the earliest period, 1990-1994,
was highest at 1.21 (although the p-value was 0.139) followed by a decline in
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Table 4.3: Model coefficients for injecting duration and survey period, main
effects model fitted to HIV data, exponentiated to give odds ratios (ORs)
(except constant). Categories are broader than HCV/HBV due to sparse
data.
OR 95% CI Z-val p-val
Injecting duration
1 0.75 0.47, 1.21 -1.18 0.240
2-4 0.72 0.48, 1.08 -1.58 0.113
5-9 1 (ref)
10-14 2.62 1.95, 3.53 6.36 <0.001
15-19 4.20 3.10, 5.69 9.30 <0.001
20-34 3.95 2.91, 5.37 8.77 <0.001
35+ 4.61 1.97, 10.78 3.52 <0.001
Survey period
1990-1994 1.21 0.94, 1.57 1.48 0.139
1995-1999 0.62 0.47, 0.82 -3.40 0.001
2000-2004 0.72 0.55, 0.95 -2.32 0.020
2005-2009 1 (ref)
2010-2014 0.61 0.46, 0.81 -3.44 0.001
Constant -4.92 -5.20, -4.63 -34.06 <0.001
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prevalence before increasing again in 2005-2009; although the odds of HIV
were then lower for 2010-2014 vs. 2005-2009 (OR=0.61). The deviance of
the main effects model was 875 on 928 degrees of freedom, indicating that the
model may be over-fitting somewhat. Examination of the deviance residuals
(Figure 4.12) indicates that both the main effects and the interaction models
tend to have small, negative deviance residuals for most data points, with a
smaller number of extreme positive outliers. This is due to the sparsity of
the data; most HIV counts are zero and the model produced overestimates of
prevalence, but for non-zero counts the model produced marked underesti-
mates. Neither a main effects or interaction model can capture this (short of
specifying a parameter for every survey year/injecting duration combination
in the saturated model); therefore although the interaction model appar-
ently produces a better fit to the data (likelihood ratio test χ2 = 93.5 on
24 degrees of freedom, p < 0.0001) the extra parameters do not materially
improve the model.
Figures 4.11, 4.12 and 4.13 show observed and predicted prevalence by in-
jecting duration and time, deviance residuals and their distributions respec-
tively. Runs tests of deviance residuals across injecting duration strongly
indicated non-randomness, with p-values of less than 0.001 for both main
effects and interaction models. Clearly assumptions of asymptotic normality
do not apply due to the sparsity of the data, and there is little that can
be done about this, short of specifying a far simpler model; the information
provided in terms of differences in HIV prevalence according to injecting
duration and time is far lower than for HCV or HBV.
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Figure 4.11: Observed and predicted HIV prevalence by injecting duration and survey year; main effects of injecting duration
and calendar time, and interaction model. 95% binomial confidence intervals are displayed around the observed prevalence.
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Figure 4.12: Deviance residuals by injecting duration and survey year from main effects and interaction models fitted to
HIV prevalence data. Reference lines are the 2.5/97.5th and 0.1/99.9th percentiles of the standard normal distribution.
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Figure 4.13: Distributions of deviance residuals from main effects and in-
teraction models fitted to HIV prevalence data. Histograms with normal
density overlaid and quantile-quantile plots.
4.1.4 Generalised linear models with covariates
In this section the models for injecting duration and survey year in section
4.1.1 are extended to include additional covariates, based on the information
provided in the UAM questionnaire. Including data on participant charac-
teristics and injecting behaviour can provide insights into risk factors for
infection and may also help to account for overdispersion in prevalence ac-
cording to injecting duration and time, which was observed in sections 4.1.1
to 4.1.3. If survey participants vary in characteristics over time, which is
quite possible in the UAM data as the service providers sampled vary from
year to year, then accounting for these changes will reduce variation in the
temporal component of the model. This will then provide a better indication
of underlying trends in the overall risk of infection.
Available covariates include age, gender and government office region, the
latter consisting of East of England (EE), London, South East (SE), South
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West (SW), West Midlands (W Mids), North West (NW), Yorkshire and the
Humber, East Midlands (E Mids), North East (NE) and Wales. SE was taken
as the baseline category for region; London and NW had the largest sample
sizes but also had higher prevalence of HCV and HIV, with lower prevalence
in more rural regions, and SE somewhere in between. Including age as
a covariate requires some caution as it is highly correlated with injecting
duration, with age at first use generally being in early adulthood. Age was
therefore parameterised in terms of age first injected, which results in a model
mathematically equivalent to including current age (if injecting duration
and time effects are included), but provides parameter estimates that are
more easily interpreted. In order to continue model assessment in terms of
categorical variables, age at first use (AAFU) was categorised as < 18, 18-24
and 25+. 93% of participants reported AAFU as 30 or below, so there is
little scope for further investigation of differences at older ages.
In addition to the demographic variables above, information on risk be-
haviour was considered. These variables include ever received works, i.e.,
used drug equipment and paraphernalia, principally needles or syringes, from
another drug user; ever used a needle exchange and age first used; ever been
in prison and age first imprisoned; number of days injected in the last 28
days; and sexual activity/risk in the last year including number of male and
female partners and condom use (always, sometimes and never).
The variables used in the analysis were coded as follows. Ever received
works is binary. Use of needle exchange is categorised as used from the first
year of injecting, used at some point following first year of injecting, and
never. Imprisonment is categorised as never imprisoned, first been to prison
before started injecting, and first been to prison after started injecting. Days
injecting is categorised as injecting for 14 or more days of the last 28, or fewer.
Variables for sexual risk are defined as two or more partners vs. none or one,
incomplete condom use (sometimes/never vs. always), and men who have
sex with men (MSM), defined as one or more male partners for males.
Many of these variables are only available from the year 2000 onwards, as
the UAM questionnaire has evolved and expanded over time, and therefore
analyses are restricted to these years, leaving 25280 observations available
for analysis. There are also missing data for a number of responses. Table
4.4 shows the available data for each of the covariates, and overall. The
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amount of missing data is less than 5% for most of the variables, but over
20% are missing for number of partners and condom use, meaning that over
a quarter of the observations would be discarded in a complete case analysis.
Age, sex and region are complete for all observations.
Table 4.4: Available data for key covariates in the UAM data from 2000
onwards, percentage of complete data from 25280 observations.
Variable % complete
Ever received works 98.8%
Needle exchange 99.3%
Prison 97.5%
Number of partners 79.9%
Condom use 78.0%
MSM 96.9%
Complete cases 74.4%
Generalised linear models (GLM) with a logit link were then fitted to the
data from 2000 onwards with complete data for all of the variables above.
Of the three infections, 4 observations were missing HBV test results, so
these were excluded also to give 17116 observations with no missing data.
Variables were considered without interactions in a 3-stage approach: the un-
adjusted effect of each variable on prevalence; an intermediate stage where
injecting duration and survey period are adjusted for; and a full multivari-
able model including all covariates. The intermediate stage was performed
as a check to see if each covariate in isolation was confounded with inject-
ing duration and/or survey year, although these results are only discussed
where of special interest and the main focus is on the univariable and full
multivariable results in the following.
4.1.5 Risk factors for HCV infection
Results for HCV from are shown in tables 4.5 and 4.6. Odds ratios (OR) for
injecting duration and survey year do not change much between univariable
and multivariable (MV) analyses, although there is slight attenuation in the
injecting duration-specific ORs. There was a strong effect of region, with
East of England, SW, W Mids, E Mids, NE and Wales having lower odds
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of HCV compared to SE England; but higher risks in London (OR=1.34,
MV) and NW (OR=1.77, MV). Results were generally similar for univari-
able and multivariable analyses. Age at first use shows an increased risk
for <18 (OR=1.35) and a slight decrease for 25+ (OR=0.95) compared to
18-24 in univariable analyses; however, after adjusting for other covariates
the relationship is almost exactly reversed, with higher risk for 25+ and a
slight decrease for <18. The difference is largely due to adjusting for in-
jecting duration, as in the univariable analysis those that began injecting at
a later age will, on average, have shorter injecting durations. Females had
no difference in risk for univariable analysis but higher risk in multivariable
analyses; this is again due to adjusting for injecting duration, as females tend
to have shorter injecting duration (median 6 vs. 9 for males) but comparable
prevalence levels.
Ever receiving works from another PWID was associated with a higher
risk of HCV infection, with an OR of 1.73, which persisted after adjusting
for other variables. Needle exchange use showed some interesting univariable
results, with an increased risk of HCV (OR=1.65) for those beginning to use
a needle exchange after 1 year vs. starting in their first year of injecting,
but a decreased risk in those that had never used a needle exchange. In
the multivariable model, there was no difference in using a needle exchange
before or after one year of injecting. Some care is required in the interpreta-
tion of these results however, as 1st year injectors must by definition either
start using needle exchange in their first year or be classed in the survey
as “never”. The OR for never using a needle exchange is rather counterin-
tuitive; a possible explanation is that this group are less frequent injectors
or otherwise have lower levels of opiate dependence. However, the result
did not change in the multivariable analysis, which includes information of
frequency of injecting and other measures of the potential “riskiness” of the
individual. In fact, the number of days injecting in the last month showed
little association in multivariable analyses.
Imprisonment was a significant risk factor, with ORs of 1.82 and 2.13
for having been to prison before or after started injecting in the multivari-
able analysis. The similarity of the ORs indicates that there may be little
difference in the timing of first prison sentence. Sexual behaviour variables
were difficult to interpret: there was no significant difference in the number
100
of partners but, strangely, a protective effect for incomplete condom use.
Although sexual transmission is thought to be rare (Balogun et al., 2003),
more risky sexual behaviour might be thought to be correlated with more
risky injecting behaviour, rather than the reverse. Being a MSM was asso-
ciated with an increase in risk; although sexual transmission is uncommon
in general, the MSM population does have a higher risk of HCV infection
due to certain high-risk sexual practices and HIV co-infection (van de Laar
et al., 2007). Model fit for the multivariable model cannot be assessed in
the same way as section 4.1.1 as the deviance relies on a sufficient number of
binomial observations for each data point. The aggregated data for the anal-
ysis above consist of 14623 combinations of the explanatory variables with
87% consisting of a single observation, and are therefore practically binary.
The Hosmer-Lemeshow statistic based on deciles of the linear predictor gives
a p-value of 0.308, indicating no evidence of a lack of fit; however, the test
is quite sensitive to the chosen percentiles; with 15 equal-size groups the
p-value is 0.033.
Having added covariates to the main effects model for injecting duration
and survey period in section 4.1.1, the presence of interactions was assessed,
starting with the interaction between injecting duration and survey period
to determine whether the interaction observed in section 4.1.1 was still nec-
essary after accounting for other risk factors. The likelihood ratio (LR) test
gave a p-value of 0.055, although model selection scores indicated that the
model may be over-parameterised, with an AIC score of 19574.7 for the main
effects model vs. 19602.7 with the addition of interactions.
Interactions between the other covariates and injecting duration and sur-
vey year were also assessed. Such interactions could arise from a variety of
causes, such as changes in prevalence over time in a particular region, dif-
ferences in risk pattern according to injecting duration in males and females
due to different risk behaviours, and so on. For injecting duration, there
were significant interactions with age at first use and prison, and possibly
ever receiving works. For survey year, there were significant interactions
with region, gender, ever receiving works and use of needle exchange. To
summarise the key findings, first-year injectors that began injecting before
the age of 18 had an increased risk of infection (OR=2.04, 95%CI 1.19-3.50),
as well as first-year injectors that had been to prison before starting injecting
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Table 4.5: Univariable and multivariable results from logistic regression
model for HCV and reported risk factors. Odds ratios and 95% confidence
intervals
Variable Univariable Multivariable
Injecting duration 0-1 0.48 (0.41, 0.57) 0.50 (0.42, 0.59)
2 0.57 (0.48, 0.67) 0.60 (0.50, 0.71)
3-4 0.82 (0.71, 0.94) 0.82 (0.71, 0.95)
5-6 1 (ref) 1 (ref)
7-8 1.34 (1.16, 1.54) 1.29 (1.11, 1.49)
9-11 1.75 (1.54, 1.99) 1.60 (1.40, 1.83)
12-14 2.21 (1.93, 2.52) 1.93 (1.68, 2.23)
15-19 3.18 (2.79, 3.61) 2.67 (2.31, 3.07)
20-24 4.94 (4.24, 5.75) 4.16 (3.52, 4.91)
25-29 6.46 (5.22, 8.00) 5.47 (4.33, 6.89)
30-34 8.87 (6.46, 12.18) 7.62 (5.45, 10.65)
35+ 9.29 (5.57, 15.49) 8.02 (4.68, 13.74)
Survey period 2000-2002 0.81 (0.74, 0.89) 0.93 (0.84, 1.03)
2003-2005 1.15 (1.04, 1.26) 1.15 (1.03, 1.28)
2006-2008 1 (ref) 1 (ref)
2009-2011 1.29 (1.17, 1.42) 1.23 (1.10, 1.37)
2012-2014 1.55 (1.40, 1.71) 1.53 (1.37, 1.72)
Region East of England 0.54 (0.46, 0.64) 0.56 (0.47, 0.67)
London 1.47 (1.30, 1.65) 1.34 (1.17, 1.53)
South East 1 (ref) 1 (ref)
South West 0.51 (0.45, 0.57) 0.54 (0.47, 0.62)
West Midlands 0.45 (0.38, 0.52) 0.49 (0.41, 0.58)
North West 1.71 (1.52, 1.93) 1.77 (1.55, 2.02)
Yorkshire and H 1.40 (1.18, 1.66) 1.09 (0.91, 1.32)
East Midlands 0.76 (0.67, 0.87) 0.83 (0.72, 0.96)
North East 0.34 (0.30, 0.38) 0.48 (0.42, 0.56)
Wales 0.44 (0.37, 0.52) 0.43 (0.36, 0.51)
Age at first use <18 1.35 (1.25, 1.45) 0.93 (0.85, 1.02)
18-24 1 (ref) 1 (ref)
25+ 0.95 (0.88, 1.03) 1.29 (1.18, 1.41)
Gender Male 1 (ref) 1 (ref)
Female 1.00 (0.93, 1.07) 1.50 (1.38, 1.64)
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Table 4.6: Continued from 4.5: Logistic regression model results for HCV.
Variable Univariable Multivariable
Ever rec’d works No 1 (ref) 1 (ref)
Yes 1.73 (1.63, 1.84) 1.67 (1.56, 1.80)
Needle Started 1st year 1 (ref) 1 (ref)
exchange Started >1 yr 1.65 (1.55, 1.76) 1.00 (0.93, 1.08)
Never 0.61 (0.49, 0.77) 0.71 (0.56, 0.92)
Days injecting <14 days/mo 1 (ref) 1 (ref)
per month 14+ days/mo 0.88 (0.83, 0.94) 1.03 (0.96, 1.11)
Prison Never imprisoned 1 (ref) 1 (ref)
Prison before injecting 2.61 (2.40, 2.83) 1.82 (1.65, 2.01)
Prison after injecting 2.18 (2.01, 2.35) 2.13 (1.95, 2.34)
Number of 0 or 1 partner 1 (ref) 1 (ref)
partners 2+ partners 0.86 (0.80, 0.91) 0.96 (0.90, 1.04)
Condom use Always 1 (ref) 1 (ref)
Sometimes/never 0.78 (0.73, 0.84) 0.79 (0.73, 0.86)
MSM No 1 (ref) 1 (ref)
Yes 1.26 (1.03, 1.54) 1.25 (0.99, 1.57)
(OR=3.14, 95% CI 1.82-5.42). Estimates for interactions with other inject-
ing durations were generally non-significant and had no particular pattern
according to injecting duration.
The interaction between survey period and region is shown in Figure
4.14 by way of predicted probabilities of HCV infection. The general trend
in SE England is of increasing prevalence over time. Significant interactions
therefore occur for East England, which has less of a trend, and Wales, which
has a higher prevalence in 2000-2002 and increases sharply in 2012-2014
(OR=2.90, 95% CI 1.70-4.93). A number of other regions show significant
differences in individual years, with relatively higher prevalence in W Mids
in 2000-2002, Yorkshire and the Humber in 2003-2005, and NE in 2000-2002;
and lower prevalence in the NW in 2009-2011.
The interaction between gender and survey period showed a further in-
crease in risk of infection in females in 2012-2014 (OR=1.45, 95% CI 1.13-
1.87), but no difference in other periods. Ever receiving works was associated
with increased risk in 2003-2005 (OR=1.26, 95% CI 1.02-1.56) and 2012-2014
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Figure 4.14: Predicted HCV prevalence by region and survey period with
95% confidence intervals, multivariable logistic model adjusting for main
effects of all risk factors and region/survey period interaction. Predictions
are made at baseline levels of other risk factors; e.g., injecting duration 5-6
years.
(OR=1.36, 95% CI 1.08-1.71), with no difference in other periods. Finally,
never using a needle exchange was associated with increased risk in 2000-
2002 (OR=2.03, 95% CI 0.97-4.23), with no difference in other periods.
At the risk of over-complicating the model and its interpretation, there
were also significant interactions between a number of risk factors in addi-
tion to the interactions described above. A base model was specified with
main effects and the survey period/region interaction, which was by far the
strongest, and the addition of interactions for other variables compared to
this model via likelihood ratio tests. Interactions were identified between
region and age at first use (p=0.002), gender (p=0.001), needle exchange
(p=0.004) and prison (p=0.006); and possibly days injecting (p=0.066). All
p-values are for LR tests. p-values for all possible two-way interactions are
shown in Table 4.7.
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Table 4.7: Interactions between risk factors for HCV, likelihood ratio test
p-values for generalised linear model with main effects, region/survey year
interaction and interaction of interest. MSM/female interaction is not de-
fined.
region aafu female erec exch d14 pris part2 cond
aafu 0.002
female 0.001 0.597
erec 0.121 0.942 0.251
exch 0.004 0.889 0.249 0.045
d14 0.066 0.993 0.965 0.359 0.400
pris 0.006 0.838 0.064 0.215 0.101 0.825
part2 0.343 0.457 0.866 0.059 0.054 0.006 0.721
cond 0.524 0.005 0.936 0.100 0.636 0.582 0.536 0.914
msm 0.937 0.906 . 0.977 0.506 0.142 0.222 0.454 0.762
aafu: age at first use, erec: ever received works, exch: needle exchange use,
d14: injected 14 or more days in last month, pris: imprisonment, part2: two or
more sexual partners, cond: condom use, msm: men who have sex with men.
4.1.6 Risk factors for HBV infection
The models described in section 4.1.4 were fitted to the HBV data and are
reported more succinctly in the following. Covariate effects for the main
effects models for injecting duration, survey period and reported risk fac-
tors are displayed in tables 4.8 and 4.9. Region showed a similar pattern
to HCV with somewhat higher prevalence in London (OR=1.24, MV) and
higher in the NW (OR=1.98, MV). In general, the regional differences where
less extreme. Age at first use showed the same pattern as HCV in univari-
able and multivariable results, with higher risk for those starting age 25+
in multivariable analyses. Risk was slightly higher in females (OR=1.26)
and for those that had ever received works (OR=1.24). First use of needle
exchange after the first year of injecting was associated with a small in-
crease in risk compared to uptake in the first year (OR=1.12) and also never
used (OR=1.23) although the latter was not significant. Days injecting per
month and number of partners showed no effect. Ever being imprisoned was
associated with increased risk, but not as high as HCV, with ORs of 1.29
and 1.45 for imprisonment before and after started injecting respectively.
Imperfect condom use showed a slight protective effect compared to always
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using a condom; and MSM had an increase in risk, with an identical OR
to HCV (1.25). It is somewhat surprising that the sexual risk factors did
not play more of a role for HBV, which is much more easily transmitted via
the sexual route than HCV. The goodness of fit for the multivariable model
was unclear; the Hosmer-Lemeshow p-value was 0.071 for deciles of the pre-
dicted probabilities, but again sensitive to the number of groups used; with
15 equal-width groups of the predicted probabilities the p-value was 0.145.
However, neither indicate a severe lack of fit.
After adjusting for other risk factors, the LR test for an interaction be-
tween injecting duration and survey year gave a p-value of 0.061, with AIC
scores preferring the simpler model (13064.4 vs. 13093.0). There were no
significant interactions between injecting duration and other risk factors, but
a number of interactions with survey period, including region (p < 0.001),
gender (p < 0.001), needle exchange (p=0.040) and injecting 14 or more days
per month (p=0.011). Females had a relatively lower risk of HBV infection
in earlier survey periods, with ORs of 0.53 (95% CI 0.40-0.72) for 2000-2002
and 0.61 (95% CI 0.45-0.83) for 2003-2005 vs. 2006-2008; and those injecting
for 14 or more days per month had a higher risk in 2000-2002 (OR=1.55,
95% CI 1.19-2.02) and 2012-2014 (OR=1.40, 95% CI 1.02-1.91). Region and
time again showed the strongest interaction, and is summarised by way of
predicted HBV prevalence in Figure 4.15. SE England, the baseline group,
has a relatively stable trend but somewhat lower prevalence to other regions
in 2000-2002, therefore many regions have a significant interaction for this
period. NW England, East Midlands and West Midlands all have a decline
in prevalence of around two-thirds, and most areas show a general decline;
the trend for the NW appears particularly striking due to the high observed
prevalence in 2000-2002. Some temporal patterns are harder to interpret:
Yorkshire and the Humber for instance had very low prevalence in 2006-
2008 and a sharp increase subsequently.
Table 4.10 shows p-values for interactions between risk factors, adjusted
for all risk factors and the survey period/region interaction. Interactions
with region were again the strongest, with generally little effect for the in-
teraction between other variables. The strongest interaction was for gender
and region, which showed lower prevalence in females for almost all regions
vs. SE England, and markedly so for London (OR=0.54, p = 0.001), NW
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Table 4.8: Univariable and multivariable results from logistic regression
model for HBV and reported risk factors. Odds ratios and 95% confidence
intervals.
Variable Univariable Multivariable
Injecting duration 0-1 0.51 (0.39, 0.66) 0.48 (0.37, 0.64)
2 0.65 (0.49, 0.86) 0.63 (0.47, 0.84)
3-4 0.98 (0.79, 1.22) 0.94 (0.75, 1.17)
5-6 1 (ref) 1 (ref)
7-8 1.16 (0.93, 1.45) 1.17 (0.93, 1.46)
9-11 1.78 (1.47, 2.16) 1.81 (1.49, 2.21)
12-14 2.18 (1.80, 2.65) 2.37 (1.93, 2.90)
15-19 2.99 (2.49, 3.59) 3.26 (2.68, 3.97)
20-24 4.75 (3.91, 5.76) 5.26 (4.26, 6.50)
25-29 7.45 (5.93, 9.38) 9.39 (7.28, 12.11)
30-34 11.61 (8.69, 15.51) 15.33 (11.17, 21.05)
35+ 12.78 (8.30, 19.68) 15.81 (9.98, 25.05)
Survey period 2000-2002 1.37 (1.22, 1.55) 1.57 (1.38, 1.79)
2003-2005 1.36 (1.20, 1.54) 1.37 (1.19, 1.56)
2006-2008 1 (ref) 1 (ref)
2009-2011 0.86 (0.74, 0.99) 0.76 (0.65, 0.88)
2012-2014 0.94 (0.81, 1.08) 0.79 (0.67, 0.93)
Region East of England 0.97 (0.78, 1.20) 0.88 (0.70, 1.11)
London 1.80 (1.54, 2.09) 1.24 (1.05, 1.47)
South East 1 (ref) 1 (ref)
South West 0.85 (0.72, 1.00) 0.84 (0.70, 1.00)
West Midlands 0.38 (0.29, 0.49) 0.46 (0.34, 0.61)
North West 2.30 (1.98, 2.67) 1.98 (1.69, 2.33)
Yorkshire and H 0.70 (0.54, 0.91) 0.70 (0.53, 0.92)
East Midlands 0.72 (0.60, 0.88) 0.84 (0.68, 1.03)
North East 0.53 (0.44, 0.64) 0.81 (0.67, 0.99)
Wales 0.57 (0.45, 0.73) 0.60 (0.46, 0.78)
Age at first use <18 1.30 (1.19, 1.44) 0.84 (0.75, 0.94)
18-24 1 (ref) 1 (ref)
25+ 0.92 (0.83, 1.02) 1.46 (1.29, 1.64)
Gender Male 1 (ref) 1 (ref)
Female 0.88 (0.80, 0.96) 1.26 (1.13, 1.40)
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Table 4.9: Continued from 4.8: Logistic regression model results for HBV.
Variable Univariable Multivariable
Ever rec’d works No 1 (ref) 1 (ref)
Yes 1.52 (1.40, 1.65) 1.24 (1.13, 1.36)
Needle exchange Started 1st year 1 (ref) 1 (ref)
Started >1 yr 1.98 (1.82, 2.15) 1.12 (1.01, 1.23)
Never 1.19 (0.90, 1.58) 1.23 (0.90, 1.67)
Days injecting <14 days/mo 1 (ref) 1 (ref)
per month 14+ days/mo 0.94 (0.86, 1.02) 1.03 (0.94, 1.13)
Prison Never imprisoned 1 (ref) 1 (ref)
Prison before injecting 1.93 (1.72, 2.15) 1.29 (1.14, 1.46)
Prison after injecting 1.60 (1.44, 1.78) 1.45 (1.29, 1.64)
Number of 0 or 1 partner 1 (ref) 1 (ref)
partners 2+ partners 0.89 (0.81, 0.96) 1.07 (0.97, 1.17)
Condom use Always 1 (ref) 1 (ref)
Sometimes/never 0.70 (0.63, 0.76) 0.83 (0.75, 0.92)
MSM No 1 (ref) 1 (ref)
Yes 1.34 (1.04, 1.71) 1.25 (0.95, 1.64)
(OR=0.46, p < 0.001) and E Mids (OR=0.50, p = 0.008).
4.1.7 Risk factors for HIV infection
The models described in section 4.1.4 were fitted to the HIV data, but due
to the low prevalence, have less scope for investigating risk patterns. In-
jecting duration and survey year were grouped into broader categories as in
section 4.1.3. Model results for univariable and multivariable main effects
logistic models are shown in tables 4.11 and 4.12; all estimates presented
subsequently are for the multivariable model.
Interestingly, after adjusting for the covariates on demographics and risk
factors the ORs for injecting durations of 20-34 and 35+ years vs. 5-9 years
show no increase in prevalence (p-values 0.101 and 0.978 respectively). The
attenuation compared to the model in section 4.1.3 largely occurs when
region is adjusted for, with substantial variation in injecting duration by
region. London had the longest median injecting duration at 12 years, com-
pared to an overall median of 9 years and as low as 5 in the NE. These are
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Figure 4.15: Predicted HBV prevalence by region and survey period with
95% confidence intervals, multivariable logistic model adjusting for main
effects of all risk factors and region/survey period interaction. Predictions
are made at baseline levels of other risk factors; e.g., injecting duration 5-6
years.
the regions with the highest and lowest prevalences respectively, so it ap-
pears that the more extreme unadjusted differences in injecting duration are
due, in part, to confounding with region. The only regions with significantly
different HIV prevalence were London, which was far higher than SE Eng-
land (OR=5.31, 95% CI 3.03-9.32) and NE, which was far lower (OR=0.15,
95% CI 0.04-0.68). However, data are too sparse in most regions to estimate
differences with any confidence.
Those that began injecting below the age of 18 had an increased risk
(OR=1.85, 95% CI 1.25-2.73), in contrast to the results for HCV and HBV;
and ever receiving works was associated with higher risk (OR=1.88, 95%
CI 1.32-2.68). The only other significant effects were MSM, which was as-
sociated with a greatly increased risk of HIV infection (OR=4.91 95% CI
2.73-8.85) and condom use, with incomplete use (vs. always used) showing
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Table 4.10: Interactions between risk factors for HBV, likelihood ratio test
p-values for generalised linear model with main effects, region/survey year
interaction and interaction of interest. MSM/female interaction is not de-
fined.
region aafu female erec exch d14 pris part2 cond
aafu 0.005
female 0.000 0.649
erec 0.414 0.962 0.084
exch 0.130 0.470 0.298 0.059
d14 0.145 0.117 0.836 0.212 0.693
pris 0.032 0.096 0.250 0.750 0.024 0.740
part2 0.046 0.374 0.791 0.574 0.256 0.640 0.942
cond 0.037 0.976 0.734 0.348 0.882 0.761 0.014 0.818
msm 0.780 0.129 . 0.623 0.293 0.311 0.024 0.523 0.094
aafu: age at first use, erec: ever received works, exch: needle exchange use,
d14: injected 14 or more days in last month, pris: imprisonment, part2: two or
more sexual partners, cond: condom use, msm: men who have sex with men.
an unexpected and substantial protective effect (OR=0.27 95% 0.19-0.37),
as for HCV and HBV.
After adjusting for other risk factors, the interaction between injecting
duration and survey year was not significant, with a LR test p-value of 0.152.
There were no significant associations for injecting duration and survey year
with risk factor variables, with the lowest p-value being 0.208; Wald tests
were employed as many interactions resulted in zero cells and a differing
number of observations between models. There were just a few significant
interactions between risk factors, with the strongest being between gender
and prison (p=0.012); in males, the baseline group, ORs for being imprisoned
before/after starting injecting were below 1 at 0.62 (95% CI 0.39-0.98) and
0.50 (95% CI 0.31-0.80) respectively; the OR for female vs. males changed
to become protective (OR=0.43, 95% CI 0.21-0.85), but females that had
been to prison had a higher risk, with OR of 2.33 (95% CI 0.93-5.88) and
4.38 (95% CI 1.65-11.62) for imprisonment before or after starting inject-
ing respectively. This could potentially be explained by prostitution, which
would likely increase the risk of HIV infection and possibly imprisonment;
although the number of sexual partners had little influence, nor was there
an interaction with gender (p=0.114).
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Table 4.11: Univariable and multivariable results from logistic regression
model for HIV and reported risk factors. Odds ratios and 95% confidence
intervals.
Variable Univariable Multivariable
Injecting duration 0-1 1.11 (0.48, 2.55) 1.26 (0.53, 3.00)
2-4 1.30 (0.67, 2.53) 1.54 (0.78, 3.03)
5-9 1 (ref) 1 (ref)
10-14 2.48 (1.40, 4.39) 2.10 (1.17, 3.77)
15-19 4.15 (2.37, 7.30) 2.64 (1.46, 4.80)
20-34 4.43 (2.52, 7.79) 1.68 (0.90, 3.14)
35+ 5.14 (1.18, 22.49) 1.02 (0.22, 4.82)
Survey period 2000-2004 0.68 (0.47, 0.98) 0.53 (0.36, 0.78)
2005-2009 1 (ref) 1 (ref)
2010-2014 0.73 (0.49, 1.09) 0.97 (0.63, 1.48)
Region East of England 0.93 (0.38, 2.27) 1.18 (0.47, 2.93)
London 4.94 (2.89, 8.45) 5.31 (3.03, 9.32)
South East 1 (ref) 1 (ref)
South West 0.50 (0.23, 1.11) 0.60 (0.27, 1.33)
West Midlands 0.36 (0.10, 1.23) 0.43 (0.12, 1.50)
North West 0.92 (0.46, 1.82) 1.12 (0.55, 2.27)
Yorkshire and H 0.18 (0.02, 1.34) 0.19 (0.02, 1.45)
East Midlands 0.72 (0.32, 1.64) 0.83 (0.36, 1.92)
North East 0.11 (0.02, 0.46) 0.15 (0.04, 0.68)
Wales 0.67 (0.24, 1.83) 0.85 (0.31, 2.35)
Age at first use <18 1.96 (1.37, 2.79) 1.85 (1.25, 2.73)
18-24 1 (ref) 1 (ref)
25+ 1.00 (0.65, 1.53) 0.95 (0.60, 1.52)
Gender Male 1 (ref) 1 (ref)
Female 0.89 (0.62, 1.30) 0.91 (0.61, 1.36)
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Table 4.12: Continued from 4.11: Logistic regression model results for HIV.
Variable Univariable Multivariable
Ever rec’d works No 1 (ref) 1 (ref)
Yes 2.22 (1.59, 3.09) 1.88 (1.32, 2.68)
Needle exchange Started 1st year 1 (ref) 1 (ref)
Started >1 yr 1.89 (1.36, 2.62) 1.10 (0.76, 1.58)
Never 1.09 (0.34, 3.50) 0.80 (0.24, 2.64)
Days injecting <14 days/mo 1 (ref) 1 (ref)
per month 14+ days/mo 0.72 (0.53, 1.00) 0.94 (0.68, 1.31)
Prison Never imprisoned 1 (ref) 1 (ref)
Prison before injecting 1.10 (0.76, 1.61) 0.78 (0.52, 1.18)
Prison after injecting 0.65 (0.44, 0.96) 0.72 (0.47, 1.10)
Number of 0 or 1 partner 1 (ref) 1 (ref)
partners 2+ partners 1.19 (0.86, 1.63) 1.16 (0.82, 1.64)
Condom use Always 1 (ref) 1 (ref)
Sometimes/never 0.24 (0.18, 0.34) 0.27 (0.19, 0.37)
MSM No 1 (ref) 1 (ref)
Yes 5.39 (3.22, 9.01) 4.91 (2.73, 8.85)
4.1.8 Summary of risk factors
The results from generalised linear models for HCV, HBV and HIV indicate
that there were significant changes in prevalence according to survey period.
Prevalence of all three blood-borne viruses increases with injecting duration,
which is taken to be the time at risk, as would be expected for infections with
long-lasting antibodies. Likelihood ratio tests indicated interactions between
injecting duration and survey period, although there was less evidence of in-
teractions in the data from 2000 onwards. In general, interaction terms were
estimated imprecisely and could be modelled more efficiently (for instance,
using parametric functions, smoothing, or within a Bayesian framework),
although the main aim here was to determine whether main effects models
were sufficient.
There were also important risk factors for infection, with region having
the strongest effect of any covariate. Prevalence of HCV is markedly higher
in London and the NW, HBV is very high in the NW, and there is far
higher HIV prevalence in London compared to all other regions. Trends in
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prevalence over the survey period also varied substantially by region. The
decrease in HBV prevalence over time is likely attributable to vaccination,
but varies across regions. Injecting epidemics were particularly severe in
the NW and London, and mixing with large migrant populations from high-
prevalence countries may have accelerated the spread of BBVs in these areas.
In this case, the subsequent effect of vaccination may be greater in these
areas, reducing both within- and between-group transmission.
Ever being imprisoned and ever receiving works were both associated
with around a two-fold increased risk of infection for HCV and HIV, and to
a lesser extent HBV. Some results are counter-intuitive: incomplete condom
use (compared to always using a condom) appeared to have a protective effect
for all infections, and never having used a needle exchange also appeared to
confer a lower risk. MSM were found to be at somewhat greater risk of
HCV and HBV infection, and markedly so for HIV. Starting injecting at
an older age (25+) was associated with an increased risk of HCV and HBV
infection, although those starting below the age of 18 were at higher risk of
HIV infection.
There is a possibility of bias in the results for condom use and number of
partners due to systematic missingness. Both are relatively sensitive ques-
tions, and prevalence of all BBVs is somewhat higher in those with missing
information. Techniques such as multiple imputation may be used to handle
missing data issues, and can reduce potential biases under the missing at
random assumption (Rubin, 1987). However, systematic differences in miss-
ing data that are not accounted for by relationships between the observed
covariates (missing not at random) are always a possibility, and there is no
guarantee of obtaining unbiased estimates (Sterne et al., 2009). Further,
sensitivity analyses were undertaken in which all missing responses were as-
sumed to have, or not have, the risk factor, with little change in estimated
odds ratios: the apparent protective effect of imperfect condom use persisted
for all infections, and results on numbers of partners were still inconclusive
for HCV and HBV.
Subsequently, condom use and number of partners are no longer consid-
ered, due to the unusual effect estimates and because answers are frequently
omitted from questionnaires, resulting in nearly a quarter of the post-2000
data being omitted. Main effects models for each of the infections were re-
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estimated with these variables excluded to ensure that multivariable results
from section 4.1.4 did not change markedly.
An important factor that has not been considered here is vaccination for
HBV. This is self-reported in the UAM data and could in theory be used for
analysis; however, interpretation is somewhat difficult as vaccination is often
provided regardless of infection status. Therefore although the decrease in
HBV prevalence over time is likely to be attributable to increased vaccination
coverage, the direct effect of HBV vaccination on prevalence cannot be tested
within this modelling framework.
4.2 Models for the force of infection
This chapter has so far investigated the relationship between injecting du-
ration and calendar time with prevalence of HCV, HBV and HIV, including
the effect of additional covariates and the various possible interactions that
may be considered. A large number of parameters are required to ade-
quately model the effect of injecting duration. This will hold generally for
age-specific current status data, in order for the piecewise constant bands
to adequately capture the relationship between exposure time and risk de-
scribed by equation 3.13. By incorporating this relationship in a model for
the force of infection (FOI), fewer parameters are needed, as only changes
to the infection rate according to time at risk need be parameterised. If the
FOI is constant, only one parameter is required.
In this section FOI models are fitted that allow for changes in the risk
of infection by injecting duration and calendar time. So far the imperfect
sensitivity of pre-dried blood spot tests for HCV and HBV has not been
accounted for, which would result in apparently lower prevalence in earlier
survey years. While this can be taken into consideration for effect estimates
of survey period, the effect of imperfect sensitivity may be more subtle on a
FOI model, potentially inducing an interaction between injecting duration
and survey period where there may be none. Therefore, models are fitted
that account for the sensitivity of tests used to recover the true prevalence
(given the assumed sensitivity), and therefore true FOI, by including the
relationship specified in equation 3.5 into the log-likelihood. This requires
that models are fitted using bespoke code, and are optimised using the BFGS
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method (Nocedal et al., 2006, p. 194) in the R routine optim.
Piecewise constant models for the force of infection (FOI) were fitted to
the HCV, HBV and HIV data, including effects for injecting duration and
calendar time as in section 3.2.3, where injecting duration is taken to be the
“age” or time at risk for people who inject drugs (PWID). Calendar time is
split into pre-1980, 1980-1985, 1985-1990, 1995-2000, 2000-2005, 2005-2010
and 2010 onwards; and injecting duration as ≤ 1, 1-3, 3-5, 5-10, 10-15, 15-25
and > 25 years. Injecting duration is assumed to be at least 1 year in all
participants. Four models are tested for the effects of injecting duration and
time for each infection: with and without interactions between injecting du-
ration and time, and additive (equation 3.18) versus multiplicative (equation
3.19) injecting duration and time effects. Interaction models are specified
via main effects for injecting duration and calendar time, with deviations
from the main effects estimated via time- and injecting duration-specific in-
teraction terms, as described in section 3.2.3. These interactions are only
estimable within the survey period, and the earliest period in the survey is
taken as the baseline, such that the relative injecting duration-specific risks
are assumed to be the same prior to and at the beginning of the survey.
Having assessed different model forms for age and time, covariates are
included in the model as described in section 3.2.5. The additive model
turns out to provide an adequate fit, and since full covariate data are only
available from 2000 onwards and sensitivity to HCV antibodies is good as
of 1998 and does not need to be accounted for, models can be fitted in the
GLM framework as specified in equation 3.22, without needing to resort
to bespoke code for maximising the likelihood. The GLM approach with
additive effects is therefore used to further explore and refine the relation-
ships between the covariates and infection status, with HCV being the main
outcome of interest.
4.2.1 Force of infection models for HCV by injecting
duration and time
The deviances for the different parameterisations of the FOI for HCV are
shown in Table 4.13. For all data, there was a large improvement in model
fit for the interaction models compared to main effects for injecting dura-
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tion and time only (multiplicative model 859.7 on 711 d.f. vs. 979.4 on 735
d.f.). There were smaller, but still substantial differences between additive
and multiplicative models, with the multiplicative model providing a better
fit without interactions, but the best fit from the additive model with in-
teractions. Differences in fit are expected for the main effects model, which
could provide a quite different fit to the data if injecting duration and time
effects are combined independently. However, the difference in fit appears
unexpected for the interaction models, as both additive and multiplicative
models contain a parameter for each injecting duration/survey period. The
difference is likely due to the constraint that the FOI is strictly positive in
the multiplicative model, but can be negative in the additive model, allow-
ing a better fit where observed prevalence does not increase monotonically
with time at risk. In addition, although no direct information is available
on interaction terms prior to the survey period, the constraint that the FOI
in the pre-survey period has constant hazard ratios/differences for injecting
duration over time could lead to a conflict with the observed prevalence in
the earliest survey period, leading to a difference in fit.
In the models fitted to data from 2000 onwards, the difference in de-
viances between the main effects and interaction models is less extreme
(multiplicative model 615.8 on 560 d.f. vs. 643.8 on 572 d.f.). This is
similar to the logistic model for HCV prevalence in section 4.1.1, which also
showed a smaller improvement with the addition of interaction terms for the
restricted data. The multiplicative model fits better for the main effects only
model, but the difference in deviances is only 4.4 for the interaction models.
Table 4.13: Deviances and degrees of freedom for force of infection models
for HCV according to injecting duration and time, additive vs. multiplica-
tive and main effects vs. interaction models. Results are presented for all
available data, and data from 2000 onwards. The degrees of freedom is the
number of unique data points (injecting duration/survey year combinations)
minus the number of parameters in the model.
All data 2000 onwards
Model Parameterisation Deviance d.f. Deviance d.f.
Main effects Additive 995.7 735 661.1 572
Main effects Multiplicative 979.4 735 643.8 572
Interaction Additive 836.3 711 620.2 560
Interaction Multiplicative 859.7 711 615.8 560
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Figure 4.16 shows predicted HCV prevalence from the models above fitted
to data from all years; the additive and multiplicative main effects models
give surprisingly similar predictions (given they might be expected to diverge
more than the interaction results) and the multiplicative main effects-only
model results are therefore omitted for clarity. All models performed poorly
at the beginning period of the survey data, years 1992 and 1994, and es-
pecially 1992. This is likely due to the constraints imposed on the FOI in
pre-survey years. There is little to distinguish between model predictions
in later survey years, and virtually no difference between the additive and
multiplicative interaction models. This supports the argument that the con-
straint of constant injecting duration hazard ratios/differences in pre-survey
years can influence model fit, despite there being no direct information to
estimate differences over time in the pre-survey period. All of the models
appear to provide a reasonable fit visually, except for some systematic diver-
gence in particular years. For instance, prevalence in 2005 for those injecting
for more than 12 years is systematically underestimated, but not for 2006.
This could point to a different composition in the UAM sample for certain
years.
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Figure 4.16: Predicted HCV prevalence by injecting duration and survey year from the force of infection models. Additive
vs. multiplicative and main effects vs. interaction models are shown, although the main effects multiplicative model is
omitted for clarity (see text).
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Table 4.14 shows the estimated FOI by injecting duration and survey
period from the multiplicative and additive interaction model. Both models
indicate a high FOI in the first year of injecting, which decreases by around
5-fold subsequently. The estimates are very similar within the survey pe-
riod, except that for some injecting durations/times the estimate from the
multiplicative model is practically zero, but slightly negative for the additive
model. This is because the multiplicative FOI is additive on the exponential
scale and constrained to be positive, whereas the additive model compo-
nents can combine to produce negative estimates if the injecting duration
and time-specific FOI does not increase monotonically. Outside the range
of the survey, there are slight differences in the estimated FOI due to the
constant injecting duration effects being either additive or multiplicative.
Table 4.14: Force of infection for HCV by injecting duration and time, mul-
tiplicative and additive interaction models.
Multiplicative
Year / injecting <1 1-3 3-5 5-10 10-15 15-25 >25
pre 1980 0.546 0.135 0.085 0.014 0.001 0.108 0.000
1980-1985 0.633 0.156 0.098 0.016 0.001 0.125 0.000
1985-1990 0.449 0.111 0.070 0.012 0.000 0.089 0.000
1990-1995 0.296 0.073 0.046 0.008 0.000 0.058 0.000
1995-2000 0.144 0.032 0.021 0.000 0.000 0.000 0.000
2000-2005 0.198 0.044 0.086 0.055 0.062 0.044 0.024
2005-2010 0.246 0.045 0.054 0.034 0.043 0.034 0.013
2010-2015 0.253 0.090 0.045 0.071 0.044 0.048 0.106
Additive
Year / injecting <1 1-3 3-5 5-10 10-15 15-25 >25
pre 1980 0.483 0.252 0.230 0.171 0.056 0.046 -0.043
1980-1985 0.477 0.246 0.224 0.165 0.051 0.041 -0.049
1985-1990 0.389 0.157 0.136 0.076 -0.038 -0.048 -0.137
1990-1995 0.309 0.077 0.056 -0.004 -0.118 -0.128 -0.217
1995-2000 0.145 0.031 0.020 -0.012 -0.017 -0.025 0.025
2000-2005 0.198 0.043 0.087 0.056 0.074 0.063 0.027
2005-2010 0.246 0.045 0.055 0.034 0.041 0.029 0.018
2010-2015 0.253 0.090 0.045 0.070 0.045 0.050 0.100
Table 4.15 shows the estimated FOI from models fitted to data from 2000
onwards. Data within the survey period, except for 2000-2005, show very
similar estimates to those from the complete data. However, estimates for
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the pre-survey period are very different: whereas the FOI was estimated to
be generally high at shorter injecting durations prior to the year 2000 and
highest in 1980-1985, estimates from the restricted dataset indicate little
difference in FOI for this group pre-2000. Conversely, the estimated FOI
in longer-term injectors (> 25 years) is estimated to be higher in the pre-
2000 period. The data from 2000 appear to be more generally consistent,
with fewer negative estimates of the FOI and less reliance on interactions to
capture the variability of the data. There are questions as to the reliability of
HCV data in earlier years (Vivian Hope, personal communication) so using
only more recent data might give more reliable estimates. However, it may
be that important changes in injecting-duration specific risks were occurring
in the 1990s, which are not captured without the earlier data.
Table 4.15: Force of infection for HCV by injecting duration and time, multi-
plicative and additive interaction models, fitted to data from 2000 onwards.
Multiplicative
Year / injecting <1 1-3 3-5 5-10 10-15 15-25 >25
pre 1980 0.057 0.015 0.026 0.014 0.019 0.017 0.034
1980-1985 0.200 0.053 0.091 0.050 0.067 0.058 0.120
1985-1990 0.177 0.047 0.081 0.044 0.059 0.051 0.106
1990-1995 0.171 0.045 0.078 0.043 0.057 0.049 0.102
1995-2000 0.130 0.035 0.059 0.032 0.044 0.038 0.078
2000-2005 0.192 0.051 0.087 0.048 0.064 0.055 0.115
2005-2010 0.245 0.049 0.051 0.035 0.046 0.032 0.000
2010-2015 0.253 0.091 0.043 0.071 0.044 0.049 0.108
Additive
Year / injecting <1 1-3 3-5 5-10 10-15 15-25 >25
pre 1980 0.113 -0.016 0.015 -0.016 -0.008 -0.017 0.063
1980-1985 0.192 0.063 0.093 0.062 0.071 0.062 0.142
1985-1990 0.176 0.047 0.078 0.047 0.056 0.047 0.127
1990-1995 0.188 0.059 0.089 0.058 0.067 0.058 0.138
1995-2000 0.151 0.022 0.053 0.022 0.031 0.022 0.102
2000-2005 0.182 0.053 0.084 0.053 0.062 0.053 0.133
2005-2010 0.243 0.050 0.055 0.033 0.044 0.034 -0.008
2010-2015 0.253 0.092 0.042 0.070 0.045 0.049 0.114
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4.2.2 Force of infection models for HBV by injecting
duration and time
The same models were then fitted to the HBV data, and deviances shown in
Table 4.16. The interaction model has substantially lower deviance for both
the full data and that restricted to 2000 onwards. None of the models fit
the data well for the full dataset, although the additive interaction model is
preferred in all comparisons and provides a reasonable fit to the data from
2000 onwards. As before however, the additive model will tend to overstate
the goodness of fit due to the allowance of negative FOI estimates.
Table 4.16: Deviances and degrees of freedom for force of infection models
for HBV according to injecting duration and time, additive vs. multiplica-
tive and main effects vs. interaction models. Results are presented for all
available data, and data from 2000 onwards.
All data 2000 onwards
Model Parameterisation Deviance d.f. Deviance d.f.
Main effects Additive 1247.4 881 697.2 572
Main effects Multiplicative 1324.6 881 793.6 572
Interaction Additive 1199.6 857 659.1 560
Interaction Multiplicative 1283.7 857 760.2 560
Figure 4.18 shows predicted HBV prevalence from the models above fitted
to data from all years. As with HCV, the predicted prevalences were similar
for the additive and multiplicative main effects models, so the latter is not
shown. The main effects model performs poorly in earlier survey years,
with a systematic underestimation of prevalence. Again, the additive and
multiplicative models produce similar predictions for all but the first few
survey years.
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Figure 4.17: Predicted HBV prevalence by injecting duration and survey year from the force of infection models. Additive
vs. multiplicative and main effects vs. interaction models are shown, although the main effects multiplicative model is
omitted for clarity (see text).
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Tables 4.17 and 4.18 show the force of infection from multiplicative and
additive interaction models for all data and data from 2000 onwards. The
two model forms produce very different patterns for the injecting-duration
specific risk in the pre-survey period, with relatively high risk in 1st year in-
jectors and those injecting for > 25 years in the multiplicative model. Both
models indicate a general decline in the FOI over calendar time, which is ex-
pected due to increasing levels of HBV vaccination in the PWID population.
However, the FOI did not decline to the same relative degree in 1st year in-
jectors compared to longer durations, whose risk approached zero from 2000
onwards. In contrast to the HCV data, there were smaller differences in the
prediction of pre-survey risk levels when the data were restricted to 2000
onwards.
Table 4.17: Force of infection for HBV by injecting duration and time, mul-
tiplicative and additive interaction models.
Multiplicative
Year / injecting <1 1-3 3-5 5-10 10-15 15-25 >25
pre 1980 0.531 0.160 0.068 0.099 0.018 0.000 0.309
1980-1985 0.303 0.092 0.039 0.056 0.010 0.000 0.176
1985-1990 0.192 0.058 0.024 0.036 0.006 0.000 0.111
1990-1995 0.104 0.031 0.013 0.019 0.003 0.000 0.061
1995-2000 0.082 0.025 0.010 0.015 0.003 0.000 0.047
2000-2005 0.083 0.025 0.011 0.015 0.003 0.000 0.048
2005-2010 0.049 0.009 0.000 0.000 0.000 0.000 0.000
2010-2015 0.042 0.000 0.000 0.000 0.000 0.000 0.000
Additive
Year / injecting <1 1-3 3-5 5-10 10-15 15-25 >25
pre 1980 0.177 0.119 0.089 0.104 0.102 0.080 0.135
1980-1985 0.153 0.094 0.065 0.079 0.078 0.056 0.110
1985-1990 0.139 0.080 0.051 0.065 0.064 0.042 0.096
1990-1995 0.095 0.037 0.007 0.021 0.020 -0.002 0.053
1995-2000 0.088 0.030 0.000 0.014 0.013 -0.009 0.046
2000-2005 0.097 0.039 0.009 0.024 0.022 0.001 0.055
2005-2010 0.052 0.014 -0.015 -0.016 -0.009 -0.026 -0.066
2010-2015 0.045 -0.004 -0.004 0.004 0.008 -0.004 -0.010
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Table 4.18: Force of infection for HBV by injecting duration and time, multi-
plicative and additive interaction models, fitted to data from 2000 onwards.
Multiplicative
Year / injecting <1 1-3 3-5 5-10 10-15 15-25 >25
pre 1980 0.452 0.124 0.058 0.066 0.000 0.000 0.511
1980-1985 0.327 0.090 0.042 0.048 0.000 0.000 0.370
1985-1990 0.211 0.058 0.027 0.031 0.000 0.000 0.239
1990-1995 0.117 0.032 0.015 0.017 0.000 0.000 0.132
1995-2000 0.099 0.027 0.013 0.014 0.000 0.000 0.113
2000-2005 0.081 0.022 0.010 0.012 0.000 0.000 0.092
2005-2010 0.049 0.010 0.000 0.000 0.000 0.000 0.000
2010-2015 0.042 0.000 0.000 0.000 0.000 0.000 0.000
Additive
Year / injecting <1 1-3 3-5 5-10 10-15 15-25 >25
pre 1980 0.196 0.131 0.114 0.124 0.115 0.079 0.133
1980-1985 0.189 0.124 0.107 0.117 0.108 0.072 0.126
1985-1990 0.150 0.085 0.067 0.078 0.069 0.033 0.086
1990-1995 0.096 0.031 0.014 0.024 0.015 -0.021 0.033
1995-2000 0.095 0.030 0.012 0.023 0.013 -0.022 0.031
2000-2005 0.094 0.029 0.011 0.022 0.013 -0.023 0.031
2005-2010 0.051 0.012 -0.009 -0.012 -0.014 -0.023 -0.074
2010-2015 0.045 -0.004 -0.002 0.002 0.008 -0.005 -0.003
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4.2.3 Force of infection models for HIV by injecting
duration and time
Finally, the FOI models were fitted to the HIV data. Resulting deviances
are shown in Table 4.19. When fitting to the whole dataset, the additive
model with interactions provided the best fit, although the multiplicative
model with interactions provided a better fit to the data from the year 2000
onwards. However, all of the deviances are smaller than the degrees of free-
dom, indicating over-fitting. In fact, the additive main effects model could
not be fitted to the data, either in the R function optim or using standard
GLM software, despite numerous attempts to improve starting values and
relax tolerances.
Table 4.19: Deviances and degrees of freedom for force of infection models for
HIV according to injecting duration and time, additive vs. multiplicative and
main effects vs. interaction models. Results are presented for all available
data, and data from 2000 onwards. Model fitting failed for the additive main
effects model.
All data 2000 onwards
Model Parameterisation Deviance d.f. Deviance d.f.
Main effects Additive - 819 - 510
Main effects Multiplicative 796.6 819 482.0 510
Interaction Additive 758.6 795 465.4 486
Interaction Multiplicative 764.5 795 460.6 486
Figure 4.18 shows predicted HIV prevalence from the models above fit-
ted to data from all years. At the level of individual years and injecting
durations, the data are too sparse for the model to capture the observed
prevalence, except for very broad trends.
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Figure 4.18: Predicted HIV prevalence by injecting duration and survey year from the force of infection models. Additive
vs. multiplicative and main effects vs. interaction models are shown, although the main effects additive model is omitted
(see text).
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Tables 4.20 and 4.21 show the force of infection from multiplicative and
additive interaction models for all data and data from 2000 onwards. Es-
timates are far more sensitive to choice of parameterisation and the inclu-
sion/exclusion of pre-2000 data. Of note is that the multiplicative model
predicts a near-zero FOI in the pre-1980 period whereas the additive model
does not. The former is far more likely, with the first cases of HIV appearing
in the early 1980s, although the data are so sparse this may not be meaning-
ful. For all models, the highest risk was estimated to be in the first year and
extremely low subsequently, with the FOI in 1st year injectors increasing
somewhat in the last decade.
Table 4.20: Force of infection for HIV by injecting duration and time, mul-
tiplicative and additive interaction models.
Multiplicative
Year / inj. <1 1-3 3-5 5-10 10-15 15-25 >25
pre 1980 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000
1980-1985 0.0142 0.0034 0.0049 0.0058 0.0046 0.0035 0.0001
1985-1990 0.0012 0.0003 0.0004 0.0005 0.0004 0.0003 0.0000
1990-1995 0.0018 0.0004 0.0006 0.0007 0.0006 0.0004 0.0000
1995-2000 0.0012 0.0003 0.0004 0.0005 0.0004 0.0003 0.0000
2000-2005 0.0049 0.0012 0.0017 0.0020 0.0016 0.0012 0.0000
2005-2010 0.0071 0.0007 0.0000 0.0000 0.0013 0.0009 0.0000
2010-2015 0.0120 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000
Additive
Year / inj. <1 1-3 3-5 5-10 10-15 15-25 >25
pre 1980 0.0092 0.0056 0.0068 0.0072 0.0070 0.0055 0.0051
1980-1985 0.0025 -0.0011 0.0001 0.0005 0.0003 -0.0012 -0.0016
1985-1990 0.0033 -0.0003 0.0009 0.0014 0.0011 -0.0004 -0.0007
1990-1995 0.0028 -0.0008 0.0003 0.0008 0.0005 -0.0009 -0.0013
1995-2000 0.0045 0.0009 0.0021 0.0026 0.0023 0.0008 0.0005
2000-2005 0.0053 0.0010 0.0010 -0.0010 0.0010 -0.0004 -0.0013
2005-2010 0.0047 0.0004 0.0006 0.0005 -0.0002 -0.0016 -0.0016
2010-2015 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000
4.2.4 Force of infection models for HCV with covari-
ates
Model results for HCV in section 4.2.1 indicated that the multiplicative
model was not substantially better than the additive model when fitted to
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Table 4.21: Force of infection for HIV by injecting duration and time, multi-
plicative and additive interaction models, fitted to data from 2000 onwards.
Multiplicative
Year / inj. <1 1-3 3-5 5-10 10-15 15-25 >25
pre 1980 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000
1980-1985 0.0108 0.0000 0.0038 0.0027 0.0058 0.0000 0.0014
1985-1990 0.0042 0.0000 0.0015 0.0011 0.0023 0.0000 0.0005
1990-1995 0.0046 0.0000 0.0016 0.0012 0.0025 0.0000 0.0006
1995-2000 0.0004 0.0000 0.0001 0.0001 0.0002 0.0000 0.0001
2000-2005 0.0062 0.0000 0.0022 0.0016 0.0033 0.0000 0.0008
2005-2010 0.0075 0.0003 0.0000 0.0000 0.0016 0.0000 0.0000
2010-2015 0.0120 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000
Additive
Year / inj. <1 1-3 3-5 5-10 10-15 15-25 >25
pre 1980 0.0086 0.0004 0.0037 0.0033 0.0043 0.0034 0.0011
1980-1985 0.0050 -0.0033 0.0001 -0.0004 0.0006 -0.0003 -0.0026
1985-1990 0.0072 -0.0011 0.0023 0.0018 0.0028 0.0019 -0.0004
1990-1995 0.0056 -0.0027 0.0007 0.0002 0.0012 0.0003 -0.0020
1995-2000 0.0074 -0.0009 0.0025 0.0020 0.0030 0.0021 -0.0002
2000-2005 0.0094 -0.0004 0.0017 -0.0010 0.0020 -0.0009 -0.0019
2005-2010 0.0086 -0.0010 0.0006 -0.0004 0.0001 -0.0022 -0.0031
2010-2015 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000
the data from 2000 onwards, although goodness of fit is overstated somewhat
for the additive models, which allow negative FOI estimates. As full covari-
ate data are only available from 2000 onwards, the additive model appears
adequate for exploratory purposes, keeping in mind the limitations of this
model. However, it must be borne in mind that the effects of covariates are
also of course assumed to be additive, which does not necessarily follow from
the above. Further, the potential for a negative FOI for some combinations
of injecting duration, time and covariates becomes more likely as the com-
plexity of the model increases, further overstating the goodness of fit of the
additive model.
In section 4.1.5, it was seen that there were marked differences in preva-
lence according to region, which also varied over time. Regional effects were
therefore investigated in a FOI model with additive effects, considering the
main effects for injecting duration, time period and region, plus potential
interactions between the three factors. As the most important difference in
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risk according to injecting duration appeared to be the excess risk in 1st
year injectors, simplified forms of interactions for 1st year vs. longer inject-
ing durations were considered. All possible combinations were fitted, and
the relative merits of different models compared via AIC scores.
The model with the lowest AIC score included interactions between re-
gion and time, a simplified interaction between region and 1st year vs. longer
injecting duration, but did not require an interaction between injecting du-
ration and time. It is worth noting that this model still includes a substan-
tial number of interaction terms, and being based on AIC scores, may be
over-complex (compared to model selection under the heavier penalty for
complexity applied by the BIC).
Estimates of the FOI according to region and time period, for 1st year
vs. 3-5 years injecting duration are shown in Figure 4.19. There is no
interaction between injecting duration and time, hence the pattern of results
for 1st year vs. 3-5 years injecting is identical. However, the relative effect
of 1st year vs. longer injecting durations can vary by region, and there are
marked differences: a particularly striking feature is that the well-known
high-risk regions of NW and London have very high FOIs in the first year,
but comparable FOIs to other regions subsequently. In fact, the majority of
regional variation appears to be in 1st year risk.
Other covariates investigated in section 4.1.5 were examined within the
GLM framework for FOI models, with all models including the regional
effects and interactions specified above. Ever receiving works was associated
with a 0.017 (95% CI 0.014, 0.019) increase in FOI, with little difference
between injecting duration and survey period if interactions are considered.
Use of needle exchange, which is entered as a time-varying covariate that
divides pre- and post-needle exchange exposure, was predicted to change the
FOI by -0.013 (95% CI -0.017, -0.008). The reduction showed no significant
difference according to injecting duration, but needle exchange use appeared
to be less efficacious (actually conferring an increase in risk) in earlier time
periods and only becoming effective from the year 2000 onwards.
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Figure 4.19: Regional difference in the force of infection for HCV, by time
and 1st year vs. 3-5 years injecting.
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4.2.5 Concluding remarks
This chapter has included a thorough investigation of patterns in BBV preva-
lence according to injecting duration, survey period and the key covariates
available for analysis. Most of the questionnaire data on risk are only avail-
able from 2000 onwards, restricting the data available for analysis. In some
cases this may simplify modelling, with interactions between injecting dura-
tion and time appearing to be less vital. It is not clear whether the earlier
data may contain important information on changes in risk over time. How-
ever, if the main interest lies in current risk differences according to injecting
duration and changes over recent times, this may not be particularly impor-
tant.
Current status data may be modelled via standard generalised linear
models for binomial data, such as logistic regression, or models that estimate
the force of infection. The underlying data and information contained therein
are of course the same, but with parameters related to the data in a different
way. Nevertheless, the FOI may be of more direct interest in determining risk
patterns: in the regional example in section 4.2.4, a striking regional pattern
in 1st year injectors vs. longer injecting durations was revealed that may be
less obvious from fitting logistic regression models. Similarly, by considering
the effect of needle exchange as a time-varying covariate, its usage was shown
to provide a general protective effect, but only in more recent years. Again,
such patterns might be revealed by careful modelling in logistic regression
models, but are harder to uncover. FOI models also model the relationship
between time at risk and infection status more naturally, requiring fewer
parameters in general; although as there is less information available from
risk differences, they also tend to be estimated less precisely.
The downside of FOI models is that only the additive form of the model
can be fitted within the GLM framework, whereas epidemiological applica-
tions tend to consider risk factors as multiplicative. This makes sense in
general: if the overall risk of infection has changed over some time period,
person A, who makes twice as many contacts with infectious individuals as
person B, would naturally be expected to still have double the risk of infec-
tion, rather than a fixed additive difference. Of course, all of the outcomes
considered here are infectious diseases, so it is difficult to predict in what way
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time at risk and calendar time will combine due to transmission dynamics.
Nevertheless, the GLM form appears to be a suitable tool for exploratory
analysis of additional covariates for FOI models, similar to the suggestion of
Ades and Nokes (1993) in their paper on age and time effects.
GLMs for the FOI use an unusual link for binary data, and are therefore
not permitted in all statistical packages: models can be fitted in Stata using
the glm command, although the R function glm will not allow such models
to be fitted. An alternative here would be to use the complementary log-
log link, which allows certain parametric forms for the FOI, such as the
Weibull model. This may be appropriate given epidemiological knowledge
of the general pattern of the FOI, but does of course impose certain shapes.
In particular, the Weibull model implies an exponential change in the FOI,
which if declining, will tend exponentially towards zero. Given the non-zero
FOI at all injecting durations, this would not fully capture the relationships
seen here.
In the next two chapters FOI models including individual frailties are
considered, which are outside the scope of standard GLMs. In these analyses,
multiplicative effects for calendar time and other covariates are assumed,
and the effect of covariates on the FOI further examined on the basis of the
findings presented in this chapter.
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Chapter 5
Individual heterogeneity and
models for multivariate data
Collecting samples from individuals in the population of interest can be
expensive and time-consuming, but the serological testing itself is often rela-
tively cheap and straightforward (moreover, given that one serological test is
undertaken, additional testing is relatively easy). In such circumstances the
same serological sample can be used to test for multiple infections (usually of
a similar nature, such as childhood diseases) resulting in current status data
for more than one infection. This can prove very useful from an epidemio-
logical point of view, broadening the potential for analytical exploration.
The models considered in chapters 3 and 4 are based on the assump-
tion that all individuals have the same risk of infection, given their age (or
time exposed), calendar time and other covariate information. However, it
is likely that individuals will differ according to some unmeasurable factor,
particularly in the absence of covariate data, which in the context of infec-
tious diseases is often given to be their propensity to make effective contacts,
or otherwise have varying levels of exposure, susceptibility, or opportunity
for infection. Such individual heterogeneity, or frailty, is of particular im-
portance in the estimation and interpretation of the age-specific force of
infection. In statistical models, frailty is expressed via a specified distribu-
tion and identified via the correlation that occurs in multivariate data when
infections share a common route of transmission. Therefore multivariate
data are central to the estimation of individual heterogeneity.
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5.1 Frailty distributions
In a frailty model, the force of infection acting on an individual is the product
of a basic rate λ(t) and an individual-specific quantity Z (see, for example,
Aalen et al. (2008, p. 234)):
λ(t|Z) = Zλ(t).
Given Z, the probability of remaining susceptible up to time t is given by
S(t|Z) = exp(−ZA(t)),
where
A(t) =
∫ t
0
λ(u) du.
The function for the population proportion susceptible is found by integrat-
ing over the distribution of Z
S(t) = E[exp(−ZA(t))]. (5.1)
The Laplace transform of Z is defined by
L(c) = E(exp(−cZ)), (5.2)
and therefore
S(t) = L(A(t)). (5.3)
The population force of infection, λp(t), may then be found by differentiating
− log(S(t)):
λp(t) = λ(t)
−L′(A(t))
L(A(t)) .
5.1.1 The gamma distribution for frailty
One of the simplest choices for the frailty distribution is the gamma distri-
bution, for which the Laplace transform is easily derived. The probability
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density of the gamma distribution is given as
f(x; k, θ) =
θk
Γ(k)
xk−1 exp(−θx), (5.4)
where θ is a rate parameter and k a shape parameter. In order for the
average FOI to be equal to the baseline FOI λ(t), it is sensible to define the
distribution with mean equal to 1, i.e., θ = k. The frailty variance is thus
given by δ = 1
θ
. Figure 5.1 shows various shapes that may be obtained under
different values of δ. With low values (δ < 0.1) the frailty, Z, is narrowly
distributed around 1; as δ increases this distribution spreads out, and with
δ > 5 the bulk of the distribution of Z tends towards zero, but with a long
tail stretching to higher values.
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Figure 5.1: Density of gamma distributions with mean 1 and variance
δ=0.05, 0.2, 1 and 5.
The Laplace transform of the gamma distribution is obtained in a similar
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way to its moment generating function:
L(c) =
∫ ∞
0
exp(−cx) θ
k
Γ(k)
xk−1 exp(−θx) dx
=
θk
Γ(k)
∫ ∞
0
xk−1 exp(−x(c+ θ)) dx
=
θk
Γ(k)
Γ(k)
(c+ θ)k
∫ ∞
0
(c+ θ)k
Γ(k)
xk−1 exp(−x(c+ θ)) dx
=
θk
(c+ θ)k
.
By the addition of terms to the numerator and denominator, an integral of
another gamma distribution with rate parameter c+ θ over the range [0,∞]
is obtained, which is equal to 1. For gamma distributions with mean equal
to 1 this can be written as:
L(c) =
(
1 +
c
θ
)−θ
. (5.5)
Combining equations 5.3 and 5.5 yields the population survivor function
S(t) =
(
1 +
A(t)
θ
)−θ
(5.6)
and the population hazard rate
λp(t) =
λ(t)
1 + A(t)
θ
. (5.7)
See, for instance Aalen et al. (2008, p. 236)). In some statistical analyses,
ignoring sources of unexplained variation will not necessarily bias estimates
(although standard errors may be underestimated), but when trying to esti-
mate time-specific forces of infection the presence of individual heterogeneity,
or frailty, can distort results. Those at higher risk will tend to experience the
event in question earlier than others, while those that remain, who have a
lower average frailty, will experience the event at a lower rate. This has the
effect of pushing down the population force of infection over time, whereas
the risk for each individual may actually be stable or increasing (see Aalen
et al. (2008, Chapter 6)).
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The difference between individual and population hazard is more than
a philosophical point. Planning of public health interventions may depend
on whether there is a genuine high risk of infection at the beginning of the
time at risk compared to an apparent high initial risk due to heterogeneity.
In the context of people who inject drugs, this might mean a shift in focus
from quickly finding those that have recently initiated injecting to engage
them in preventative measures, compared to increased targeting of high-risk
individuals in a heterogeneous population.
Equation 5.7 shows the effect of frailty on the population hazard. When
the frailty variance (δ = 1
θ
) is zero there is no difference between λp(t) and
λ(t). However, as δ increases the denominator becomes greater than 1 and
increases over time, decreasing the population hazard compared to that of the
individual over time. Figure 5.2 shows the age-specific proportion susceptible
under a constant FOI at different percentiles of the gamma distribution,
under different frailty variances. When the frailty variance δ is high, a large
proportion of the population have almost no risk of infection, whereas a
fairly small group have a high risk and the proportion susceptible within
this group declines rapidly with age.
The gamma distribution is often used for its mathematical convenience,
but also has some nice properties. It can be explicitly differentiated any
number of times (Aalen et al., 2008, p. 236) and heterogeneity remains con-
stant in survivors; i.e., conditional on not having yet experienced the event,
individual heterogeneity remains the same over time. This is an important
feature and makes the gamma distribution the reference distribution against
which other frailty distributions are compared, as other choices will result in
increasing or decreasing heterogeneity in the remaining survivors over time.
5.1.2 The inverse Gaussian distribution
The inverse Gaussian distribution can also make for a useful choice of frailty
distribution. Its probability density function is given as
f(x;µ, θ) =
√
θ
2pix3
exp
[
−x θ
2µ2
− θ
2x
+
θ
µ
]
; (5.8)
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Figure 5.2: The age-specific proportion susceptible in a population with
hazard=0.02 at the 10th, 25th, 75th and 90th percentile (pctl) points of
different gamma frailties. Results are shown with no heterogeneity; and
frailty variance δ=0.2, 1 and 5.
and has mean µ and variance µ
3
θ
. The Laplace transform is derived as follows:
L(c) =
∫ ∞
0
exp(−cx)
√
θ
2pix3
exp
[
−x θ
2µ2
− θ
2x
+
θ
µ
]
dx
=
∫ ∞
0
√
θ
2pix3
exp
[
−cx− x θ
2µ2
− θ
2x
+
θ
µ
]
dx
= exp(−Φ)
∫ ∞
0
√
θ
2pix3
exp
[
−x θ
2µ2c
− θ
2x
+
θ
µc
]
dx,
where µ2c =
θµ2
θ+2cµ2
and Φ =
θ
√
θ+2cµ2√
θµ
− θ
µ
. The integral now takes the form
of another inverse Gaussian pdf and is equal to 1. As interest is in frailty
distributions with mean 1, the formula can be simplified to
L(c) = exp
[
θ
(
1−
√
1 +
2c
θ
)]
; (5.9)
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and therefore the population survivor function is
S(t) = exp
[
θ
(
1−
√
1 +
2A(t)
θ
)]
. (5.10)
The frailty variance is defined as δ = 1
θ
. Figure 5.3 shows the pdf of the
inverse Gaussian distribution under various values of δ. For small values of
δ there is little difference in shape between the inverse Gaussian and the
gamma distribution, but as shown in figure 5.1, as δ approaches 1 the mode
of the gamma distribution is pushed towards zero, and for δ ≥ 1 there is
no point of inflection. The inverse Gaussian however is “bell-shaped” (if
potentially very skewed) for all values of δ. In a practical sense, this would
mean the difference between a population whose low-risk individuals had
risk approaching zero (gamma distribution) compared to a population that
may include very low-risk individuals but those with risk approaching zero
were more rare (inverse Gaussian).
An important distinction between the two distributions is that under the
inverse Gaussian distribution the heterogeneity of survivors declines over
time; i.e., they become more homogeneous. If this appears to be the case,
and it is believed that this declining heterogeneity is due to a selection effect
(rather than changes in the heterogeneity in risk behaviour over time), then
the inverse Gaussian distribution may be appropriate.
5.1.3 Frailty distribution families
The power variance function (PVF) family of distributions suggested by
Hougaard (2000) provides a number of interesting possibilities for frailty
distributions. PVF distributions are defined as those having the Laplace
transform
L(c; ρ, ν,m) = exp
[
−ρ
(
1−
(
ν
ν + c
)m)]
. (5.11)
A number of distributions are special cases of the PVF family. If ρ → ∞
and m → 0 in such a way than ρm → η then the Laplace transform ap-
proaches that of the gamma distribution with scale parameter ν and shape
parameter η (Aalen et al., 2008, p. 238). The inverse Gaussian distribution
also belongs to the PVF family (m = −1
2
, ρ < 0). Another example is the
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Figure 5.3: Density of inverse Gaussian distributions with mean 1 and vari-
ance δ=0.05, 0.2, 1 and 5.
compound Poisson distribution. This includes a probability atom at zero,
corresponding to a group with zero frailty, or a nonsusceptible group. This
might arise in the context of people who inject drugs if some people never
share needles or equipment, or otherwise are somehow never at risk of in-
fection. The distribution is the sum of independent gamma variables, and
hence corresponds to a cumulative damage model, whereby repeated “in-
sults” increase an individual’s susceptibility. This is somewhat implausible
in this context, as the risk of infection is unlikely to be cumulative, although
Farrington et al. (2012) describe an alternative family (the Addams family!)
from which other discrete frailty distributions can be derived, which might
be appropriate for the number of sexual partners in the modelling of sexually
transmitted disease. In the context of injecting drug use, this might be the
size of social group in which needle sharing might arise. The possibility of
a zero-risk group is potentially interesting, but limited in that the relative
frailty variance must be non-decreasing (Farrington et al., 2012).
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Frailty distributions may be characterised by their relative frailty vari-
ance (RFV), the heterogeneity in survivors at time t, defined by Farrington
et al. (2012) as:
RFV (t) = var(Ut|T > t) = var(U |T > t)
E(U |T > t)2 , (5.12)
where U is a non-negative random variable corresponding to individual
frailty, and Ut =
U
E(U |T>t) is the relative frailty, conditional on surviving
to time t. The gamma distribution is the only choice resulting in a constant
RFV, whereas the inverse Gaussian (and many others) result in a decreasing
RFV. The RFV is discussed further in section 5.2.3.
5.1.4 Time-varying frailty
In addition to the selection effect induced by particular frailty distributions,
heterogeneity in risk may genuinely be decreasing (or increasing) over time.
Farrington et al. (2013) describe a selection of time-varying frailty models
with one or two components. The single component model is:
Z(t) = 1 + (Z − 1)h(t), (5.13)
where Z is a time invariant frailty of unit mean (for instance, a gamma
distribution) and 0 ≤ h(t) ≤ 1 is a deterministic function, such as h(t) =
exp(−ρt), which results in an exponential decay. This model was adapted
slightly such that instead of heterogeneity declining to zero, a two-parameter
function is used such that frailty declines toward an asymptote:
h(t) =
exp(−ρt) + exp(q)
1 + exp(q)
. (5.14)
Thus ρ controls the rate of decline of the relative frailty variance, and the
asymptote towards which it declines is given by exp(q)
1+exp(q)
, the exponents being
required to ensure the function is bounded within [0, 1] and q taking any real
value (q → −∞ yields a zero asymptote and q → ∞ no decline in relative
frailty variance).
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The survivor function with such a time-varying frailty distribution is
S(t|Z) = exp
[
−
∫ t
0
λ(u)
(
1 + (Z − 1)
(
exp(−ρu) + exp(q)
1 + exp(q)
))
du
]
.
(5.15)
Integrating over the frailty distribution to obtain the unconditional survivor
function is not as straightforward as for the gamma and inverse Gaussian
distributions. To proceed, the function is split into a “baseline” part of the
expression and a “frailty” part,
S(t|Z) = exp
[
−
∫ t
0
λ(u)
(
1− exp(−ρu)
1 + exp(q)
− exp(q)
1 + exp(q)
)
du
]
exp
[
−
∫ t
0
Zλ(u)
(
exp(−ρu)
1 + exp(q)
+
exp(q)
1 + exp(q)
)
du
]
, (5.16)
with the marginal form of the latter being obtained by its Laplace transform
in the usual way. For a piecewise constant FOI the derivation is as follows,
using a slight change in notation to chapter 3. With k time bands and
cutpoints c0 = 0, c1, c2...ck =∞, the FOI is given by
λ(t) =

λ1, if t ≤ c1;
λ2, if t > c1 and t ≤ c2;
...
λk, if t > ck−1,
and the cumulative hazard A(t) as
A(t) =
∫ t
0
λ(u) du =
k∑
i=1
λi max(0,min(t− ci−1, ci − ci−1)).
Defining the time spent in band i as ti = max(0,min(t− ci−1, ci− ci−1)) and
vi = ci−1 + ti, the terms in equation 5.16 requiring evaluation are∫ t
0
λ(u) du =
k∑
i=1
λiti,
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∫ t
0
λ(u) exp(−ρu) du =
k∑
i=1
−λi exp(−ρu)
ρ
∣∣∣vi
ci−1
=
k∑
i=1
λi(exp(−ρci−1)− exp(−ρvi))
ρ
and the Laplace transform for the frailty part of equation 5.16, with Z having
a gamma distribution with mean 1 and variance 1
θ
L(c) =
(
1 +
c
θ
)−θ
.
Inserting these expressions into equation 5.16 yields the unconditional sur-
vivor function
S(t) =
exp
[ k∑
i=1
−λiti
(
1− exp(q)
1 + exp(q)
)
− λi
(
exp(−ρvi)− exp(−ρci−1)
ρ(1 + exp(q))
)]
[
1 +
k∑
i=1
λi(exp(−ρci−1)− exp(−ρvi))
ρθ(1 + exp(q))
+
λiti exp(q)
θ(1 + exp(q))
]−θ
. (5.17)
More complex structures are of course possible. For instance, frailty may be
considered to change from one level to another throughout the at-risk period,
with a frailty distribution representing variability in rates of infection during
childhood and a separate frailty distribution for adulthood. Farrington et al.
(2013) proposed a model with two gamma components, Z1 and Z2, with
Z(t) = (1 + (Z1 − 1)h(t))Z2. (5.18)
Obtaining the unconditional survivor function for the two component model
requires integration over the distributions of Z1 and Z2, and so is not as
straightforward as the Laplace transforms considered so far.
The 2-component model could conceivably be applied to people who in-
ject drugs, with a component for new initiates (“childhood”) and for ex-
perienced users. The difficulty here is the comparatively short initiation
period. A more general issue with the model is that the two components
are independent, whereas high or low risk is likely to persist to some extent
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in experienced users. The model could potentially be extended to allow for
correlations between the components, although this is not pursued further
and the single component model in equation 5.13 used to capture the likely
decline in heterogeneity over time.
A general disadvantage of this time-varying frailty model is that the
frailty has limited support, with a minimum value of 1 − h(t) for equation
5.13. This implies a lower bound on the force of infection in the popula-
tion, which may not be epidemiologically plausible if some individuals are
at very low risk in comparison to the rest of the population. For people
who inject drugs the existence of a low-risk group may be unlikely, given the
high prevalence of blood-borne viruses and monotonic increase with time at
risk. Another criticism of the distribution in equation 5.13 is that the frailty
variance declines at a constant rate towards an asymptotic value, which may
be slightly restrictive. However, in practice there is unlikely to be sufficient
information to estimate such changes over time.
An alternative to the model form in 5.18 is to use functions for h(t) based
on powers, which do not suffer from the same issues of limited support, but
are difficult to work with algebraically (Enki et al., 2014).
5.1.5 Piecewise constant frailties
An alternative to time-varying frailties based on deterministic functions of
the form considered in section 5.1.4 is the piecewise gamma frailty proposed
by Paik et al. (1994). Their definition is for a nested structure in which
Zi = Z + εi (5.19)
in age band i, where Z has a gamma distribution for the overall frailty of
an individual and εi have independent gamma distributions corresponding
to age-specific fluctuations in band i; and the mean of the two distributions
sums to 1 (µ1 + µ2 = 1). This form is particularly easy to work with in
conjunction with piecewise constant hazards: if the age bands of the baseline
FOI and frailties coincide, the population survivor function is given by
S(t) = exp
[
−µ1
γ
log(1 + γA(t))−
k∑
i=1
µ2
γi
log(1 + γiλiti)
]
, (5.20)
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where µ1 and µ2 are the means of the overall and the component frailties
respectively, γ and γi their scale parameters, A(t) the usual cumulative haz-
ard, λi the baseline hazard in age band i and ti the exposure time in age
band i. Rather than multiplying components raised to the power of µ1
γ
and
µ2
γi
, as defined in Paik et al. (1994), the expression above sums log terms
then exponentiates, which may be more numerically stable as the number of
piecewise constant terms grows.
The interpretation of the Paik model is a little unusual, potentially lim-
iting its practical application. Under the hierarchical structure individuals
have an overall frailty and an age-specific frailty. These age-specific com-
ponents are independent, so individuals may be high risk in one age band
and low risk in another; the component part of the individual frailty is “re-
set” in each age band, therefore there is no inter-age band selection effect
in survivors. These properties may or may not be desirable, but it seems
intuitively more likely that some correlation between frailties would persist
within individuals over time. In particular, this structure may not be viewed
as a piecewise alternative to equation 5.13 or 5.18, in which individuals have
a persistent but declining frailty or transition between two values. Farrington
et al. (2012) propose a multiplicative alternative that allows compounding of
frailties; this would allow dependence to be incorporated by allowing frailty
components to persist across age bands, with the multiplicative relationship
preserving the unit mean of the overall frailty distribution.
5.2 Multivariate models
With univariate data, the only information available to estimate the parame-
ters of a given frailty distribution is via distortion in the population survivor
function (as observed in Figure 5.2). This implies that the shape of the
unconditional survivor function has to be assumed, or rather, the shape of
the underlying hazard function. This might be reasonable in some settings,
where biological or epidemiological considerations strongly suggest a partic-
ular parametric form (for instance, the Weibull distribution), but in general
it would appear unsafe to make strong assumptions about the age-specific
risk of infection. In particular, under the piecewise constant models that
have been the focus so far there would be no information with which to es-
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timate the frailty distribution, provided that the cut-points are sufficient to
capture the general shape of any plausible hazard function.
Multivariate models address this problem by providing information on
the fraily via the correlation between infections. Infections that share a
transmission route will naturally be correlated, although correlation may
occur for other reasons, such as variation in individuals’ general biological
susceptibility to infection. Assuming for now that transmission routes are
identical, the degree of correlation determines the extent of individual het-
erogeneity. An individual that has a higher risk of infection with A due to
certain risk behaviours or susceptibility will also have a higher risk of infec-
tion with B if the route of transmission is the same, inducing an association
between A and B. There may still be some interplay between the assumed
frailty distribution and function for the FOI; for instance, models incorpo-
rating age and time effects, or covariates, might allow distortions from the
population survivor function to “feed into” the estimated frailty; but in gen-
eral if the baseline FOI function is sufficiently flexible then the estimated
frailty should give a true indication of the extent of individual heterogeneity.
5.2.1 Implementation of simple frailty models
Infection status probabilities are denoted as follows: let pi00(t) be the prob-
ability that neither infection has occurred by time t, pi10(t) the probability
that infection 1 has occurred by time t but infection 2 has not, pi01(t) the
probability that infection 2 has occurred by time t but infection 1 has not,
and pi11(t) the probability that both infections have occurred by time t. Then
the survival function for remaining free from both infections may be derived
as in equation 3.13. Assuming for now that the risks of infection 1 and 2 are
independent gives
pi00(t) = P (T1 > t)P (T2 > t)
= exp
(
−
∫ t
0
h1(u) du
)
exp
(
−
∫ t
0
h2(u) du
)
= exp
(
−
∫ t
0
h1(u) du−
∫ t
0
h2(u) du
)
,
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where Ti is the time infection i occurs and hi(t) is the hazard for infection
i. It is simplest to then derive the probabilities for a single infection pi10(t)
and pi01(t) in terms of the marginal probability of remaining free from the
other infection, minus the probability of neither infection. The probability
of both infections occurring is then the remaining probability. With Ai(t) =∫ t
0
hi(u)du, the cumulative hazard for infection i,
pi00(t) = exp (−A1(t)− A2(t))
pi10(t) = exp (−A2(t))− pi00(t)
pi01(t) = exp (−A1(t))− pi00(t)
pi11(t) = 1− pi00(t)− pi10(t)− pi01(t).
(5.21)
The log-likelihood for paired infection data then takes the product multino-
mial form ∑
t
1∑
i,j=0
nijt log(piij(t)),
where nijt is the number of individuals with disease status (i, j) at time t.
In the case that some individuals are missing status data for one infection,
these individuals contribute to the likelihood via marginal terms, e.g.,
∑
t
1∑
i=0
ni.t log(pii0(t) + pii1(t))
for data on infection 1 only.
The formulae outlined above are not particularly useful in themselves, as
no further information is gained from analysing the joint data compared to
fitting separate models for each infection, but the equations form the basis of
the multivariate frailty models. For a gamma distributed frailty, using the
expression S(t|Z) = exp (−ZA(t)), then integrating out Z as in equation
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5.6, leads to
pi00(t) =
(
1 +
A1(t) + A2(t)
θ
)−θ
pi10(t) =
(
1 +
A2(t)
θ
)−θ
− pi00(t)
pi01(t) =
(
1 +
A1(t)
θ
)−θ
− pi00(t)
pi11(t) = 1− pi00(t)− pi10(t)− pi01(t)
(5.22)
The equations for the inverse Gaussian distribution may be derived in a
similar way. These models may readily be extended to an age- and time-
specific force of infection by substituting cumulative force of infection func-
tions A(a, t) =
∫ t
0
h(u, t − a + u)du for infections 1 and 2; and indeed any
of the general forms of covariate model described in section 3.2.5. The like-
lihood then follows the same multinomial form, but is of course indexed by
age, time, and any other covariates. As with the univariate models, the
observed probabilities of infection may be related to true infection status if
information is available on the sensitivity and specificity of the tests. The
tests for the infections considered in this thesis have imperfect sensitivity but
near-100% specificity, so only sensitivity need be considered. This results in
the following formulae:
p00 = pi00 + (1− S1)pi10 + (1− S2)pi01 + (1− S1)(1− S2)pi11
p10 = pi10S1 + S1(1− S2)pi11
p01 = pi01S2 + S2(1− S1)pi11
p11 = pi11S1S2,
(5.23)
where pij are expected proportions observed for infection 1 and 2, piij the
true probabilities, and S1 and S2 the sensitivity of tests for infection 1 and 2
respectively. This approach is based on the assumption that the sensitivity
of the two tests is independent and the sensitivity of one test is not altered
by positive infection status for the other test.
Model fitting will generally require bespoke code to maximise the likeli-
hood under frailty models. Extending such models to include covariates in
piecewise constant models with additive effects is relatively simple. Covari-
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ates are simply added to the linear predictor in the GLM form of the model,
with a parameter representing the additive difference in the force of infection,
multiplied by the exposure time at that covariate level, being added to the
cumulative FOI (see equations 3.22 and 3.23). For multiplicative models the
relationship between covariates, exposure time and the cumulative hazard is
more difficult to specify in a general form. For instance, for a model with
piecewise age-specific FOI exp(µi) for age band i and proportional hazards
for a covariate x with hazard ratio exp(β) the survivor function is given by
S(a, x) = exp[−(exp(µ1 + βx)A1(a) + exp(µ2 + βx)A2(a)+
...+ exp(µk + βx)Ak(a)].
(5.24)
It is straightforward to extend the model in equation 5.24 to incorporate
additional covariates, interactions with age, time and so on, but will require
adapting the code used to run the model (in contrast to additive models,
which will only require specification of a different design matrix). Therefore
testing alternative model forms can be time-consuming.
An alternative approach is to create multiple data rows for each observa-
tion, where each row consists of a particular age, time and covariate pattern
in the individual’s exposure history, and the exposure time at this covariate
combination. With indicator variables for a particular covariate combina-
tion, the FOI is the exponentiated sum of the relevant parameters, which is
multiplied by the exposure time. For instance, in equation 5.24 there is a sep-
arate row in the data corresponding to each of the terms exp(µi + βx)Ai(a).
These contributions to the cumulative hazard are then summed across each
individual’s history, and it is far easier to derive general-purpose model code
to calculate each such contribution to the cumulative hazard (model code
is provided in appendix section 9.2.2). Table 5.1 shows an example of such
data, which are similar in form to that used for time-varying covariates in
survival analysis.
This formulation requires larger datasets and increased computation time
(the summation across rows and columns must be performed at each iteration
of the numerical search procedure), but the advantage is generalisable model
code.
The time-varying frailty models require some care in implementation,
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Table 5.1: Example data for split exposure periods, with three age bands
(a1, a2, a3) and three time bands (t2, t3; baseline period is 1), a covariate x
that can modify the hazard in the first age period and the exposure time t
for individual i at exposure period j.
i j a1 a2 a3 t2 t3 x t
1 1 1 0 0 0 0 1 3
1 2 1 0 0 1 0 1 2
1 3 0 1 0 1 0 0 7
1 4 0 1 0 0 1 0 3
1 5 0 0 1 0 1 0 4
2 1 1 0 0 1 0 0 5
2 2 0 1 0 1 0 0 2
...
...
...
...
...
...
...
...
...
as unlike the simple frailty models, which consist of the cumulative hazard
within an expression for the Laplace transform, time-varying frailty models
include a number of terms involving cumulative hazards and different pa-
rameters. In particular, the piecewise constant model defined in equation
5.17 includes cumulative sums of the exposure times and FOI up to each
age band, which for models that include both age and time effects becomes
complicated. Again, splitting observations into exposure periods simplifies
things somewhat; with exposure periods sorted in their temporal sequence
the necessary sums are easier to calculate. Model code is provided in ap-
pendix section 9.2.3.
5.2.2 Separable mixing and shared parameters
It is important to remember when modelling data on infectious diseases that
changes in the FOI according to age (or exposure time) and calendar time
are the result of changes in the frequency and patterns of contact between
infected and susceptible individuals. This may be accounted for in infectious
disease models via the formulation of a contact matrix, representing the
relative frequencies of effective contacts (“mixing”) between individuals of
age group i and age group j (see for instance, Farrington et al. (2001)). A
specific form of contact frequencies is separable mixing, in which the contacts
of age i are distributed according to the activity level in each age group j.
If the contact functions for each infection are proportional, then the age-
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specific FOI for the two infections must also be proportional (Farrington
et al., 2001). Specifying the age-specific FOI for infection 1 as λa1 = λa, if
the age-specific FOI for infection 2 is proportional to that for infection 1, it
is given by λa2 = cλa, where c is a constant. Likelihood ratio tests or other
model fit statistics may then be used to test the null hypothesis that the
FOIs are proportional. If this null hypothesis is rejected, then the model
with non-proportional FOIs is preferable.
This test may also be extended to the case where there is individual het-
erogeneity; in fact, when heterogeneity is present but not allowed for in the
analysis, the test may reject the separable mixing model even if this model
is sufficient. If separable mixing is tested for while incorporating frailty ap-
propriately however, the test is then valid. For instance, the multinomial
proportions for infection status under the gamma frailty model in equation
5.22 would be:
pi00(t) =
(
1 +
A1(t) + cA1(t)
θ
)−θ
pi10(t) =
(
1 +
cA1(t)
θ
)−θ
− pi00(t)
pi01(t) =
(
1 +
A1(t)
θ
)−θ
− pi00(t)
pi11(t) = 1− pi00(t)− pi10(t)− pi01(t).
(5.25)
Calendar time may also be considered. HCV, HBV and HIV are likely to
differ in temporal effects due to improvements in HBV vaccination and HIV
treatment (which decreases infectivity), while until relatively recently there
has been no such direct intervention on infection risk for HCV. In this case,
the temporal effects for two infections might differ, while having proportional
injecting duration (age) effects. In this case, if the model is specified in terms
of injecting duration-specific hazard ratios (HR) as in equation 3.19 then the
HRs would be the same for the two infections.
In general, proportionality tests may be applied for age, time or any
other other covariate, to assess whether the change in risk according to cer-
tain factors is proportional for the two infections. The interpretation of the
test as a test for separable mixing may become somewhat muddied for more
complex models in which some factors are shared and some are not. In par-
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ticular, temporal changes due to HBV vaccination and HIV treatment may
not have a proportional effect at different injecting durations, and therefore
the contact matrix may effectively change over time. Nevertheless, tests
of proportionality for different factors may yet provide insights into shared
elements of risk behaviour.
5.2.3 Associations between infections and further in-
vestigation of heterogeneity
The correlation between infections provides information on shared frailty
(Farrington et al., 2001), and therefore investigation of the dependence struc-
ture can provide an indication of suitable frailty distributions. Archimedean
copulas provide a framework for doing this, in which a bivariate distribu-
tion on the unit square is specified in terms of its marginal distributions,
in this context the marginal survivor functions S1(t) and S2(t) for infec-
tions 1 and 2 respectively, and an associated dependence function C (Genest
and Rivest, 1993). This allows the dependence structure to be investigated
independently of the marginal effects.
The Clayton copula is particularly useful for bivariate survival data
(Clayton, 1978). The resulting cross-ratio function (CRF) can be written
as
θ∗(t1, t2) =
S(t1, t2)D1D2S(t1, t2)
[D1S(t1, t2)][D2S(t1, t2)]
, (5.26)
where Dj denotes the derivative operator δ/δtj. The CRF may be interpreted
as the ratio of the hazard rates for event 1 given event 2 has, or has not yet,
occurred (and vice versa) (Oakes, 1989). A key feature of this measure is its
frailty interpretation, as θ∗(t1, t2) depends only on (t1, t2) through S(t1, t2)
(Oakes, 1989).
Clayton (1978) provides an alternative derivation of this model based
on the Cox model (Cox, 1972) and frailty with a gamma distribution, which
has constant RFV. Alternative models would therefore not result in constant
θ∗(t1, t2) when the underlying RFV is constant and would therefore not be
suitable for the purpose of choosing an appropriate frailty distribution. Plots
of the CRF can thus be used to suggest an appropriate frailty distribution,
with the gamma distribution suggested by a constant CRF, and decreasing
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or increasing CRFs suggesting alternative distributions.
For current status data, the joint survivor function S(t1, t2) is not ob-
servable and the CRF cannot be evaluated. Unkel and Farrington (2012)
proposed a measure of association that tracks the RFV over time in bi-
variate current status data, which can help to choose an appropriate frailty
distribution. This measure is defined as the value Φ solving the implicit
equation
(
p1(t)
1−exp(Φ) + p2(t)1−exp(Φ) − 1
)1/[1−exp(Φ)]
= p00(t), (5.27)
where p00(t) is the proportion of individuals susceptible to both infections
at time t and p1(t) and p2(t) the proportion susceptible to infection 1 and
2. This approach is preferable to other measures of association, such as the
odds ratio, which can increase over time even if the RFV is not increasing
(Unkel and Farrington, 2012).
Examination of plots of Φ against time at risk (injecting duration in this
context) can help to understand whether the RFV is constant or changes
over time, with a common pattern in epidemiology being a decreasing RFV.
Such plots may also be constructed according to subgroups based on covari-
ate information, such as gender and calendar time, to examine whether the
evolution of the RFV differs. If important differences are revealed, strati-
fied analysis may then be undertaken to examine differences in heterogeneity
between the subgroups. Stratification also allows the baseline FOI and any
other covariates to differ between subgroups, which may or may not be de-
sirable. An alternative approach would be to allow some shared parameter
values across strata in the structural part of the model, but a stratified frailty
distribution; for instance, different frailty variances for males and females,
a fixed HR for females compared to males and common effects for calendar
time and injecting duration.
The FOI for a stratified frailty variance model with age-specific FOI λi(t)
in subgroup i and frailty variance Zi in subgroup i is therefore
λi(t|Zi) = Ziλi(t). (5.28)
The marginal survivor functions are obtained as in section 5.1 for any of
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the frailty distributions considered so far, with the δi parameters for frailty
variance (and the rate and asymptote parameters ρ and q for the TVF model)
being estimated separately for each subgroup i of the data. For instance,
under a gamma frailty the marginal survivor function with FOI and frailty
variances as in equation 5.28 becomes
Si(t) =
(
1 +
Ai(t)
θi
)−θi
. (5.29)
This model is readily extended to include calendar time and any other co-
variates, and may include a mixture of parameters that are specific to each
subgroup, common across subgroups, or based on proportional FOIs across
subgroups. If differences in frailty variance are being examined across sub-
groups, then the baseline FOI should also vary across these subgroups, at
least allowing for differences under a proportional hazards assumption (for
example a FOI of λ(t) in males and cλ(t) in females, where c is a constant).
As ever, the frailty variance is being estimated conditional on the baseline
FOI structure, so some care is required to incorporate relevant sources of
measured heterogeneity, which might include interactions between the sub-
group variable with age or time.
Further extensions might allow some aspects of the more complex models,
such as the TVF model, to vary but not others. For instance, stratified δ but
a common shape for the decline in frailty variance or asymptote parameters.
The frailty variance might also be allowed to vary according to more than one
covariate factor. However, further complexity is not considered subsequently,
and only the basic stratified frailty variance models are considered.
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Chapter 6
Bivariate models for
blood-borne viruses in people
who inject drugs
In this chapter the methods described in chapter 5 are applied to the UAM
data on people who inject drugs (PWID). Chapter 4 focussed on two main
areas: firstly, how the risk of infection for HCV, HBV and HIV changed
with injecting duration, over calendar time, and whether injecting duration-
specific risk changed over time (interactions). The second aim was to exam-
ine a broad range of covariates using demographic and risk factor data col-
lected by the UAM survey that might be of potential interest for modelling.
In this chapter the aim is to conduct further modelling of covariates within a
force of infection (FOI) model while incorporating a frailty distribution that
represents individual heterogeneity. The use of different distributions that
reflect different types of individual heterogeneity is investigated, in order to
understand how risk evolves over the course of injecting career.
The combination of covariate models and frailty distributions allows the
interplay between these two factors to be explored. One obvious question is
whether the frailty variance is decreased by the addition of covariate infor-
mation; as the frailty distribution accounts for unmeasured heterogeneity,
accounting for some of the differences in risk should of course decrease the
level of residual variation. Secondly, the frailty distribution itself might be
altered by the inclusion of covariates, especially where the distribution of
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covariate levels changes with exposure or calendar time, or there are in-
teractions or time-varying covariates. Including covariates may therefore
lead to different patterns of residual variation with increasing time at risk.
The inclusion of individual heterogeneity will also answer the more common
question considered in survival analysis and analysis of current status data:
whether a FOI/hazard that apparently decreases with time at risk is due to
selection effects induced by heterogeneity.
Finally, individual heterogeneity may vary according to different risk
groups, such as by region or gender. Such differences can be explored via
stratified analysis. Alternatively, the problem may be framed within a co-
variate model with group-specific frailty variances but some covariate effects
common to the different groups. This approach may be preferable to fit-
ting separate models to each stratum, which might be inefficient and lead to
estimation problems if the data are too finely subdivided.
The chapter is organised as follows. Firstly, patterns of relative frailty
variance are examined via the measure of association Φ described in section
5.2.3 to determine appropriate functional forms for the frailty distribution.
Multiplicative models are then used to examine the injecting duration- and
time-specific force of infection, with and without interactions, under a range
of frailty distributions. The following section then focusses on the inclusion
of covariates: demographic information on region, age and gender, and risk
factor information on ever received works (needles, syringes etc.) from an-
other person, ever use and age at first use of needle exchange, ever/age first
imprisoned, and men who have sex with men. Finally, stratified frailty vari-
ances are implemented in order to explore whether certain subgroups exhibit
greater levels of individual heterogeneity.
The focus of the analysis is on the bivariate HCV-HBV data, with HCV
being the the key outcome of interest and the correlation with HBV pro-
viding information on individual variability. Data are far more limited for
HIV, although the key models are examined for HCV-HIV and HBV-HIV
pairings, with a particular view as to how the HIV data can inform more
complex structures for the correlation between infections. The HBV-HIV
pair is therefore also of particular interest, as these infections have a wholly
shared transmission route, namely both injecting and sexual contacts. All
analyses are based on data from 2000 onwards that have complete informa-
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tion on the key covariates.
6.1 Measures of bivariate association: het-
erogeneity in risk of BBV infection in
people who inject drugs
The measure of association Φ described in section 5.2.3 tracks the relative
frailty variance (RFV) over exposure time, showing how frailty evolves in
survivors and suggesting an appropriate structure for the frailty distribution
(Unkel and Farrington, 2012). Figure 6.1 shows Φ by injecting duration
for the three infection pairs, HCV-HBV, HCV-HIV and HBV-HIV. For all
three pairings there is a general decline in RFV with injecting duration. For
HCV-HBV, Φ drops sharply over the first three years of injecting, before
declining more slowly subsequently, although still significantly above zero
(which would indicate no heterogeneity). A similar pattern is observed for
HCV-HIV, although HIV infections are sparse and estimates more variable
across injecting duration, with wide confidence intervals. For HBV-HIV
there is also some decline, but more slowly, and heterogeneity is greater
than the other pairings, although again, data are sparse.
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Figure 6.1: Associations between the three infection pairs by injecting du-
ration, estimates of Φ and 95% confidence intervals, and Lowess curve. In-
jecting durations are grouped where data are sparse to prevent zero cells.
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It is worth considering the routes of transmission for the different in-
fections, with all being transmitted via sharing of injecting equipment but
the addition of sexual transmission for HIV and HBV (which can be consid-
ered relatively uncommon for HCV). The Lowess curves for HCV-HBV and
HCV-HIV pairs are more similar than the HBV-HIV pair (albeit with wide
confidence intervals for the HIV pairs). This is as would be expected if the
correlation is due to heterogeneity in injecting behaviour.
The HCV-HIV pair may have a slightly lower correlation, and in particu-
lar decline fastest towards zero. Data are too sparse to be conclusive, but this
might point to a smaller component of shared risk of infection following the
high-risk initiation period. Conversely, the HIV-HBV pair, which have iden-
tical transmission routes, show the highest level of correlation, which may
reflect the additional shared heterogeneity resulting from the sexual trans-
mission route. Although conclusions are uncertain, the observed patterns are
consistent with epidemiological considerations. Also of note is that sexual
exposure may occur prior to injecting for HBV and HIV, which could affect
the evolution of the RFV in unpredictable ways, depending on the baseline
forces of infection and correlation between the routes of transmission.
It is also of interest to see whether the RFV may have different patterns
over time and according to covariate levels. Data are too sparse for further
subdivision of the HIV pairs, but this can be investigated for HCV-HBV. The
following plots therefore show the measure Φ for HCV-HBV by injecting du-
ration according to survey year, region, age at first use, gender, ever received
works and ever imprisonment (it was not possible to examine whether men
who have sex with men and those that have never used a needle exchange
have different patterns, as both these groups are too small).
Figure 6.2 shows Φ according to survey year, which is divided into three
5-year periods from 2000 onwards. The relative frailty variance appears to
change pattern across periods, with a continuous decline for 2000-2004, a
sharp decline over the first 5 years of injecting and more constant thereafter
for 2005-2009, and fairly constant for 2010-2014.
Results for region are shown in Figure 6.3, with North East combined
with Yorkshire and Humber and East and West Midlands combined due to
sparsity of data. Φ appears to be high initially but declining for London,
compared to a lower, but more stable value in the North West. Results
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Figure 6.2: Association between HCV-HBV by survey period and injecting
duration, estimates of Φ and 95% confidence intervals, and Lowess curve.
Injecting durations are grouped where data are sparse to prevent zero cells.
are less precise for other regions, but appear to point to different regional
patterns, with a sharp decline and lower correlation subsequently in the
South West, higher correlation in Wales, and an unusual “bathtub” (de-
creasing then increasing) shape for the combined North East and Yorkshire
and Humber region.
Figure 6.4 shows Φ for males and females. The decline in RFV is slightly
sharper for males compared to females, and interestingly HCV-HBV infec-
tion in males has a generally stronger association, indicating that females
may be more homogeneous in their risk of infection.
Figure 6.5 shows Φ by age at first use. The pattern for those that began
injecting at less than 18 years of age shows a slow decline over injecting
career, while those aged 18-24 have a steeper decline over the first 5 years
and more stable thereafter. The pattern is similar for those that began
injecting at 25 or older, but with a lower value of Φ at initiation.
There was little difference in pattern according to whether ever received
works or not (Figure 6.6), although Φ may remain slightly elevated at longer
injecting durations in those that report never receiving works. The difference
is plausible: those that report never sharing equipment are a mixture of those
that genuinely have never shared and those that have incorrectly answered
the question (if all responses were genuine, prevalence in this group would be
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Figure 6.3: Association between HCV-HBV by region and injecting duration,
estimates of Φ and 95% confidence intervals, and Lowess curve. Injecting
durations and some regions are grouped where data are sparse to prevent
zero cells.
extremely low, as those infected with a blood-borne virus are highly likely
to have acquired infection via sharing injecting equipment). Conversely,
those that report sharing equipment would probably be less likely to have
misreported their answer, and therefore be a more homogeneous group in
terms of risk.
Finally, Figure 6.7 shows Φ by ever-imprisoned status. Φ is at around the
same level at initiation, but declines more quickly to a slightly lower value
for those ever imprisoned. For most PWID, imprisonment is likely at some
point in injecting career (69% of those in the data from 2000 onwards have
been imprisoned) and therefore those that have never been imprisoned are
the rarer, and apparently more heterogeneous group. There may also be an
aspect of under-reporting of imprisonment, similar to that for ever receiving
works, which would result in a mixture of risk-types in the never-imprisoned
group.
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Figure 6.4: Association between HCV-HBV by gender and injecting dura-
tion, estimates of Φ and 95% confidence intervals, and Lowess curve. Inject-
ing durations are grouped where data are sparse to prevent zero cells.
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Figure 6.5: Association between HCV-HBV by age at first use and injecting
duration, estimates of Φ and 95% confidence intervals, and Lowess curve.
Injecting durations are grouped where data are sparse to prevent zero cells.
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Figure 6.6: Association between HCV-HBV by ever receiving works and
injecting duration, estimates of Φ and 95% confidence intervals, and Lowess
curve. Injecting durations are grouped where data are sparse to prevent zero
cells.
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Figure 6.7: Association between HCV-HBV by ever-imprisonment and in-
jecting duration, estimates of Φ and 95% confidence intervals, and Lowess
curve. Injecting durations are grouped where data are sparse to prevent zero
cells.
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6.1.1 Conclusions
The data from all three pairs of infections point strongly toward a declining
frailty variance in survivors, which is consistent for the majority of sub-
groups across a range of covariates. However, the pattern of decline changes
markedly across some subgroups, and according to survey year. Stratified
plots of Φ can reveal such differences, but may not capture the structure
of residual heterogeneity after accounting for time and other covariates; in
other words, although the patterns may appear to vary across subgroups,
a common frailty distribution might still capture the residual heterogeneity
adequately in more complex models. This can be assessed via the predicted
association between infections, with Φ calculated from the bivariate preva-
lence predicted by a frailty model and plotted against the observed values
to examine how well the chosen distribution for residual frailty fits. These
plots require some care in interpretation, representing the estimated associ-
ation between infections conditional on both the frailty distribution and any
modelled covariates.
6.2 Bivariate frailty models: trends and risk
patterns
The inclusion of frailty distributions is first examined within models with in-
jecting duration and time effects only, with and without interactions between
them. Data from 2000 onwards are considered, for which key covariates are
non-missing (equipment sharing, needle exchange, imprisonment and men
who have sex with men. Region, age and sex are always complete). Within
this subset of data, all individuals have data on at least one infection test
within each bivariate pair (HCV-HBV, HCV-HIV and HBV-HIV). Therefore
the same dataset is used in all subsequent analyses.
Calendar time and injecting duration are defined as in section 4.2: pre-
1980, 1980-1985, 1985-1990, 1995-2000, 2000-2005, 2005-2010 and 2010 on-
wards; and injecting duration as ≤ 1, 1-3, 3-5, 5-10, 10-15, 15-25 and > 25
years. Four models are considered for the frailty distribution: independence
(no frailty), gamma, inverse Gaussian and a single-component time-varying
frailty (TVF) model as described in section 5.1.4. The gamma distribution
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provides a constant relative frailty variance (RVF), such that the hetero-
geneity of survivors is unchanged, whereas the inverse Gaussian distribution
results in declining RVF due to selection effects. The TVF model uses a
gamma distribution that declines in variability over time towards an asymp-
tote (equation 5.14).
6.2.1 Estimated frailty variance and model fit
Table 6.1 shows frailty variances and AIC scores for the eight possible models
(four frailty distributions, with and without interaction between time and
injecting duration) fitted to the bivariate HCV-HBV data. Under the no
interaction models, the frailty variance δ is greater for the inverse Gaussian
than the gamma model, and highest for the TVF model. These values are
for the frailty variance at t = 0, when all individuals are susceptible, but
this variability decreases over time for the non-gamma frailty models. The
ρ parameter for the TVF model is 0.99 (see equation 5.14), such that the
frailty variance declines rapidly towards the asymptotic lower bound; the
estimate of q is 0.74 such that this lower bound is 0.68, around two-thirds
of the initial frailty variance.
Table 6.1: Bivariate model statistics for HCV-HBV data, with and with-
out interaction between injecting duration and time and under four different
frailty distributions. Frailty variance δ, -log-likelihood, number of parame-
ters k and AIC score.
No interaction Interaction
Distribution δ -LL d.f. AIC δ -LL k AIC
Independence NA 22798.1 28 45652.3 NA 22770.3 52 45644.6
Gamma 0.97 22445.8 29 44949.6 0.98 22424.5 53 44955.0
Inv. Gaussian 1.94 22422.0 29 44901.9 1.92 22398.2 53 44902.3
Time-varying 3.16 22416.0 31 44893.9 3.18 22392.0 55 44894.1
There is a substantially better fit to the data under the frailty models
compared to independence, and a fair improvement under the inverse Gaus-
sian and TVF models compared to the gamma model, indicating that the
RFV in survivors declines over time in some way. The TVF model provides
some further improvement on the inverse Gaussian, although the two extra
parameters for the rate of decline and asymptotic minimum will provide more
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flexibility so this cannot necessarily be viewed as evidence for a time-varying
frailty rather than a selection effect; it may be that neither distribution is
quite right.
There is very little change in any of the frailty parameter estimates when
including an interaction between injecting duration and time. For all frailty
models the AIC score is increased by the addition of interaction terms, al-
though there is an improvement for the independence model. Figure 6.8
shows the observed and predicted bivariate proportions of HCV-HBV under
the inverse Gaussian model. The model fit appears reasonable from visual
inspection, although there is some lack of fit at longer injecting durations.
This occurs for models with and without interactions and is due to the fixed
effects of injecting duration in the pre-survey period: as the cumulative haz-
ard must increase monotonically, there is a lower bound on prevalence at
longer injecting durations. There is little that can be done to address this,
as interaction terms outside the range of the survey data are not identifiable.
As in section 4.2.1, models with and without interactions are very similar for
the data from 2000 onwards, and the predicted prevalences are also similar
for other frailty distributions.
Figure 6.9 shows estimates of the measure of association Φ based on
the predicted bivariate prevalence from the different frailty models, with in-
teractions between injecting duration and calendar time. This is close to
constant for the gamma model, as would be expected, but increases and
decreases slightly with injecting duration due to changes in covariates for
calendar time. The predicted value of Φ for the inverse Gaussian model
decreases over time, as expected, due to the selection effect. Finally, under
the TVF model Φ decreases rapidly over the first 3 years of injecting du-
ration, but then continues to decrease, and more rapidly than the inverse
Gaussian. This may be counter-intuitive, as under the estimated parameters
for the TVF distribution the frailty variance is very close to its asymptotic
value within a few years and is no longer declining substantially. However,
the association measure Φ at time t reflects the cumulative impact of the
association over the interval (0, t], rather than its impact at time t; this is
unavoidable with current status data, as event times are not observed. For
all frailty distributions, estimates of Φ are very close for the models with
and without interactions.
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Figure 6.8: Observed and predicted bivariate HCV-HBV prevalence (positive
+, negative -) by injecting duration and survey period, inverse Gaussian
frailty. Models with and without interactions between injecting duration
and calendar time effects. Observed proportions are plotted according to
sample size.
Assessing the absolute fit of the models is complicated by the sparsity
of the multinomial data, with HBV-positive HCV-negative individuals com-
paratively rare. Of the possible survey year, injecting duration and bivariate
infection status combinations, 21.6% of cells are zero, 13.6% are ones and
61% of all cells less than or equal to 5. Categories are therefore first col-
lapsed before calculating the deviance, according to the categorisation of
survey year and injecting duration used for the logistic regression models in
section 4.1.1 and removing injecting durations of > 35 years. This results
in 60 combinations of survey period/injecting duration category and only
13.3% of cells less than or equal to 5. The deviance of the inverse Gaussian
model with no interaction between calendar time and injecting duration ef-
fects was 332.4 on 151 degrees of freedom, and the interaction model 296.7
on 127 degrees of freedom, indicating neither fit the data very well. Exam-
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Figure 6.9: Observed and predicted estimates of association between HCV
and HBV under different frailty distributions, with interactions between in-
jecting duration and calendar time. Injecting durations are grouped where
data are sparse to prevent zero cells.
ination of the data points with high deviance contributions reveals little in
the way of a regular pattern, with areas of poor fit spread across injecting
durations and survey years, and pointing more to overdispersion rather than
inadequate model structure.
To further assess the fit of the model the univariate deviance for HCV and
HBV were examined separately. As data are less sparse, survey year is not
grouped and injecting duration can be grouped at a finer level (un-aggregated
for durations up to 10 years, 2-year bands from 10-20 years, 5-year bands
subsequently). The univariate deviance for HCV was 282.7 on 255 degrees
of freedom for the model with no interaction between injecting duration
and calendar time and 254.6 on 243 degrees of freedom for the interaction
model, and for HBV a deviance of 417.5 on 255 degrees of freedom for the
no interaction model and 397.5 on 243 degrees of freedom for the interaction
model. The fit is therefore adequate for HCV but somewhat poor for HBV.
Plots of deviance residuals are shown in figures 6.10 and 6.11 for HCV and
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HBV. As would be expected from the deviances, the variability of deviance
residuals is higher for HBV than HCV. There do not appear to be obvious
systematic patterns in the residuals for HCV, although there is perhaps more
variability in residuals at shorted injecting durations. For HBV there are
some systematic patterns, but this tends to occur in individual survey years;
for instance most of the residuals are negative in 2009 and 2014. This was
noted in section 4.1.2: such “local” patterns can only be captured within the
model if the structural part of the model includes parameters for individual
years. Further, the FOI model is parameterised in terms of cumulative risk
over calendar time and injecting duration, so sharp changes in prevalence in
individual survey years would only be captured by interaction terms at the
level of individual years.
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Figure 6.10: Deviance residuals for HCV under bivariate HCV-HBV model,
with survey year and injecting duration interaction and inverse Guassian
frailty.
For the HCV-HIV and HBV-HIV pairings there were some model fitting
issues: there is far less information to estimate the frailty variance, in partic-
ular changes over time, which is made yet more difficult with the inclusion
168
-
4
-
2
0
2
4
-
4
-
2
0
2
4
-
4
-
2
0
2
4
-
4
-
2
0
2
4
0 10 20 30 40
0 10 20 30 40 0 10 20 30 40 0 10 20 30 40
2000 2001 2002 2003
2004 2005 2006 2007
2008 2009 2010 2011
2012 2013 2014
D
ev
ia
nc
e 
re
si
du
al
s
Injecting duration
Figure 6.11: Deviance residuals for HBV under bivariate HCV-HBV model,
with survey year and injecting duration interaction and inverse Guassian
frailty.
of interactions between injecting duration and time. Table 6.2 shows the
model fit statistics and frailty variances for the bivariate HCV-HIV model.
Patterns are similar to those for HCV-HBV, but somewhat less conclusive,
with a declining frailty variance being preferred to the gamma model but
little difference between the inverse Gaussian and TVF models, and a very
high estimate of the frailty variance under the latter (9.17). For the TVF
model the estimate for ρ, the rate of decline in relative frailty variance, is
73.0, resulting in an immediate decline to the asymptote, estimated at 0.47.
The interaction model results appear unreliable, with the gamma frailty be-
ing preferred to the inverse Gaussian, and an extremely high estimate of the
frailty variance for the TVF model (361). Results are also inconclusive as to
whether the interaction terms are necessary or not, with a better AIC score
for the independence and gamma models with the interaction, but worse for
the two other models.
Table 6.3 shows the model fit statistics for the bivariate HBV-HIV mod-
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Table 6.2: Bivariate model statistics for HCV-HIV data, with and without
an interaction between injecting duration and time and under four different
frailty distributions. Frailty variance δ, -log-likelihood, number of parame-
ters k and AIC score.
No interaction Interaction
Distribution δ -LL d.f. AIC δ -LL k AIC
Independence - 15048.6 28 30153.2 - 15020.9 52 30145.8
Gamma 0.84 15042.9 29 30143.9 0.56 15008.4 53 30122.8
Inv. Gaussian 0.89 15033.4 29 30124.7 0.82 15015.1 53 30136.3
Time-varying 9.17 15032.3 31 30126.6 360.8 15004.2 55 30118.4
els. The pattern is similar to the HCV-HBV results, and appear more or-
derly: the AIC scores decline for the independence, gamma, inverse Gaus-
sian, and TVF models in turn for models with and without interactions,
and there is a fairly consistent preference for the no interaction model over
the interaction model. The frailty variance is estimated to be higher for
the inverse Gaussian model, which is to be expected, given that the vari-
ance in survivors will decline. The TVF model has a high variance (11.5 no
interaction, 8.7 interaction) and a less rapid rate of decline than the other
pairings(ρ = 0.43 and 0.18 for no interaction/interaction models). However,
the asymptotic minimum is far lower at 0.26 for the no interaction model and
practically zero for the interaction model, indicating far less heterogeneity
in survivors over time.
Table 6.3: Bivariate model statistics for HBV-HIV data, with and without
an interaction between injecting duration and time and under four different
frailty distributions. Frailty variance δ, -log-likelihood, number of parame-
ters k and AIC score.
No interaction Interaction
Distribution δ -LL d.f. AIC δ -LL k AIC
Independence NA 10378.8 28 20813.7 NA 10368.6 52 20841.2
Gamma 1.42 10352.1 29 20762.2 1.44 10328.1 53 20762.3
Inv. Gaussian 2.34 10349.3 29 20756.5 2.30 10325.9 53 20757.7
Time-varying 11.46 10341.8 31 20745.5 8.73 10320.9 55 20751.9
Figure 6.12 shows the observed and predicted proportions of bivariate
HCV-HIV status by survey period and injecting duration. The fit is generally
good for those not infected with HIV, but proportions of HIV positive are
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Figure 6.12: Observed and predicted bivariate HCV-HIV prevalence (posi-
tive +, negative -) by injecting duration and survey period, gamma frailty.
Models with and without interactions between injecting duration and cal-
endar time effects, and no-interaction model with shared injecting duration
effect. Observed proportions are plotted according to sample size; y-axis
scales vary for clarity.
very low, and models both with and without interactions do not capture the
variability in observed proportions very well due to the sparsity of the data.
Figure 6.13 shows the observed and predicted proportions of bivariate
HBV-HIV status by survey period and injecting duration. As with the HCV-
HBV model, there is some lack of fit for HBV at longer injecting durations.
Proportions of HIV positive are very low, and models both with and without
interactions do not capture the variability in observed proportions very well.
The figure also displays predictions according to a shared injecting duration
effect (see section 6.2.2).
Figure 6.14 shows estimates of the measure of association Φ between HCV
and HIV based on the predicted bivariate prevalence from the different frailty
models, with interactions between injecting duration and calendar time. The
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Figure 6.13: Observed and predicted bivariate HBV-HIV prevalence (posi-
tive +, negative -) by injecting duration and survey period, gamma frailty.
Models with and without interactions between injecting duration and cal-
endar time effects, and no-interaction model with shared injecting duration
effect. Observed proportions are plotted according to sample size; y-axis
scales vary for clarity.
inverse Gaussian model shows a slight decline in association as injecting
duration increases, but is generally comparable to the gamma frailty model.
The TVF model captures the decline in Φ better; this is due to the very
high estimate of initial frailty variance and subsequent high rate of decline,
although this was somewhat less for the model without interactions. For the
other frailty distributions, there was little difference between models with or
without interactions.
Figure 6.15 shows estimates of the measure of association Φ between
HBV and HIV based on the predicted bivariate prevalence from the different
frailty models, with interactions between injecting duration and calendar
time. The inverse Gaussian model shows a slightly higher association at
shorter injecting durations but Φ declines to the same level as the estimates
172
-1.5
-1
-.5
0
.5
1
1.5
2
f
0 5 10 15 20 25 30
Injecting duration
Observed Gamma Inv G TVF
Figure 6.14: Observed and predicted estimates of association between HCV
and HIV under different frailty distributions, with interactions between in-
jecting duration and calendar time effects. Injecting durations are grouped
where data are sparse to prevent zero cells.
from the gamma distribution at longer durations (over 20 years). Neither fit
the observed pattern well for shorter injecting durations. The TVF model
however captures the decline in Φ better over this period and although data
are sparse, appears the most plausible model for the observed frailty. There
are only minor differences in the estimates for models with and without
interactions.
Assessment of model fit is again difficult, as data are even sparser for
infection pairs including HIV, with 46% of cells equal to zero and 72% with
counts of five or less. Grouping survey year and injecting duration as for
HCV-HBV gives a deviance of 308.9 on 151 degrees of freedom for the gamma
frailty model with no interaction between injecting duration and survey year
effects, and 270.5 on 127 degrees of freedom for the interaction model. Again,
this appears to be partly due to overdispersion and the constrained lower
bound on prevalence at longer injecting durations, with models with and
without interaction terms overestimating HBV prevalence at longer injecting
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Figure 6.15: Observed and predicted estimates of association between HBV
and HIV under different frailty distributions, with interactions between in-
jecting duration and calendar time effects. Injecting durations are grouped
where data are sparse to prevent zero cells.
durations in more recent years.
6.2.2 Trends and risk patterns under bivariate frailty
models
Parameter estimates for the baseline FOI by calendar time and injecting
duration-specific HRs for HCV and HBV are shown in Table 6.4, for each of
the frailty distributions, in the model with no interaction between injecting
duration and calendar time. As observed in section 4.2, there is a substan-
tially increased risk of infection in the 1st year of injecting (compared to 3-5
years) for both HCV and HBV. This is reduced somewhat under the frailty
models compared to the independence model, but still very high. Accounting
for heterogeneity therefore only partly explains the high prevalence of BBVs
in 1st year injectors. Subsequent to the first year of injecting, the FOI stays
relatively constant for HCV and HRs for injecting durations of 5-10 and
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10-15 years are fairly similar under the different frailty models. Beyond 15
years the estimates differ according to the choice in frailty distribution. This
is due to a combination of sparse data and the constraining effect described
above.
Temporal patterns for HCV suggest that risk was highest in the early
1980s and declined slightly until 1995, was markedly reduced in 1995-2000
but then slowly increasing from this point onwards. Temporal patterns are
fairly similar for the different models (the baseline rates vary due to the dif-
ferent estimates of injecting duration, but the patterns are similar) except
for the period before 1980, which are affected by the choice of frailty dis-
tribution. All of the frailty models estimate a low or practically zero risk
(unlike the independence model) prior to 1980, which may be epidemiologi-
cally plausible.
For HBV, as well as a very high FOI in the 1st year, the FOI for years
1-3 is 2-3 times higher than the baseline group of 3-5 years. The estimated
FOI is then similar for 3-5 years and 5-10 years, but estimates are practically
zero from 10 years onwards, such that all of the estimated risk of infection
occurs in the first 10 years of injecting. Therefore although observed HBV
prevalence increases monotonically with injecting duration, according to the
model this is solely due to higher levels of risk in the past, which has de-
creased steadily since 1980.
Obtaining parameter estimates for injecting duration-specific hazard ra-
tios is problematic for HIV. This is due to sparsity of the outcome, and a
general pattern of injecting duration-specific prevalence that causes difficul-
ties in fitting: prevalence rises sharply at initiation, but then does not in-
crease monotonically, staying at around the same level from durations 2-10
years before increasing again. This results in HRs for injecting duration-
specific risk being estimated as practically zero or extremely high in some
categories, with variable patterns in estimated risk depending on the infec-
tion pair (HCV-HIV or HBV-HIV) and chosen frailty distribution (although
an excess risk in the first year is a common feature). Despite this instability
in estimated injecting duration-specific risk, estimates for temporal trends
are plausible and similar across different models and infection pairs. Never-
theless, it would be preferable to model the data according to a reasonable
pattern of risk, rather than one in which the estimated at-risk periods only
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Table 6.4: Parameter estimates for bivariate HCV-HBV model under dif-
ferent frailty distributions: independence (Indep), gamma, inverse Gaussian
(Inv G) and time-varying frailty (TVF). Model with main effects for calendar
time and injecting duration (no interaction).
HCV HBV
Parameter Indep Gamma Inv G TVF Indep Gamma Inv G TVF
Time-specific baseline rate (3-5 years injecting)
pre-1980 0.054 0.000 0.016 0.000 0.059 0.145 0.179 0.225
1980-1985 0.075 0.119 0.153 0.145 0.032 0.057 0.074 0.095
1985-1990 0.069 0.098 0.124 0.115 0.020 0.029 0.037 0.048
1990-1995 0.066 0.103 0.129 0.128 0.012 0.016 0.020 0.025
1995-2000 0.046 0.062 0.072 0.069 0.009 0.012 0.015 0.018
2000-2005 0.060 0.089 0.107 0.103 0.007 0.009 0.010 0.012
2005-2010 0.066 0.099 0.119 0.114 0.003 0.004 0.005 0.006
post-2010 0.076 0.117 0.142 0.136 0.002 0.003 0.003 0.004
Injecting duration-specific hazard ratios
1st year 3.21 2.39 2.14 2.38 11.60 9.34 8.38 7.18
1-3 yr 0.83 0.72 0.69 0.72 3.06 2.62 2.39 1.92
3-5 yr 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref)
5-10 yr 0.66 0.69 0.69 0.64 1.04 0.85 0.82 0.53
10-15 yr 0.79 1.04 1.02 0.87 0.00 0.00 0.00 0.00
15-25 yr 0.68 1.35 1.27 0.99 0.00 0.00 0.00 0.01
25+ yrs 0.76 3.22 2.31 1.48 0.00 0.00 0.00 0.01
occur at initiation and 5-10 or 10-15 years, with a FOI of practically zero at
other times.
Here, assuming common hazard ratios for injecting duration-specific risk
becomes useful. HBV and HIV have identical transmission routes, and al-
though risk has clearly changed over time, the relative hazards according to
injecting duration should be broadly comparable. The likelihood ratio test
(LRT) for separate injecting duration HRs vs. shared parameters, under
the gamma model with no interaction between injecting duration and time,
gave a p-value of 0.844, so no evidence of a poorer fit. Conversely, assuming
shared hazard ratios for calendar time effects provided an extremely small
LRT p-value (p < 0.0001) and therefore the assumption of common time
trends is not tenable. The assumption of shared common parameters had
some impact on the estimate frailty variance, decreasing from 1.42 to 1.29
with common injecting duration parameters, and to 0.54 under common time
parameters.
Table 6.5 shows parameter estimates for calendar time and injecting du-
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ration under separate and shared injecting duration effects. The time effect
(which is expressed as a hazard ratio vs. 2005-2010) is little changed for
HBV under shared effects, but shifted somewhat for HIV with a generally
higher risk of infection prior to 1995, although following the same declining
pattern, and higher risk post-2010. Estimates of injecting duration-specific
risk differ for both infections, with the estimates being an average of the
patterns of risk for the individual infections, but more heavily weighted to-
ward the HBV estimate. Of note is that although the shared HRs appear
markedly higher than for HBV for 1st year and 1-3 years injecting dura-
tions, this is more to do with the estimated FOI in the baseline category,
3-5 years, being “pushed” downwards, as all the HRs are increased. Figure
6.13 shows estimated bivariate prevalence from the shared parameter model
in comparison with the non-shared model. There is little visual difference
in estimated HBV prevalence for those that are HIV negative, and for HIV
prevalence the data are too sparse to tell whether the estimates are better
or worse.
For comparison, the equivalence of injecting duration and calendar time-
specific HRs was tested for the other infection pairs, under the same model
and frailty structure above. For HCV-HIV, there was also no difference in
model fit under common injecting duration-specific hazard ratios (p = 0.795)
and little difference with common time effects (p = 0.221). The frailty vari-
ance was again reduced, from 0.84 to 0.46 under common injecting duration
parameters, and 0.59 under common time parameters. For HCV-HBV the
fit was significantly worse when either effect was assumed to be the same
(p < 0.0001). However, there was little change in the frailty variance (0.97
under no shared parameters, 0.90 with shared injecting duration parameters,
1.03 with shared time parameters).
6.2.3 Conclusions
Under the model with no interaction between injecting duration and time
effects and a gamma frailty distribution, the estimated frailty variances were
0.97 for HCV-HBV, 0.84 for HCV-HIV and 1.42 for HBV-HIV, with gen-
erally similar results under the interaction models. These values represent
a moderate level of individual heterogeneity, with the hazard ratio between
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Table 6.5: Estimated hazard ratios from bivariate HBV-HIV model under
gamma frailty distribution with separate and shared injecting duration ef-
fects. Model with main effects for calendar time and injecting duration (no
interaction).
Separate Shared
Parameter HBV HIV HBV HIV
Time-specific baseline rate (3-5 years injecting)
pre-1980 48.6 2.20 42.5 3.32
1980-1985 16.1 1.67 15.1 2.56
1985-1990 7.81 1.23 7.41 1.42
1990-1995 4.08 1.15 3.93 1.81
1995-2000 3.05 0.43 3.04 0.60
2000-2005 2.13 1.08 2.14 1.06
2005-2010 1 (ref) 1 (ref) 1 (ref) 1 (ref)
post-2010 0.70 1.18 0.68 1.78
Injecting duration-specific hazard ratios
1st year 7.89 571.2 20.9
1-3 yr 2.15 0.00 5.56
3-5 yr 1 (ref) 1 (ref) 1 (ref)
5-10 yr 0.78 62.0 2.71
10-15 yr 0.00 141.8 0.31
15-25 yr 0.00 0.00 0.01
25+ years 0.00 0.00 0.01
the 75th percentile and the 25th percentiles of the estimated gamma distri-
bution being 4.7 for HCV-HBV, 4.1 for HCV-HIV and 7.3 for HBV-HIV.
There is strong evidence of a declining relative frailty variance, and the in-
verse Gaussian distribution provides a better fit and with a higher variance,
predictably so as the correlation between infections naturally declines due
to a selection effect, and therefore must be higher to start with.
The TVF model provides the most detail on how the frailty variance
changes over time, although it is also the most sensitive to the parameterisa-
tion of the baseline FOI. For HCV-HBV there is a rapid decline in variance,
dropping to around two-thirds the initial value. For HCV-HIV the initial
variance is very high, but the decline is near-immediate, to around half the
initial value. Due to the rapid decline the period of time that the frailty vari-
ance is near its initial value at t = 0 is extremely short. For the HBV-HIV
pair the decline in variance is slower, but tends toward a low asymptotic
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value, indicating homogeneity in long-term injectors.
None of the frailty models fully captured the pattern of relative frailty
variance indicated by plots of Φ for HCV-HBV, which showed a sharp initial
decline followed by a slower decline in RFV. As the frailty variance in the
TVF model declines toward an asymptote, it can only capture one of these
features unless additional parameters are introduced. The observed plots
indicate a slight underestimation of the variability in the first 1-3 years of
injecting, although the slow decline is present in the model predictions. For
HBV-HIV, the TVF model gives a more plausible approximation of the ob-
served pattern of Φ. There is something of a dip in RFV around 4-7 years,
but data are extremely sparse and the global pattern appears to have been
captured well.
As noted in section 6.1, the two routes of transmission are only shared
by HBV and HIV, with this pairing showing the strongest association and a
smaller decline in RFV over time. Conversely, the HCV-HIV pairing showed
the least association, with a generally smaller frailty variance in most models.
Following this line of reasoning, heterogeneity in risk may be underestimated
for HCV, given that the transmission route is only partially shared, although
it appears the overlap between HCV and HBV risk is still high.
Identification of parameters is a problem for the HIV data. Tests of
common parameters for each infection indicate that the effect of injecting
duration is comparable for HIV and HBV. However, results also showed
no evidence for a difference between the HCV and HIV injecting duration-
specific HRs, although there was a significant difference for the HCV and
HBV HRs. Clearly there is a lack of data on HIV to conclusively demonstrate
similar patterns of risk according to injecting duration. Nevertheless, a com-
mon effect for injecting duration-specific risk for HBV and HIV is plausible,
due to a wholly shared route of transmission. Conversely, there was strong
evidence for differences in risk according to calendar time for HBV and HIV,
confirming that direct and indirect infection control measures (HBV vacci-
nation, HIV treatment) are likely to have had a different impact on levels
of risk over time for these infections. For the HIV pairings, the estimated
frailty variance was sensitive to the choice of shared parameters. However,
the frailty variance for HCV-HBV showed little change, despite the shared
parameter models giving a markedly poorer fit, so this again may be more
179
due to the sparsity of the HIV data, rather than a systematic effect of con-
straints on the injecting duration parameters.
6.3 Bivariate frailty models with covariates
In this section covariates are introduced into the frailty models to examine
their effect on the force of infection and residual frailty. This is a somewhat
different approach to model building than that usually employed, which
would seek to identify relevant covariates and model structure before exam-
ining whether random effects were required to account for residual variation.
However, the analysis of multivariate current status data largely focuses on
unmeasured heterogeneity, and it is the introduction of covariate data that
is relatively novel here.
The key factors of interest are the covariates identified in sections 4.1.4
and 4.2.4: demographic variables for region, age and sex, and risk factor
information on sharing equipment, needle exchange use, imprisonment and
men who have sex with men (MSM). There are 10 regions, with SE England
set as the baseline group, and the age variable is defined in terms of age
at first use, with < 18, 18 − 24 and 25+. Gender is binary (1 for females
vs. 0 for males) and estimates the difference between females and men
who do not have sex with men: a binary variable for MSM (1) vs. non-
MSM (0) is included to estimate differences in MSM risk in males. Ever
receiving “works” (injecting equipment) is binary, and the needle exchange
use and imprisonment variables are defined in terms of ever occurring plus a
time-varying covariate for pre- and post-first occurrence. This formulation is
intended to unpick the possible effects for being the type of individual that is
ever imprisoned or uses a needle exchange and the change in risk subsequent
to having been first imprisoned or starting to use a needle exchange. An
example of these two aspects of risk would be that heavier users may be
more likely to have ever used a needle exchange, but experience a decline in
risk once usage is initiated.
In most models in section 6.2 there was not a strong preference for includ-
ing interactions between injecting duration and time, and little difference in
the estimates of parameters for the frailty distribution. Therefore only the
main effects for injecting duration and time are considered in this section,
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which reduces the number of models that need be considered and avoids
estimation problems that occur where data are sparse and a number of co-
variates included. Model building is conducted hierarchically in four steps,
starting from the model with no interaction between injecting duration and
calendar time effects in section 6.2 (1). Models 2-4 then successively add
covariates to the model: (2) region (this being the most important factor
identified in section 4.1.4), (3) age and sex, and (4) the risk factor covari-
ates. The sequence is repeated for each of the three infection pairs under
the four frailty models, giving 16 possible models for each pair of infections.
6.3.1 Estimated frailty variance and model fit
Table 6.6 shows the estimated frailty parameters under models with dif-
ferent covariate structures and frailty distributions. For the Gamma and
inverse Gaussian models there is a sequential decline in the frailty variance
δ as covariates are added to the model; however the reductions in variance
are only 20% and 26% respectively. The pattern is similar for the TVF
model, with a marked reduction in δ for the model with region vs. no co-
variates, although initial variance is slightly higher in the full model. In
all the TVF models with covariates, the initial variance is lower but the
asymptotic value to which the frailty variance declines is between 0.80 and
0.84, compared to 0.68 without covariates. The decline toward the asymp-
tote is near-immediate under the covariate models, with ρ ranging from 18.7
to 41.1, but very rapid under the model without the covariates also: with
ρ = 0.99 the frailty variance is two-thirds of the way from the initial value to
the asymptote within 1 year. These results may point to a high variance on
initiation of injecting, which rapidly stabilises, although it is worth noting
that the information to detect changes in frailty is low and models, and their
estimates, are somewhat sensitive.
Model fit is steadily improved by the addition of covariates, with AIC
scores decreasing by 1414.5, 167.1 and 619.0 as region, age and sex, and risk
factors are added sequentially to the model (inverse Gaussian frailty). For
the full covariate models, the inverse Gaussian distribution provides the low-
est AIC score, with a difference in AIC score of 28.4 compared to the gamma
distribution and 6.6 compared to TVF. The TVF model, while providing the
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Table 6.6: Estimated variance parameters for HCV-HBV data under co-
variate models with different frailty distributions. No covariates (No cov);
region; region, age and gender (R,A,G) and all covariates and risk factors
(Full). Frailty variances δ and parameters for time-varying model: ρ, rate
of decline; and asymptotic proportion to which the initial variance at t = 0
declines.
Frailty (1) No cov (2) Region (3) R,A,G (4) Full
Gamma δ 0.97 0.86 0.83 0.77
Inv. Gaussian δ 1.94 1.58 1.52 1.44
Time-varying δ 3.16 1.83 1.74 1.96
ρ 0.99 41.1 18.7 24.8
Asymptote 0.68 0.84 0.84 0.80
best fit without covariates, appears unnecessarily complex once covariate in-
formation is incorporated. Nevertheless, there is still significant residual
heterogeneity, and this appears to follow the same pattern of declining RFV
identified in sections 6.1 and 6.2.
The absolute fits of the covariate models are difficult to assess, as the
data are now cross-classified according to a number of factors. Examining
the deviance according to data collapsed by survey period and injecting
duration categories, as in section 6.2.1, reveals a modest improvement in
fit but with a large number of additional parameters (deviance of 265.2 on
115 degrees of freedom, vs. 332.4 on 151 degrees of freedom). However, a
substantial improvement would not be expected, as the covariates are not
part of the survey year/injecting duration cross-classification used in the
calculation of the deviance.
Figure 6.16 shows estimates of the measure of association Φ obtained
under the full covariate model. Under the gamma frailty model the estimate
declines over time: due to the covariate mix changing with injecting dura-
tion, accounting for covariates has partly explained the declining RFV. The
inverse Gaussian predictions are similar, but with a more marked decline,
as expected. Interestingly, the TVF results are near-identical to those pre-
dicted from the inverse Gaussian model, and therefore do not capture the
initial high RFV at the start of injecting.
Table 6.7 shows the estimated frailty variances for the bivariate HCV-
HIV models. Unlike HCV-HBV, there was not an orderly reduction in frailty
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Figure 6.16: Observed and predicted estimates of association between HCV
and HBV under different frailty distributions and including full covariate in-
formation. Injecting durations are grouped where data are sparse to prevent
zero cells. Inv G=inverse Gaussian, TVF =time-varying frailty.
variance with the addition of extra parameters, with the variance increasing
for both gamma and inverse Gaussian distributions when region was added
to the model. The AIC scores indicated substantial improvement with the
addition of covariates, reducing by 1249, 120 and 617 as each set of covari-
ates was added to the model (gamma frailty). With region, age and sex, and
under the full model, the gamma frailty gave the lowest AIC score. However,
the TVF model could not be fitted at all, with estimation problems when re-
gion was entered in the model. Simplifications of the baseline FOI, grouping
of regions or examining covariates other than region may have allowed some
form of this model to be fitted, but as the HCV-HIV pair is of less interest
this was not pursued further.
Table 6.8 shows the estimated frailty variances for the bivariate HBV-HIV
models. There is some evidence that the frailty variance declines with the
addition of covariates, but the reduction is small and does not sequentially
decrease with the addition of each set of covariates, as for HCV-HBV. The
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Table 6.7: Estimated variance parameters for HCV-HIV data under covariate
models with different frailty distributions. No covariates (No cov); region;
region, age and gender (R,A,G) and all covariates and risk factors (Full).
Frailty variances δ; time-varying model not fitted.
Frailty (1) No cov (2) Region (3) R,A,G (4) Full
Gamma δ 0.84 1.16 0.92 0.75
Inv. Gaussian δ 0.89 0.95 0.96 0.86
TVF model shows very different patterns under different covariates. For
region only, the initial variance is lower but does not decrease as markedly
over time, to an asymptotic value of 0.86 of its initial value. When age
and gender are added, the initial variance is higher than with region alone
and decreases to an asymptote of near-zero, but the decrease is very slow
(ρ=0.07). Finally, with the other covariate information (full model) the
decline in RFV is faster than with region, age and sex, but with a lower
initial variance and a higher asymptote.
Table 6.8: Estimated variance parameters for HBV-HIV data under covariate
models with different frailty distributions. No covariates (No cov); region;
region, age and gender (R,A,G) and all covariates and risk factors (Full).
Frailty variances δ and parameters for time-varying model: ρ, rate of decline;
and asymptotic proportion to which the initial variance at t = 0 declines.
Frailty (1) No cov (2) Region (3) R,A,G (4) Full
Gamma δ 1.42 1.29 1.26 1.30
Inv. Gaussian δ 2.34 1.93 2.01 2.03
Time-varying δ 11.46 3.46 6.08 3.69
ρ 0.43 0.51 0.07 0.15
Asymptote 0.26 0.86 0.00 0.34
Figure 6.17 shows predictions of the measure of association Φ for the
TVF model under different sets of covariates. With no covariates, the esti-
mate of Φ declines steadily over injecting duration and slightly overestimates
the strength of association at longer injecting durations (over 15 years). Es-
timates appear worse with region only: the declining RFV is not captured
by the model and only a slight decline is predicted, with overestimation of
association at longer injecting durations. With age and sex also included
the pattern is captured better and the predicted association is similar to the
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Figure 6.17: Observed and predicted estimates of association between HBV
and HIV under different covariate models under the time-varying frailty
model. R,A,G=region, age and gender. Injecting durations are grouped
where data are sparse to prevent zero cells.
no covariate model. Under the full model the pattern is shifted again, with
similar estimates as the region-only model for injecting durations less than
10 years, but a lower predicted association at longer durations.
6.3.2 Covariate effects
The inclusion of covariates altered the estimated trend over calendar time for
HCV and HBV, largely due to the inclusion of region as a covariate (Figure
6.18). For HCV there was a smoother U-shape in the post-1980 period: the
FOI falls from a peak in 1980-1985 to its lowest point in 1995-2000 before
rising again. Without covariates, there is a sharper dip in 1995-2000 and a
far lower FOI in the pre-1980 period. For HBV the fall in FOI over time is
very steep in any case, but including region suggests that the fall in risk from
1990-1995 to post-2010 is slightly less than the estimates without covariates.
Region is a very important factor, as shown in chapter 4, and crucial
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Figure 6.18: Estimated temporal trends for HCV and HBV under different
covariate models with inverse Gaussian frailty, hazard ratios for 5-year survey
periods vs. 1990-1995. No covariates; region; region, age and gender (R,A,G)
and full model (all the above plus risk factor information).
to understanding trends over time due to changing patterns of the injecting
epidemic and the sampling frame of the UAM data. Figure 6.19 shows the
proportions of individuals at risk over time across regions. Of those sampled
by the survey who were injecting in the 1970s, a large proportion were in
the London region (35−40%), but this proportion has declined steadily over
time, to 10% or less since 2010. The proportion of those injecting in the
North West grew steadily from 1980 to 1995, from 10% to 21%, but declined
subsequently to 10% or less since 2010. These areas have markedly higher
prevalence of BBVs, and if region is not adjusted for then estimated trends
over time will be distorted by the changing composition of the sample. This
is seen in the estimated trends, with the underlying risk increasing more
noticeably for HCV and declining less markedly for HBV once region is
adjusted for. The declining frailty variance observed in Figure 6.16 may also
be due to changes in sampled regions; as the high-risk areas of London and
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the North West are proportionally less-represented in the sample over time,
the population may have become more homogeneous. Having accounted for
regional effects in the analysis, the variability of residual frailty declines less
over time. Therefore the predicted RFV in Figure 6.16 declines under the
gamma model, despite the gamma distribution having constant RFV.
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Figure 6.19: Proportion of injectors across regions over time, from those
participating in the UAM survey from 2000 onwards with complete covari-
ate information. The injecting career length of each participant is used to
calculate the numbers injecting in 1971, 1972, etc. in each region. Bars are
stacked in the same order that they appear in the legend on the right.
Figure 6.20 shows the estimated temporal trend from the full covariate
model under different frailty distributions. The choice of frailty distribution
has little impact on the estimated trend, but all trends with frailty differ from
that under independence, particularly in early years. For HCV, the pre-1980
risk is much lower under the frailty distribution but higher for 1980-1985,
which is epidemiologically plausible. For HBV, the decrease in risk over time
is somewhat steeper under the frailty models.
Patterns of injecting duration-specific risk for HCV and HBV were not
changed markedly by the inclusion of different covariates, and the estimated
HRs for the covariate effects were similar across different frailty distribu-
tions. The best-fitting model is therefore focussed on, which included all
covariate effects and an inverse Gaussian frailty distribution. Similarly, the
estimated HRs for HIV were fairly consistent for different frailty distribu-
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Figure 6.20: Estimated temporal trends under different frailty models with
all covariates, hazard ratios for 5-year survey periods vs. 1990-1995. Inde-
pendence, gamma, inverse Gaussian (Inv. G) and time-varying frailty (TVF)
distributions.
tions, adjustment for other covariates, and for both HCV-HIV and HBV-HIV
pairings. Therefore HIV results are taken from the HBV-HIV model, also
with inverse Gaussian frailty for consistency. Estimated hazard ratios and
95% confidence intervals from these models are shown in Table 6.9.
The patterns of estimated HRs, in terms of higher/lower risk for different
regions, ages of first use, gender and risk factors, are very similar to the
estimated odds ratios from generalised linear models of prevalence in section
4.1.4. Briefly, London has a higher FOI for HCV and HBV, and much higher
for HIV; and the North West has a higher FOI for HCV, and particularly
high for HBV. Older age at first use is associated with a higher FOI for HCV
and HBV, but younger age at first use for HIV. The interesting additions
are the time-varying aspects of risk factors: ever-use of needle exchange is
possibly associated with an increased FOI for HCV (HR=1.18, 95% CI: 0.94-
1.49) but the period following first use also has a higher FOI (HR=1.19, 95%
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Table 6.9: Hazard ratios for covariates for HCV, HBV and HIV under bivari-
ate inverse Gaussian frailty models; HCV-HBV estimates and HIV estimates
from HBV-HIV bivariate model. NX : needle exchange.
HCV HBV HIV
Region
East England 0.58 (0.50, 0.67) 0.82 (0.63, 1.07) 0.84 (0.39, 1.81)
London 1.35 (1.21, 1.50) 1.28 (1.07, 1.53) 4.43 (2.87, 6.84)
South East 1 (ref) 1 (ref) 1 (ref)
South West 0.56 (0.50, 0.63) 0.70 (0.55, 0.89) 0.58 (0.31, 1.10)
West Midlands 0.51 (0.44, 0.58) 0.42 (0.33, 0.53) 0.40 (0.15, 1.06)
North West 1.70 (1.53, 1.90) 2.04 (1.67, 2.48) 1.37 (0.81, 2.30)
Yorskshire & Humber 1.04 (0.90, 1.21) 0.53 (0.38, 0.73) 0.09 (0.01, 0.64)
East Midlands 0.88 (0.78, 0.99) 0.80 (0.65, 0.97) 0.93 (0.51, 1.72)
North East 0.46 (0.41, 0.52) 0.77 (0.61, 0.99) 0.29 (0.12, 0.71)
Wales 0.47 (0.40, 0.54) 0.62 (0.49, 0.77) 0.41 (0.17, 1.03)
Demographics
Age first used < 18 0.94 (0.87, 1.01) 0.80 (0.71, 0.91) 1.75 (1.29, 2.39)
Age first used 18-24 1 (ref) 1 (ref) 1 (ref)
Age first used 25+ 1.32 (1.23, 1.42) 1.54 (1.38, 1.72) 1.21 (0.84, 1.73)
Female vs. male 1.38 (1.28, 1.48) 1.22 (1.08, 1.37) 0.78 (0.55, 1.09)
Risk factors
Ever rec’d works 1.56 (1.47, 1.65) 1.23 (1.10, 1.38) 1.56 (1.18, 2.06)
Ever used NX 1.18 (0.94, 1.49) 0.90 (0.67, 1.19) 1.59 (0.73, 3.49)
Post-first NX 1.19 (1.02, 1.37) 0.90 (0.78, 1.02) 0.57 (0.35, 0.92)
Ever imprisoned 1.48 (1.27, 1.73) 1.20 (0.93, 1.55) 0.95 (0.54, 1.65)
Post-first prison 1.32 (1.13, 1.54) 1.17 (0.93, 1.49) 0.75 (0.41, 1.37)
MSM 1.07 (0.90, 1.27) 1.21 (0.95, 1.54) 4.01 (2.56, 6.28)
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CI: 1.02-1.37). For HBV, both ever using a needle exchange and post-first
use period have a reduced FOI, although the 95% CI for the HR crosses 1.
For HIV, there is a possible, but uncertain, increase in FOI for those ever
using a needle exchange, but reduced risk following first use (HR=0.57, 95%
CI: 0.35-0.92). For imprisonment, the FOI for both ever being imprisoned
and the period following imprisonment is increased for HCV, somewhat less
for HBV, and shows little effect for HIV. As for the analysis in section 4.1.4,
ever receiving works is associated with an increased risk of all BBVs, and
MSM a substantially increased risk of HIV infection.
6.3.3 Age, gender and individual frailty
In this section patterns of HCV and HBV infection by age and gender are
further explored. The base model considered here includes injecting dura-
tion and time (without interaction), an overall region effect (vs. the South
East) and examines age at first use (< 18, 18 − 24 and 25+), females vs.
males and an interaction between age at first use and gender. Multiplicative
covariate effects are assumed and an inverse Gaussian distribution used to
model individual variability.
Despite fairly strong differences in risk according to age at first use and
gender, models fit was not improved by including interactions between them;
in other words, the effect of age at first use was similar for males and fe-
males. There was also no evidence of an interaction between gender and
injecting duration, with little improvement in model fit, despite the addi-
tional parameters. There was however evidence of a difference in injecting
duration-specific risk according to age at first use, with a reduction of 5.7
in AIC under the latter. Examination of the interaction terms showed that
the strongest effect was in those starting injecting at age 25 or older, with
an excess risk in the first year but a broadly comparable FOI subsequently.
A simplified model including only interaction terms for the first year risk of
injecting provided a similar AIC score, with an increase of just 0.4 vs. the
more complex model.
In section 6.1 there were apparent differences in the measure of associa-
tion, Φ, according to gender and possibly age at first use. The base model was
extended to incorporate separate frailty variances for males and females, and
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for the three categories of age at first use. For the former, a somewhat higher
frailty variance was estimated for males (δ = 1.64) vs. females (δ = 1.17),
compared to an overall frailty variance of (δ = 1.52). AIC scores indicated
a modest improvement under the stratified frailty variance model, with a
decrease of 3.0 under stratified frailty variances. A similar model was fitted
with separate frailty variances for those aged < 18, 18− 24 and 25+ at first
use, giving frailty variances of 1.35, 1.68 and 1.47 respectively. AIC scores
indicated that there was no benefit to the additional parameters however,
with an increase of 2.1 for the more complex model.
6.3.4 Conclusions
The inclusion of covariates reduced the frailty variance, which represents
residual heterogeneity. Although model fit is enormously improved, the re-
duction in residual heterogeneity is relatively modest, indicating substantial
variability in risk that is not captured by the covariates. A wealth of ques-
tionnaire data is available in the UAM data, but it seems that there are
underlying differences in risk that are not easily captured.
The inclusion of covariates may have altered the shape of the residual
frailty distribution, with the inverse Gaussian model being preferred over the
TVF model for HCV-HBV, whereas the more complex model was favoured
without covariates. Model predictions are virtually identical for the inverse
Gaussian and TVF models, and estimates of Φ do not match the observed
pattern as well as the models without covariates in section 6.2.1. This might
be partly an identifiability problem: the covariate information is more easily
identifiable than the correlation between infections, with the latter poten-
tially being distorted by the inclusion of covariates. The measure of associa-
tion is based on the 2x2 tables of bivariate status, with the proportion that
are positive for both (++) typically small, especially at short injecting du-
rations where the RFV is changing most rapidly. Therefore underestimates
of the ++ cell (resulting in a weaker estimated association) may have less
impact on maximising the likelihood in comparison to fitting to the mean
prevalence according to different covariates. In other words, the univariate
fit of each infection (or just one if the second is sparse) may take precedence.
Shifts in the estimated frailty distribution also occur for HBV-HIV. When
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region alone is added to the model, the resulting estimates of Φ do not match
the observed pattern well, although once age and sex are also added to the
model, the pattern is a better match. In general, estimates of the shape of
the frailty distribution appear quite sensitive to the inclusion of covariates.
The estimated hazard ratios for covariates are generally comparable to
the odds ratios obtained under logistic regression models in section 4.1.4.
The function that links the covariates to the mean of the response variable
differs, but ultimately the two models are both estimating ratios of infection
prevalence at different levels of the covariate. In order to uncover more detail
with regard to the effect of risk factors on the FOI, covariate interactions
or time-varying covariates are required. However, there is limited scope for
increasing model complexity due to sparsity of data.
The time-varying covariates here provided some interesting but unusual
results, being parameterised in terms of ever-occurrence and change in risk
post-first occurrence. For needle exchange use, there is a different pattern
for each infection: increased risk for ever and post-first use for HCV, a slight
decrease for both for HBV, and increased risk for ever use but decreased
risk post-first use for HIV. It is somewhat difficult to make sense of these
results, with an increase in the risk of HCV infection following use of harm
reduction services, and inconsistencies in the direction of effects across in-
fections. Possibly they are the result of the combination of the propensity
for injecting and sexual risk, the correlations between these factors and their
relative importance for each infection; or, there may be no sensible epidemi-
ological interpretation. Both ever and post-first imprisonment are associated
with an increased risk of HCV infection, slightly increased risk of HBV in-
fection, but little association for HIV. If the relative importance of injecting
to sexual risk is high for HCV, sexual risk somewhat important for HBV and
more important than injecting risk for HIV, and prison is a high-risk envi-
ronment for injecting but not for sexual transmission, this may be plausible.
Further, individuals that have ever been imprisoned may have lower sexual
risks and vice versa; a purely speculative idea, but one that would explain
the attenuation of the risk associated with imprisonment for HBV and HIV.
Further investigation of age at first use and females vs. males confirmed
that risk of HCV and HBV infection in males is more variable than that of
females. This was indicated by plots of the association between infections in
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section 6.1 but the inclusion of a stratified frailty variance, while accounting
for relevant covariate information, provides a basis for statistical hypothesis
testing. Further exploration of patterns of RFV might be considered in
this way (for instance, via group-specific parameters in time-varying frailty
models) but are likely to be hampered by a lack of information.
An interaction between age at first use and injecting duration was also
noted, in particular an apparent excess risk in the first year of injecting for
those starting at older ages. This may reflect the different circumstances
in which individuals start injecting, with more comparable levels of risk
post-initiation. However, another explanation is misreporting of age at first
use, as these results would also be consistent with a portion of individuals
erroneously giving their current age as the age they first injected, and in fact
having been at risk for longer.
6.4 Concluding remarks
This chapter has shown that the inclusion of demographic and risk factor
information as covariates reduces residual individual heterogeneity in the
risk of infection in people who inject drugs, but the effect is modest. De-
spite identifying several risk factors that are strongly predictive, there is
still substantial variability in the risk of infection. The data clearly point
to a declining RFV, such that the pool of uninfected individuals become
more homogeneous over time. Under the inverse Gaussian model, this is
attributed to a selection effect, while the TVF model assumes the decline
is due to changes in the underlying risk of individuals. The TVF model
provides more flexibility and in the absence of covariates improves model fit,
although still does not quite capture the patterns of relative frailty variance
for HCV-HBV. With the inclusion of covariates, simpler frailty distributions
are preferred. However, rather than this being due to a simpler distributional
structure (whose variance does not decline over time) it may be that the es-
timated frailty distribution is being distorted by the presence of covariates,
as the estimate association between infections sometimes provided a poorer
approximation of the pattern of RFV when additional covariate information
were included.
A full understanding of individual heterogeneity in people who inject
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drugs requires appropriate modelling of the different routes of transmission,
incorporating both injecting and sexual risk. People who inject drugs may
have high sexual risks (BMA Board of Science, 2013, Chapter 4) due to
decreased inhibitions (both a cause and consequence of drug use) and a
general variability in levels of inhibition could result in a correlation between
injecting and sexual risk. In order to identify the sexual component, or any
structural form for the frailty variance that involves different components
of risk (i.e., beyond the shared frailty model) requires the use of trivariate
data. The HIV data are however very sparse and therefore the identification
of complex correlation structures is challenging.
One way to make progress would be to either simplify the baseline FOI
or place constraints on model parameters, an example of the latter being
the shared injecting duration-specific hazard ratios explored in section 6.2.2.
Such constraints will generally take the form of assumptions: there is no
evidence against a common injecting duration-specific risk for HBV and
HIV, but it is only considered as a modelling possibility because data are
insufficient to distinguish between different parameter estimates for the two
infections in the first place. Estimation is then conditional on the assumed
model structure - as with any statistical model of course, but the assumptions
here cannot be verified by the data. In section 6.2.2, the estimated frailty
variance was altered by the assumptions of shared parameters, and indeed,
the estimated frailty, particularly the TVF model, sensitive to covariates and
other model structure where data are sparse. The situation is similar in ways
to the estimation of frailty in a univariate model, which is only detectable via
divergence from an assumed model structure. In the bivariate case, under
a collection of covariates which may or may not be shared, estimates of the
frailty distribution may be influenced by divergence from the assumed model
structure in unpredictable ways.
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Chapter 7
Trivariate models and
components of risk
7.1 Introduction
The extension from univariate to bivariate analysis considered in chapters 5
and 6 allows for individual heterogeneity to be estimated and a more detailed
investigation of the infection process. Trivariate data allow yet more complex
structures to be considered, in terms of different aspects of heterogeneity in
individual risk for different infections. A key consideration for HCV, HBV
and HIV in people who inject drugs (PWID) is that injecting risk is common
to all infections, but there is potentially an additional component of sexual
risk for HBV and HIV, which is negligible for HCV. There is also the more
general issue that individual variability may have components that are not
wholly shared by all three infections, for instance, variation in biological
susceptibility.
Components of individual heterogeneity in survival analysis have largely
been considered within the framework of correlated gamma frailties : the
correlation in frailties for different outcomes occurring due to there being a
common component for all outcomes, but with additional components spe-
cific to each outcome. For current status data this presents a problem: as
with shared frailty models, heterogeneity is only identified via the correla-
tion between infections, and components that are specific to a single infection
cannot be identified at any single time point. Models in which frailty com-
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ponents are common to at least two infections are therefore required, as
parameters for the variance components can be identified directly from the
correlation structure of the data.
This chapter is organised as follows. The correlated gamma frailty model
is reviewed, and two forms of additive model based on shared components
are proposed, based on the correlated frailty model. Multiplicative compo-
nent structures are then considered. For both types of model, simplifications
of the full (saturated) model are likely to be required in practice, and possi-
ble sub-models are explored. Some epidemiological considerations are then
discussed in terms of suitable models for trivariate data on blood-borne in-
fections in PWID. The proposed models are then fitted to the UAM data.
7.2 Correlated frailties and component
frailty models
7.2.1 The correlated gamma frailty model
A limitation of the shared frailty model is that individual heterogeneity is
assumed to have an identical effect on the risk of each infection, and (equiv-
alently) that there are no aspects of individual frailty that are specific to
one infection; or at least, any such factors are not considered in the analysis.
This is a necessary assumption unless the baseline hazard is parameterised
to have a certain shape, from which any deviation would be assumed to arise
from some component of individual frailty (Farrington et al., 2001).
A more flexible form of frailty model is the correlated frailty model, in
which the frailties for each infection are positively correlated, but not identi-
cal (Yashin et al., 1995). This is achieved by specifying additive components,
usually with gamma distributions, with the overall frailty for each infection
being the sum of a shared component, plus individual frailty components
that are specific to each infection. This approach has generally been applied
to bivariate data, but could readily be extended to higher-order multivariate
data.
For general survival analysis models, the bivariate survivor function for
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the shared gamma frailty model with frailty variance σ2 can be written as
S(t1, t2) =
(
S1(t1)
−σ2 + S2(t2)−σ
2 − 1
)− 1
σ2
(see for example, Wienke et al. (2005)). The bivariate correlated frailty
model described by Yashin et al. (1995) is defined in terms of additive com-
ponents. The components Yi (i = 0, 1, 2) are independent random variables
that have gamma distributions with scale parameter 1, and Zi = σ
2
i (Y0 +Yi)
for i = 1, 2. Y0 therefore corresponds to the shared component of individual
frailty and Y1, Y2 the non-shared components, while the σi terms control the
variance. With k0, k1 and k2 positive parameters, Yi ∼ Γ(ki, 1) for i = 0, 1, 2,
σ2i = (k0 + ki)
−1 for i = 1, 2 and ρ = k0[(k0 + k1)(k0 + k2)]−
1
2 , the bivariate
survivor function proposed by Yashin et al. (1995) is
S(t1, t2) = S1(t1)
1−ρσ1/σ2S2(t2)1−ρσ2/σ1 [S1(t1)−σ
2
1 + S2(t2)
−σ22 − 1]−ρ/(σ1σ2),
(7.1)
The shared frailty model is therefore a special case of the correlated model
where ρ = 1, or equivalently k1 = k2 = 0, and individual frailty is identical
for both infections.
The bivariate correlated frailty model may readily be extended to a
trivariate or higher order model, and a general formulation is given in Yashin
et al. (1995) for the multivariate survivor function, which can be written as
S(t1, ..., tn) =
(
n∑
i=1
Si(ti)
− 1
k0+ki − n+ 1
)−k0 n∏
i=1
Si(ti)
1−k0/(k0+ki), (7.2)
where k0 is the inverse of the variance of the gamma frailty component
common to all outcomes and ki for the components specific to each outcome
i.
7.2.2 The correlated gamma frailty model for current
status data
For current status data observed at a single time point t, equation 7.2 can
be written in terms of the cumulative hazard functions Ai(t) for infection i
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as:
S1,...,n(t) =
(
1 +
n∑
i=1
Ai(t)
k0 + ki
)−k0 n∏
i=1
(
1 +
Ai(t)
k0 + ki
)−ki
. (7.3)
Having defined the multivariate survivor functions for up to n infections,
this can be used as the basis of deriving the 2n table of probabilities for each
possible infection status in a similar way as the bivariate case, as in equation
5.22. This chapter is primarily concerned with models for trivariate data, in
which case we define univariate, bivariate and trivariate survivor functions
with cumulative hazards Ai(t) at time t for infection i as:
S1(t) =
(
1 +
A1(t)
k123 + k1
)−(k123+k1)
S12(t) =
(
1 +
2∑
i=1
Ai(t)
k123 + ki
)−k123 2∏
i=1
(
1 +
Ai(t)
k123 + ki
)−ki
S123(t) =
(
1 +
3∑
i=1
Ai(t)
k123 + ki
)−k123 3∏
i=1
(
1 +
Ai(t)
k123 + ki
)−ki
,
(7.4)
where k123 is the inverse of the variance of the component shared by all three
infections and ki those specific to infection i = 1, 2, 3. S2(t), S3(t), S13(t)
and S23(t) are defined similarly, and the probabilities of trivariate infection
status pabc(t) with a = 0, 1 for infection 1, b = 0, 1 for infection 2 and c = 0, 1
for infection 3 at time t are:
p000(t) = S123(t)
p100(t) = S23(t)− p000(t)
p010(t) = S13(t)− p000(t)
p001(t) = S12(t)− p000(t)
p110(t) = S3(t)− p000(t)− p100(t)− p010(t)
p101(t) = S2(t)− p000(t)− p100(t)− p001(t)
p011(t) = S1(t)− p000(t)− p010(t)− p001(t)
p111(t) = 1− p000(t)− p100(t)− p010(t)− p001(t)− p110(t)− p101(t)− p011(t)
(7.5)
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Equation 7.5 also holds for models that involve both age and time and any
other covariates in the cumulative hazard functions featuring in equation 7.4.
The general approach of combining survivor functions for 1,2,...n infections
to obtain the 2n cell probabilities can readily be extended to higher-order
multivariate data.
Correlated frailty models have been shown to be identifiable for bivariate
event times (Iachine, 2004), although the information contained in current
status data is weaker: at a single time point, frailty can only be estimated
via the correlation between infections. Therefore any component of variabil-
ity attributable to a single infection cannot be reliably identified without
fairly strong assumptions. From the perspective of statistical modelling of
bivariate current status data, given an unconstrained hazard function and
some specified frailty distribution for the common frailty component, an im-
provement in model fit might still be achieved via the addition of infection-
specific components. It may be tempting to interpret such an improvement
as evidence of infection-specific components of frailty, but the improvement
could also arise from particular selection effects or time-varying aspects of
the underlying frailty that are not captured by the assumed functional form.
Even if the functional form is correct, the amount of information available
to estimate frailty components is likely to be very low.
7.2.3 Shared component models
For current status data, information on individual frailty should ideally be
identifiable solely from the correlation structure of the data at a single time
point, thereby avoiding the need to gain information on individual frailty via
distortions in the baseline hazard function(s). For a 2× 2 table of bivariate
infection status at a single time point, there are three degrees of freedom:
given the total sample size, once three cells are known the fourth is deter-
mined. Therefore the two cumulative hazards may be estimated, with one
degree of freedom remaining to estimate the correlation between the two
infections, and thereby the frailty variance.
Given the 8 cells of the 2 × 2 × 2 table for trivariate data, there are
7 degrees of freedom with which to estimate parameters. Three cumulative
hazards need to be estimated, leaving 4 degrees of freedom for the estimation
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of the correlation (frailty) structure. As components cannot be specific to a
single infection, there is a unique saturated model consisting of frailty com-
ponents for each pair of infections, plus a frailty parameter that acts on all
three infections. This is conceptually similar to log-linear modelling of three
binary covariates, in which the baseline is the sum-to-one constraint, the
cumulative hazards are main effects, and frailty parameters are interaction
terms (three 2-way, one 3-way).
Assuming that additive gamma frailty components are to be considered,
where the overall frailty for each infection consists of a weighted sum of vari-
ables with a gamma distribution, the general form for the trivariate saturated
component frailty model is
Z1 = w123Y123 + w12Y12 + w13Y13
Z2 = w123Y123 + w12Y12 + w23Y23
Z3 = w123Y123 + w13Y13 + w23Y23,
(7.6)
where the 123 subscript refers to components common to all three infections
and 12, 13 and 23 the pairwise components; w123, w12, w13 and w23 are real
numbers corresponding to the weight of each frailty component, and Y123,
Y12, Y13 and Y23 are independent random variables with a gamma distribu-
tion. This general form requires some constraints to be usable in practice,
namely that the w terms and random variables combine such that Z1, Z2 and
Z3 each have unit mean. Two possible specifications that achieve this are
(1) to use gamma variables with unit mean and set the sum of the weights
to equal one, and (2) to use gamma variables with scale parameter 1 and
use properties of sums of such gamma variables to derive another gamma
distribution that has mean one. Both models are additive shared component
models, and the first is referred to as the fixed weight model and the second
the variable weight model. The reason that one or the other must be chosen
is that there is not sufficient information to estimate both the variances of
the random variables and the weight terms, again assuming that the infor-
mation from time-variation in the correlation structure is likely to be weak
and unreliable for this purpose and we wish to be able to estimate the frailty
structure from a single time point. Therefore if the variances are uncon-
strained the weight terms must be fixed. The variable weight model is a
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modification of the approach used for the correlated frailty model described
in section 7.2.2, where the weights and variances are linked by the same
parameters. Properties of each of these models are discussed subsequently.
7.2.4 Fixed weight component model
In the fixed weight component model Y123 ∼ Γ(k123, k123), Y12 ∼ Γ(k12, k12),
Y13 ∼ Γ(k13, k13) and Y23 ∼ Γ(k23, k23). The four k parameters for the shape
and scale of the component gamma distributions with mean one are the
inverses of the variances of each frailty component, for example δ123 =
1
k123
.
These four parameters use all of the available degrees of freedom for the
correlation structure, and therefore the weight parameters w must be set at
fixed values.
Although the weight terms are not strictly identifiable, there may still
be aspects of the data that would result in a better or worse fit for certain
combinations of w terms. Firstly, as already mentioned, the way in which the
correlation structure evolves over time might provide weak information on
the relative importance (weights) of each component. These would be subtle
differences, as the difference between a component with low variance and high
weight and one with high variance and low weight is likely to be slight. Again,
this would also require that the frailty distributions themselves are of the
correct form and not inherently time-varying. Secondly, component models
in general require all of the correlations to be positive, as frailty variances
must be non-negative. Although not usually considered as a potential issue
for the shared frailty model as infections do not usually show a negative
correlation, the saturated model in equation 7.6 requires that each pairwise
correlation and the three-way (or “residual”) correlation are all non-negative.
This means that the saturated model does not guarantee a perfect fit to
the data, even at a single time point, and this could result in one or more
of the weight terms being estimated at zero in order to accommodate the
negatively-correlated component. However, such issues would point to the
model being generally incorrect, and not a good basis for obtaining estimates
of the weight terms.
In the absence of any external information, a natural choice for the weight
terms is just to set all of them equal to 1
3
. A priori information might
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indicate that the component shared by all infections, Y123 has greater or lesser
importance than the others; for instance w123 = 0.5, w12 = w13 = w23 = 0.25,
and different values could potentially be explored in sensitivity analyses. It
is of course possible to assign different weight terms to each component,
and potentially different contributions for a component to the risk of each
infection, although the expert knowledge required for appropriate choices is
likely to be lacking.
Assuming for now that w123 = w12 = w13 = w23 =
1
3
, the overall frailty
terms for infections 1, 2 and 3 are
Z1 = (Y123 + Y12 + Y13)/3
Z2 = (Y123 + Y12 + Y23)/3
Z3 = (Y123 + Y13 + Y23)/3.
(7.7)
The variances of the overall frailties (specified in terms of their component
variances) are
var(Z1) = (δ123 + δ12 + δ13)/9
var(Z2) = (δ123 + δ12 + δ23)/9
var(Z3) = (δ123 + δ13 + δ23)/9.
(7.8)
WithAi(t) the baseline cumulative hazard function for infection i, the trivari-
ate survivor function, bivariate survivor function for infections 1 and 2 and
univariate survivor function for infection 1 are:
S123(t) =
(
1 +
A1(t) + A2(t) + A3(t)
3k123
)−k123 (
1 +
A1(t) + A2(t)
3k12
)−k12
(
1 +
A1(t) + A3(t)
3k13
)−k13 (
1 +
A2(t) + A3(t)
3k23
)−k23
S12(t) =
(
1 +
A1(t) + A2(t)
3k123
)−k123 (
1 +
A1(t) + A2(t)
3k12
)−k12
(
1 +
A1(t)
3k13
)−k13 (
1 +
A2(t)
3k23
)−k23
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S1(t) =
(
1 +
A1(t)
3k123
)−k123 (
1 +
A1(t)
3k12
)−k12 (
1 +
A1(t)
3k13
)−k13
. (7.9)
The bivariate survivor functions for pairs 1-3 and 2-3 and univariate func-
tions for infections 2 and 3 are defined similarly. The probabilities for trivari-
ate infection status are then defined as in equation 7.5.
It is important to note that the shared frailty model is not a special case
of this model when the variances of the pairwise components are zero. If
the variances of the pairwise components in equation 7.6 are zero then the
overall frailties become
Z1 = w123Y123 + w12 + w13
Z2 = w123Y123 + w12 + w23
Z3 = w123Y123 + w13 + w23,
(7.10)
such that Z1, Z2 and Z3 have limited support and can only take values in the
range (1 − w123,∞). This model may therefore have a tendency to provide
non-zero variance estimates for the pairwise components, even if individual
variability genuinely is predominantly related to a single component shared
by all infections, as the potentially limited support may not be compatible
with the correlation structure in the data. The parameters for the fixed
weight model should therefore be interpreted as the relative importance of
each component, rather than the amount of variation directly attributable
to each component.
Also of note is that if k123 = k12 = k13 = k23 = k and the weight terms
are equal, then the sum of gamma distributions for each Zi have the form
of another gamma distribution with variance 1
3k
. The univariate survivor
function in equation 7.9 will therefore be equivalent to that of a shared
frailty model; however, the bivariate and trivariate functions are not.
The fixed weight model is therefore an alternative to the shared frailty
model which allows for non-perfect correlation in the frailties Zi for each
infection, but with limited support for frailties that have low correlation
in the case that the variance of one or more components approaches zero.
The correlations between the Zi terms, which again may be expressed more
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naturally in terms of their component variances, are
ρ12 =
(
(δ123 + δ12)
2
(δ123 + δ12 + δ13) (δ123 + δ12 + δ23)
) 1
2
ρ13 =
(
(δ123 + δ13)
2
(δ123 + δ13 + δ12) (δ123 + δ13 + δ23)
) 1
2
ρ23 =
(
(δ123 + δ23)
2
(δ123 + δ23 + δ12) (δ123 + δ23 + δ13)
) 1
2
.
(7.11)
It can be seen from equation 7.11 that the values of the variance components
restrict the range of the correlations, although to a lesser degree than the
correlated frailty model described in section 7.2.2.
Another consideration for this model is the variability of survivors and
how the relative frailty variance (RFV) changes over time (Unkel and Far-
rington, 2012). Except for the special case where all of the components have
equal variance and the weights are equal, the overall frailties Z1, Z2 and Z3
will not have a gamma distribution and therefore do not have the property
of constant RFV.
7.2.5 Variable weight component model
As mentioned previously the way in which the gamma components are de-
fined for the correlated frailty model proposed by Yashin et al. (1995) spec-
ifies the weights of the general form for additive components in equation
7.6 via the k terms. This approach also has the property that the resulting
overall frailties Zi have gamma distributions. This approach therefore does
not have the potentially limited support for the overall frailty of the fixed-
weight approach described in section 7.2.4, and will preserve the property of
constant RFV that the shared gamma frailty model has.
The components are expressed as independent gamma variates:
Y123 ∼ Γ (k123, 1)
Y12 ∼ Γ (k12, 1)
Y13 ∼ Γ (k13, 1)
Y23 ∼ Γ (k23, 1)
(7.12)
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and the overall frailties defined as
Z1 =
1
k123 + k12 + k13
(Y123 + Y12 + Y13)
Z2 =
1
k123 + k12 + k23
(Y123 + Y12 + Y23)
Z3 =
1
k123 + k13 + k23
(Y123 + Y13 + Y23).
(7.13)
WithAi(t) the baseline cumulative hazard function for infection i, the trivari-
ate survivor function, bivariate survivor function for infections 1 and 2 and
univariate survivor function for infection 1 are:
S123(t) =
(
1 +
A1(t)
k123 + k12 + k13
+
A2(t)
k123 + k12 + k23
+
A3(t)
k123 + k13 + k23
)−k123
(
1 +
A1(t)
k123 + k12 + k13
+
A2(t)
k123 + k12 + k23
)−k12
(
1 +
A1(t)
k123 + k12 + k13
+
A3(t)
k123 + k13 + k23
)−k13
(
1 +
A2(t)
k123 + k12 + k23
+
A3(t)
k123 + k13 + k23
)−k23
S12(t) =
(
1 +
A1(t)
k123 + k12 + k13
+
A2(t)
k123 + k12 + k23
)−(k123+k12)
(
1 +
A1(t)
k123 + k12 + k13
)−k13 (
1 +
A2(t)
k123 + k12 + k23
)−k23
S1(t) =
(
1 +
A1(t)
k123 + k12 + k13
)−(k123+k12+k13)
. (7.14)
The functions for S13, S23, S2 and S3 are expressed similarly, and the trivari-
ate cell probabilities derived as in equation 7.5. These equations can be
expressed more compactly by substituting σ2i =
1
k123+kij+kik
as in equation
7.1, but writing in terms of k terms illustrates the similarities and differ-
ences to the fixed weight model expressed in equation 7.9. In the case where
k123 = k12 = k13 = k23 = k, this model is equivalent to the fixed weight
model with k123 = k12 = k13 = k23 = k, as the gamma contributions have
equal weights and variances.
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The variable weight model has properties that may make it implausible
for many applications. The variances of the overall frailties (specified in
terms of their component variances) are
var(Z1) =
1
1/δ123 + 1/δ12 + 1/δ13
var(Z2) =
1
1/δ123 + 1/δ12 + 1/δ23
var(Z3) =
1
1/δ123 + 1/δ13 + 1/δ13
.
(7.15)
Under the fixed weight model in section 7.2.4, the larger the variance com-
ponents in equation 7.8, the larger the overall frailty variance. Under the
variable weight model, if all the components are large then the frailty vari-
ance is also large, however smaller components will increase the denominator
in equation 7.15 and thus limit the size of the overall frailty variance.
There are further constraints on the correlations between frailties for the
different infections. The correlations between the Zi terms, which again may
be expressed more naturally in terms of their component variances, are
ρ12 =
(
1/δ2123 + 1/δ
2
12
(1/δ2123 + 1/δ12 + 1/δ13) (1/δ
2
123 + 1/δ12 + 1/δ23)
) 1
2
ρ13 =
(
1/δ2123 + 1/δ
2
13
(1/δ2123 + 1/δ12 + 1/δ13) (1/δ
2
123 + 1/δ13 + 1/δ23)
) 1
2
ρ23 =
(
1/δ2123 + 1/δ
2
23
(1/δ2123 + 1/δ12 + 1/δ23) (1/δ
2
123 + 1/δ13 + 1/δ23)
) 1
2
.
(7.16)
Therefore pairs of infections with higher overall frailty variances will tend
to have a lower correlation under the variable weight model, whereas the
converse is true under the fixed weight model (equation 7.11). These are
similar issues to those of the correlated frailty model described in section
7.2.2.
The fixed weight model therefore makes more sense from an epidemi-
ological perspective and is easier to interpret: frailty components directly
represent the variability in transmission risks that are shared between in-
fections. The components of the variable weight model do not have such
a natural interpretation, and infections with higher overall frailty variances
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are less correlated than those with a smaller variance. Given that the frailty
models considered here estimate components of frailty that are shared be-
tween infections, this is a rather unusual property and it is questionable
whether such a model is useful.
7.2.6 Multiplicative component models
The two models consisting of additive gamma components proposed in sec-
tions 7.2.4 and 7.2.5 are restricted by the potentially limited support for
the overall frailty components for the fixed weight model and restrictions on
the correlation between frailties for the variable weight model. Fixed weight
models are also not nested, so it is not possible to build up a sequence of
models for comparison; for instance, two or more components compared to
a shared frailty model. Models based on multiplicative frailties do not suffer
these issues. The general form of a 2-component multiplicative frailty is:
Z = Y1Y2, (7.17)
where Y1 and Y2 are independent random variables with unit mean. Provided
both variables have support over the range (0,∞) then Z will also not be
limited, and if Y1 or Y2 have zero variance then the model will naturally
reduce to some simpler model that does not have limited support. The
multiplicative version of the shared component model for trivariate data in
equation 7.6 is
Z1 = Y123Y12Y13
Z2 = Y123Y12Y23
Z3 = Y123Y13Y23,
(7.18)
which would reduce to a shared frailty model if the pairwise components
have zero variance.
Multiplicative models based on gamma components do not have an al-
gebraic expression for the survivor functions: only one of the gamma com-
ponents can be integrated out via the Laplace transform, leaving some part
of the function that must be evaluated numerically (or approximated) for
the remaining random variable(s). In the univariate case for instance, with
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cumulative hazard function A(t) and gamma-distributed frailty components
x1, x2 with shape parameters θ1, θ2 and rate parameters k1, k2, the survivor
function is derived as
S(t) =
∫ ∞
0
∫ ∞
0
exp(−A(t)x1x2) θ
k1
1
Γ(k1)
xk1−11
exp(−θ1x1) θ
k2
2
Γ(k2)
xk2−12 exp(−θ2x2)dx1dx2
=
∫ ∞
0
θk22
Γ(k2)
xk2−12 exp(−θ2x2)
θk11
(A(t)x2 + θ1)k1∫ ∞
0
exp(−x1(A(t)x2 + θ1))(A(t)x2 + θ1)
k1
Γ(k1)
xk1−11 dx1dx2
=
∫ ∞
0
θk22
Γ(k2)
xk2−12 exp(−θ2x2)
θk11
(A(t)x2 + θ1)k1
dx2
=
θk11 θ
k2
2
Γ(k2)
∫ ∞
0
xk2−12 exp(−θ2x2)
(A(t)x2 + θ1)k1
dx2.
Under the full shared component model, with an overall frailty term and
three pairwise components, the trivariate and bivariate functions involve
four frailty components. As only one can be integrated out algebraically, the
resulting functions require 3-dimensional integration, and therefore substan-
tial computation time. Simpler models are therefore likely to be needed in
practice, or an alternative approach to estimation used.
7.3 Identifiability and model simplification
Although the models described in sections 7.2.4 and 7.2.5 are technically
identifiable, the information available to estimate differences in variances in
the “saturated” forms is likely to be very low. In particular, the sparsity of
HIV data in the UAM study is likely to result in a lack of identifiability of
components shared by all infections and the pairwise components. A small
simulation study was conducted under the fixed weight model (equation 7.9)
and indicated that even with large amounts of data in all of the trivariate
2 × 2 × 2 table, the log-likelihood surface did not have a well-defined op-
timum. Briefly, the k123 parameter can be higher (lower) and the pairwise
208
components lower (higher) with negligible difference to the likelihood.
The model also has some issues with convergence. As
λ1|Z1 = λ0,1(Y123 + Y12 + Y13)/3
λ2|Z2 = λ0,2(Y123 + Y12 + Y23)/3
λ3|Z3 = λ0,3(Y123 + Y13 + Y23)/3,
if the variance of any component is high, then the mean of the frailty vari-
ance will still be 1, but the majority of the distribution has extremely low
values. For instance, for a gamma distribution with variance of 100, over
90% of the distribution is less than 0.01. As variance components tend to
infinity, the baseline hazard is therefore effectively reduced by about 1
3
, and
if two components have variance approaching infinity (or very high) then the
reduction is 2
3
. The baseline hazard is thus inflated by a factor of 1.5 or 3
if 1 or 2 components are effectively reduced to zero in this way. Care must
therefore be taken, as the model can easily converge to a local optimum
at very high estimated variance components, with individual frailty being
attributed wholly to k123 or to the pairwise components.
The multiplicative form of component model does not have quite the
same issue with local optima, but there is likely to still be little information
to identify individual components of frailty. Further, as only one component
can be integrated out algebraically, the saturated model would require 3-
dimensional numerical integration, which is time-consuming to carry out
with a sufficient degree of precision. Simpler models would therefore be
preferable in both the additive and multiplicative framework.
7.3.1 Pairwise-only models
Pairwise-only components may be a pragmatic approach for an investigation
of frailties for different infections with no specific hypothesis. The general
form of the overall frailty for trivariate data under this model is
Z1 = w12Y12 + w13Y13
Z2 = w12Y12 + w23Y23
Z3 = w13Y13 + w23Y23.
(7.19)
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The survivor functions for the fixed weight model (equation 7.9) reduce to
S123(t) =
(
1 +
A1(t) + A2(t)
2k12
)−k12
(
1 +
A1(t) + A3(t)
2k13
)−k13 (
1 +
A2(t) + A3(t)
2k23
)−k23
S12(t) =
(
1 +
A1(t) + A2(t)
2k12
)−k12 (
1 +
A1(t)
2k13
)−k13 (
1 +
A2(t)
2k23
)−k23
S1(t) =
(
1 +
A1(t)
2k12
)−k12 (
1 +
A1(t)
2k13
)−k13
,
(7.20)
with the bivariate survivor functions for pairs 1-3 and 2-3 and univariate
functions for infections 2 and 3 defined similarly. The survivor functions for
the variable weight model in equation 7.14 reduce to
S123(t) =
(
1 +
A1(t)
k12 + k13
+
A2(t)
k12 + k23
)−k12
(
1 +
A1(t)
k12 + k13
+
A3(t)
k13 + k23
)−k13 (
1 +
A2(t)
k12 + k23
+
A3(t)
k13 + k23
)−k23
S12(t) =
(
1 +
A1(t)
k12 + k13
+
A2(t)
k12 + k23
)−k12
(
1 +
A1(t)
k12 + k13
)−k13 (
1 +
A2(t)
k12 + k23
)−k23
S1(t) =
(
1 +
A1(t)
k12 + k13
)−(k12+k13)
,
(7.21)
with the bivariate survivor functions for pairs 1-3 and 2-3 and univariate
functions for infections 2 and 3 defined similarly.
The multiplicative model is also simplified: two-dimensional integration
is still required, which is still slow, but feasible for relatively small datasets
(in terms of the number of binomial data points).
Pairwise models are much less likely to suffer from convergence issues,
as each component kij is informed exclusively by the pairwise correlation
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between infection i and j, rather than differences between correlations that
inform k123 and kij in saturated models. However, this also severely restricts
the range of variance estimates that can be obtained from the model, as if
pairs 1-2 and 1-3 are positively correlated, 2-3 must be also. As with many of
these models, the pattern of parameters and hypothesis tests against simpler
models may be more informative than attempts at direct interpretation of
the estimates. However, this is something of a problem with the pairwise-
only model as it does not include the shared frailty model as a special case,
either in the additive or multiplicative form.
7.3.2 Asymmetric models
An alternative approach to simplifying the saturated shared component
model is to add just one (or two) of the three possible pairwise terms to
the shared frailty model. Although there may still be difficulties in distin-
guishing the 3-way and pairwise component(s), this simplified version is less
likely to be problematic than the full flexibility of the saturated form, and
can be used to test specific hypotheses about certain infection pairs.
The model is asymmetric in the sense that different infections may have
different numbers of frailty components. For an additive component model,
this requires that a constant is added to the overall frailty for one or more in-
fections. This is the same issue as the limited support of additive component
frailty distributions described in section 7.2.4, as the variances of some of
the pairwise components are effectively set to zero. For instance, the single
pair asymmetric model with the additional component for pair 1-2 may be
specified as
Z1 = (Y123 + Y12)/2
Z2 = (Y123 + Y12)/2
Z3 = (Y123 + 1)/2,
(7.22)
where Y123 and Y12 are gamma distributions with unit mean. For a two-pair
asymmetric model that also includes a component for pair 1-3 the model
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may be specified as
Z1 = (Y123 + Y12 + Y13)/3
Z2 = (Y123 + Y12 + 1)/3
Z3 = (Y123 + Y13 + 1)/3.
(7.23)
Again, the multiplicative model more naturally handles the asymmetric spec-
ification as pairwise components with mean 1 are simply multiplied to pro-
duce the overall frailty density, which also has mean 1. The multiplicative
version of equation 7.23 for instance is
Z1 = Y123Y12Y13
Z2 = Y123Y12
Z3 = Y123Y13,
(7.24)
and the model may be simplified to a single component by omitting Y12
or Y13, or the shared frailty model if both are omitted. The shared frailty
model is therefore nested in multiplicative asymmetric models and hypoth-
esis tests can be conducted to determine whether the additional complexity
is warranted.
7.4 Epidemiological considerations
Two approaches for additive gamma components have been proposed with
slightly different properties: the fixed weight model and the varying weight
model. The varying weight model scales the weights of each component ac-
cording to their variances, while the fixed weight model assumes that the
weights are fixed, regardless of the variance of each component. The latter
results in a potentially limited support, which may or may not be appropri-
ate for the data. However, the variable weight model has restrictions on the
range of possible correlations between the overall frailties for each infection.
The alternative is to specify frailty components that combine multiplica-
tively, although these models are more challenging to work with, requiring
approximation of the necessary integrals.
It is worth considering the potential scenarios in which the shared frailty
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model requires extension, i.e., where individual susceptibility to infection is
not determined by some factor that has an identical effect on the risk of all
infections. This may occur where there is more than one route of infection,
and the relative importance of these routes differs between infections. In
the context of blood-borne viruses in PWID, HCV, HBV and HIV may
all be transmitted via sharing of injecting paraphenalia, but there is also a
risk of sexual aquisition which is comparatively low for HCV (Balogun et al.,
2003), while HIV is transmitted sexually more easily than via blood-to-blood
contact and therefore would have a smaller component of injecting risk.
In the case of two infection routes A and B, each of which have an
associated frailty distribution YA and YB with unit means, the overall hazard
at time t may be written as
λ(t|YA, YB) = λA(t)YA + λB(t)YB, (7.25)
where λA(t) and λB(t) are the route-specific baseline forces of infection.
Writing the relative contribution of infection A as wA(t) =
λA(t)
λA(t)+λB(t)
and
wB(t) = 1−wA(t), the frailties combine additively in a similar way to that of
the general additive components model in equation 7.6, acting on the overall
hazard. However, there would likely be insufficient information to estimate
both the weight term wA(t) and the variances. Some progress might be made
if the FOIs could be considered proportional, although strong assumptions
are required in order to consider this model as directly representing route-
specific frailty.
Considering further the route-specific risks of infection through sexual
and injecting risk, there is in fact some information to investigate their rel-
ative contributions in the UAM data. Assuming an average age of sexual
maturity, the data consist of time at sexual risk only (pre-injecting) and time
at risk of both injecting and sexual risk, plus infection status.
Denoting Ai(t) the cumulative hazard due to injecting, equal to zero for
t < ti, the age at start of injecting, and As(t) the cumulative hazard due to
sexual transmission, equal to zero for t < ts, the age at sexual maturity, the
survivor function is defined as
S(t) = exp (−Ai(t)− As(t)) . (7.26)
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This model may therefore estimate age-specific variation in the hazard for
sexual transmission within the age range of age at first use available in the
data (before the two hazards become confounded) and injecting-duration
specific risk, provided the risk of sexual infection is not modified by the
onset of injecting. The latter might be a strong assumption, as both overall
risk and heterogeneity in risk may be strongly influenced by injecting drug
use. This model may therefore be of limited usefulness in determining the
injecting and sexual components of risk in PWID, although could provide a
basis for exploring alternative weight terms for components of injecting and
sexual risk in the model described in section 7.2.4.
The multiplicative frailty model is a less natural representation for route-
specific frailties, which would not generally have a multiplicative effect: in
the UAM example, a doubling of risk in sexual and injecting risks would not
result in a 4-fold increase in overall risk. However, this may approximate the
route-specific components themselves being positively correlated (without
this correlation being explicitly modelled).
One scenario in which the multiplicative model does directly represent
component frailties is when overall frailty is the product of behavioural het-
erogeneity and biological susceptibility, in which case the two components
naturally have a multiplicative effect on the overall hazard. Some biological
knowledge may be required to specify a model representing these effects,
as again the frailty components must be specified in terms of components
shared by all three infections or pairwise components. Again, the model
might be considered more generally as representing components of risk that
act on different infection pairs and overall, rather than an attempt to directly
quantify variability in a particular aspect of the risk of infection.
7.5 Fitting trivariate frailty models to the
UAM data
In this section trivariate frailty models are fitted to the UAM data on peo-
ple who inject drugs (PWID). The fixed weight additive components model
(with equal weights), variable weight model and multiplicative components
models are fitted to the data, assuming pairwise-only shared components as
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described in section 7.3.1. These models are used to examine general pat-
terns in pairwise correlations and compared with the shared frailty model,
which assumes a single common frailty component that acts equally on all
infections. Model fit statistics may then be used to determine if the addi-
tional complexity of the component models is necessary, although the shared
frailty is not a nested model for either the additive or multiplicative mod-
els. Asymmetric models are then considered, primarily to test the hypothesis
that additional variability in risk for HIV and HBV may arise through sexual
transmission. These models are fitted in their multiplicative form such that
the nested structure can be explicitly tested, and likelihood ratio statistics
used to compare against the shared frailty model.
The dataset considered is that used in section 6.2, which includes data
from 2000 onward with complete data for HCV, HBV and HIV tests. Al-
though the likelihood can incorporate partial data where one or more tests
are missing, the number of incomplete observations is small and these are
discarded. Those injecting for greater than 35 years are also excluded, leav-
ing 24977 observations for analysis. In order to simplify modelling, injecting
duration-specific baseline hazards are estimated but no other covariates, in-
cluding time, are included in the model. The data therefore take the form
of the standard age-specific seroprevalence data used in many epidemiologi-
cal studies (see for example Farrington et al. (2001)). Imperfect sensitivity
and specifity are accounted for in the observed data as described previously
(section 3.1.2). The trivariate data are summarised in Table 7.1.
Piecewise constant hazards are fitted with injecting duration bands of
≤ 1, 1-3, 3-5, 5-7, 7-10, 10-15, 15-20, 20-25 and > 25 years. Models were
fitted in R using bespoke code (see appendix section 9.2.4), and numer-
ical integration for the multiplicative models performed using integrate
and adaptIntegrate from the cubature package for univariate and bivari-
ate integrations respectively as required. Deviances were calculated based on
observed and predicted numbers in each trivariate cell, grouped by injecting
durations of ≤ 1, 2, 3-4, 5-7, 8-10, 11-14, 15-19, 20-24, 25-29 and 30-35 years
in order to reduce zero cell counts.
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Table 7.1: Trivariate infection status data by injecting duration (t) from the
UAM survey, 2000-2014. Cell counts are denoted nijk with 0=uninfected
and 1=infected for HCV (i), HBV (j) and HIV (k).
t n000 n100 n010 n110 n001 n101 n011 n111
1 1946 395 65 64 7 5 1 3
2 1222 287 55 55 7 3 0 3
3 978 266 57 56 4 3 2 3
4 870 338 67 63 3 1 0 0
5 864 360 69 68 5 1 0 0
6 821 382 68 67 4 3 0 2
7 685 371 47 77 3 5 0 2
8 649 371 47 87 5 2 0 5
9 554 325 50 97 0 2 0 2
10 595 441 76 109 1 4 1 3
11 483 345 58 111 3 1 0 5
12 451 322 36 125 5 3 0 4
13 414 381 40 118 1 8 1 6
14 364 314 44 109 5 6 0 5
15 298 335 36 141 5 5 0 4
16 274 285 37 137 2 3 1 3
17 247 277 38 130 3 8 2 4
18 199 267 41 114 4 2 0 2
19 196 234 28 108 4 4 2 6
20 152 245 34 145 3 6 4 2
21 107 184 26 114 1 5 2 1
22 97 166 25 100 0 6 0 3
23 97 147 16 85 1 5 0 6
24 69 138 29 74 2 1 0 3
25 55 111 18 70 0 1 0 8
26 41 103 5 65 0 3 0 2
27 39 54 10 66 0 3 1 1
28 28 63 6 58 0 0 1 0
29 18 54 16 54 0 1 0 1
30 23 49 8 48 1 1 1 1
31 6 38 3 35 0 2 0 0
32 13 28 10 49 0 1 1 0
33 15 26 4 46 0 0 0 1
34 11 20 2 32 0 0 0 4
35 4 15 3 26 0 0 0 0
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7.5.1 Pairwise component model results
Estimated baseline hazards from the four models are shown in Table 7.2.
The estimates show a similar pattern to those in chapters 4 and 6, with a
far higher risk in the first year of injecting and constant, or no particular
pattern thereafter; although the estimated hazards increase again somewhat
at longer injecting durations. This is partly due to sparsity of data, but
also likely due to not adjusting for variation in calendar time, with those
with longer injecting durations having been at risk during the peak of the
epidemic in the 1980s. Nevertheless, both of the additive component models
produced implausible estimates for the hazard for HCV infection in the 20-25
and 25+ groups, and for the HBV hazard in the 25+ group.
Table 7.3 shows the estimated frailty parameters from the pairwise com-
ponent models. The components themselves have different interpretations
for each model: the fixed weight additive components are scaled by a fac-
tor of 1
2
whereas the variances of the multiplicative components produce a
higher overall frailty variance. However, the patterns of these two models
are comparable and suggest that the HCV-HBV and HBV-HIV pairs have
a stronger component (correlation) than that of the HCV-HIV pairs. This
is reflected in the overall frailty variance, which is highest for HBV, as the
overall frailty does not include the weaker HCV-HIV component shared by
the other two infections. This is not the case for the variable weight addi-
tive model however, which has the smallest overall variance for HBV, due
to overall frailties being based on inverses of components (equation 7.15).
The HCV-HIV component is the largest, which is somewhat implausible as
HCV and HIV are expected to have the weakest correlation from an epidemi-
ological perspective and would therefore be expected to have the smallest
variance component.
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Table 7.2: Estimates of injecting duration-specific baseline hazards for HCV, HBV and HIV infection from trivariate frailty
models: shared frailty model, pairwise-only additive models (fixed weight, FW; variable weight, VW) and pairwise-only
multiplicative component model.
Injecting Shared Additive (FW) Additive (VW) Multiplicative
duration HCV HBV HIV HCV HBV HIV HCV HBV HIV HCV HBV HIV
≤ 1 0.233 0.075 0.0048 0.317 0.113 0.0027 0.287 0.074 0.0061 0.265 0.081 0.0044
1-3 0.048 0.024 0.0008 0.063 0.000 0.0014 0.077 0.024 0.0000 0.049 0.022 0.0008
3-5 0.088 0.008 0.0001 0.230 0.041 0.0009 0.152 0.017 0.0001 0.104 0.030 0.0004
5-7 0.034 0.006 0.0002 0.000 0.012 0.0007 0.147 0.004 0.0010 0.084 0.014 0.0011
7-10 0.088 0.031 0.0006 0.357 0.067 0.0014 0.206 0.040 0.0017 0.141 0.049 0.0010
10-15 0.144 0.030 0.0033 0.501 0.089 0.0025 0.472 0.032 0.0000 0.203 0.055 0.0020
15-20 0.136 0.036 0.0004 0.875 0.137 0.0009 0.910 0.063 0.0028 0.247 0.089 0.0015
20-25 0.118 0.027 0.0010 2.513 0.457 0.0017 1.492 0.044 0.0000 0.292 0.120 0.0016
25+ 0.227 0.103 0.0004 1.644 2.141 0.0011 3.982 0.202 0.0003 0.579 0.469 0.0016
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Interestingly however, the correlations between overall frailties, ρij, are
very similar under the three models, and support the hypothesis that HCV
and HBV are likely to have a strong correlation due to the importance of the
shared route of injecting transmission, and HBV and HIV will have a strong
correlation (compared to HCV-HIV) due to the shared sexual component.
The shared frailty model estimated the overall frailty variance to be 0.90,
less than any of the infection pairs under any of the component frailty models.
This might be due in part to the way that the relative frailty variance evolves
under the different models: the component models result in declining relative
frailty variance, while it is constant for the shared frailty model. A similar
pattern was observed under an inverse Gaussian model compared to gamma
frailties in chapter 6.
Table 7.3: Estimates of frailty parameters from trivariate frailty models:
pairwise-only additive models (fixed weight, FW; variable weight, VW) and
pairwise-only multiplicative component model. δ terms are component vari-
ances, var(Z) the overall frailty variances and ρ the correlations for infection
1, 2 and 3 (HCV, HBV and HIV).
Parameter Infection(s) Additive (FW) Additive (VW) Multiplicative
δ12 HCV-HBV 10.75 3.70 1.22
δ13 HCV-HIV 3.70 12.50 0.36
δ23 HBV-HIV 11.36 4.55 1.79
var(Z1) HCV 3.63 2.82 2.01
var(Z2) HBV 5.60 2.02 5.16
var(Z3) HIV 3.82 3.29 2.79
ρ12 HCV-HBV 0.60 0.65 0.60
ρ13 HCV-HIV 0.25 0.24 0.25
ρ23 HBV-HIV 0.62 0.58 0.63
Predicted trivariate infection status under the fitted models are shown in
Figure 7.1. In general, the model fit appears similar, and reasonably good, for
infection combinations for which there are sufficient data (uninfected, HCV
only, HCV-HBV coinfection) but with greater differences between models
where data are sparse (HBV without HCV, any combination with HIV).
In terms of formal model comparison, the multiplicative model provides an
improvement over the shared frailty model, with a difference in AIC scores
of 10.6. However, the fixed weight additive model provided a substantially
worse fit, with an increase in AIC of 49.0, which was particularly poor for
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Figure 7.1: Observed and predicted trivariate infection status by inject-
ing duration under a shared frailty model and pairwise-only additive (fixed
weight, FW; variable weight, VW) and multiplicative component models.
the HIV data. Despite its questionable interpretation, the variable weight
additive model provided the best fit to the data, with an improvement in
AIC score of 16.5 compared to the multiplicative model.
These results indicate that there is additional complexity in the data that
warrant a different model to the shared frailty model, but the additive pair-
wise component model with fixed weights is not the most appropriate choice.
The overall model fits were passable but not ideal, with a deviance of 366.7
for the shared frailty model on 35 octonomial observations (multinomial data
points with 8 possible categories) with 28 parameters. For the pairwise mod-
els (with 30 parameters) deviances were 410.9 for the fixed weight additive
model and 355.4 for the multiplicative model. Although the model fit was
best under the variable weight additive model, the multiplicative model has
a more natural interpretation and is likely to be a more suitable choice.
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7.5.2 Asymmetric model results
Multiplicative asymmetric models were fitted to the UAM data, primarily
with the purpose of testing for additional variability for HBV-HIV due to
sexual transmission, but also to examine any pairwise differences for the
infection pairs HCV-HBV and HCV-HIV beyond the shared frailty model.
Even these simple models showed some issues with identifiabilty, and fre-
quently converged to a lower log-likelihood than the shared frailty model.
Starting values were therefore based on estimates from the shared frailty
model, with a low initial variance assigned to pairwise components. Result-
ing estimates of frailty variances and AIC scores are shown in Table 7.4.
The HBV-HIV model provided a significant improvement in model fit,
with a reduction in AIC score of 9.6 compared to the shared frailty model,
and estimated an additional variance of 0.373 for HBV and HIV. The esti-
mate of the shared frailty component was very similar to the model including
a shared frailty only, indicating a similar variability for HCV but a marked
increase for HBV and HIV.
The HCV-HBV model provided a greater improvement in model fit, with
a reduction in AIC score of 23.0 compared to the shared frailty model. In-
terestingly, the variance of the shared frailty component was estimated to
be lower, but with a substantial HCV-HBV component. This results in the
overall frailty variance for HCV and HBV being comparable to the shared
frailty model, but a lower variance for HIV, in contrast to the HBV-HIV
component model. The HCV-HIV model provided a negligible improvement
in model fit, with a reduction in AIC score of 1.8, and the variance of the
HCV-HIV component estimated to be practically zero.
The results of the single pairwise component models indicated that a
model with both HCV-HBV and HBV-HIV components warranted investi-
gation. This model was fitted to the data using model estimates as initial
values from (1) the HCV-HBV model, and (2) the HBV-HIV model, with low
initial value for the added components. Different estimates were obtained
from the two starting points, with the estimated variance of the added com-
ponent remaining low. In both cases there were only modest improvements
in model fit, with a change in AIC score of 2.2 and 3.2 from the first and
second sets of initial values.
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Table 7.4: Estimates of frailty parameters from shared frailty and asymmet-
ric trivariate frailty models, with additional pairwise components for HCV-
HBV (var(YCB)), HBV-HIV (var(YBI)) and HCV-HIV (var(YCB)). The
model with both HCV-HBV and HBV-HIV components (C-B B-I) is started
from two sets of initial values: (1) estimates from the HCV-HBV model, and
(2) from the HBV-HIV model.
Model var(YCBI) var(YCB) var(YBI) var(YCI) AIC
Shared frailty 0.896 54675.2
HBV-HIV 0.911 0.373 54665.6
HCV-HBV 0.638 0.318 54652.2
HCV-HIV 0.898 0.050 54673.4
C-B B-I (1) 0.642 0.319 0.016 54650.0
C-B B-I (2) 0.893 0.037 0.352 54662.4
Deviances for the HBV-HIV and HCV-HBV models were 357.0 and 337.4
for 35 octonomial observations and 29 parameters; and for the best-fitting
HCV-HBV and HBV-HIV model 333.5 with 30 parameters. These results
indicate that there is a substantial improvement in model fit with the ad-
dition of HCV-HBV or HBV-HIV parameters, but the model fit is still not
ideal.
7.6 Conclusions
The models proposed in this chapter extend the available models for cur-
rent status data. Nevertheless, even with trivariate data there are limits
to what can be understood about aspects of frailty that are not shared by
all infections, due to the restriction that any component of frailty must be
common to at least two infections to be identifiable. Key areas of interest
in this topic, namely the contributions of different routes of infection and
behavioural heterogeneity vs. biological susceptibility, therefore have limited
scope for investigation.
The results obtained in section 7.5.1 are suggestive of a plausible epidemi-
ological explanation, in that both HCV and HBV are commonly transmitted
in PWID through the sharing of needles and syringes, whereas HIV trans-
mission is relatively rare due to its inherently lower infectiousness through
blood-borne routes. However, HIV is readily transmitted sexually, and this
is the component that is shared by HBV, while sexual transmission of HCV is
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relatively rare. This may therefore have produced the observed pattern here,
with HBV having the highest frailty variance and (equivalently) a weaker
correlation between HCV and HIV.
This is a plausible explanation, but is only a tentative hypothesis. One
argument against it is that for HBV to have a markedly higher frailty vari-
ance than HCV, the component of sexual transmission (or wi parameter, to
use the form of equation 7.6) would need to be of comparable magnitude to
that of injecting risk in order to have any substantial contribution to overall
heterogeneity. Although it is difficult to unpick the relative contributions of
injecting and sexual risk in this population, unless sexual risk is markedly
higher than that of the general population, injecting transmission risk would
far outweigh that of sexual risk.
The asymmetric models fitted in section 7.5.2 support the sexual risk
hypothesis for HBV-HIV, but the HCV-HBV model provided a better fit
still. The two models provided different estimates of frailty variance for
HIV; it is possible that both models have converged to local optima in the
likelihood and did not find the overall optimum. Some care is required in
the interpretation of these results, as the HIV data are very sparse and likely
outweighed by any potential improvements in model fit to the other data.
Differences in model fits, although substantial in a statistical sense, do not
markedly improve the absolute fit of the models, which remains adequate
rather than good.
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Chapter 8
Conclusions
8.1 Summary of findings
In this thesis models for current status data on people who inject drugs
(PWID) have been studied, using data from the Unlinked Anonymous Mon-
itoring (UAM) survey of PWID. Key themes have been the investigation of
risk factors and patterns of unmeasured heterogeneity in different groups,
which are examined in the framework of force of infection (FOI) models.
This thesis has explored technical developments of the FOI model, such as
the inclusion of covariate information and extension to trivariate frailty mod-
els; and addressed practical questions on patterns of risk that can be used
to develop public health policy.
FOI models provide a natural framework for investigating age-specific
current status data, which in this thesis are the injecting duration-specific
prevalence of HCV, HBV and HIV. The relationship between time at risk and
infection status can be economically modelled by the FOI. If it is constant, a
single parameter can describe how prevalence increases with time at risk, and
the rate of infection is also the most meaningful parameter when considering
public health policy. A key result of this thesis is that risk of infection with
HCV (and other viruses) is very high in the first year, but largely constant
thereafter; thus the risks of infection in PWID can be summarised by the
two parameters for the 1st year and subsequent FOI.
Fitting FOI models requires some technical expertise, but under the as-
sumption of additive risk this can be done using generalised linear model
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routines with standard software. This approach can therefore be used to
quickly investigate different models, in particular when considering a num-
ber of covariates and potential interactions. Additive covariate models were
fitted to the UAM data and revealed striking regional patterns in risk dur-
ing the first year of injecting, and a more homogenous risk across regions
for the remainder of injecting career. Differences in temporal trends were
also identified, although model comparison scores indicated that a three-
way interaction between region, injecting duration and time was not needed,
leading to a more parsimonious model than fitting models to each region
separately.
Covariate effects can be fixed, having the same effect on the FOI at
all injecting durations, or varying according to injecting duration, calendar
time, or both. Time-varying covariates can also be included, where effects
change according to exposure time, as in survival analysis. This approach
was used to determine the risk of infection before and after starting to use
needle exchange services, based on the reported age at first use of such
services. Results were somewhat difficult to interpret, indicating a decrease
in the risk of infection after starting to use needle exchange services, but
only in the post-2000 period (a time-varying covariate with changing effect
over calendar time). Nevertheless, this analysis shows that information on
the timing of a certain risk factor can be incorporated in force of infection
models, and could be considered when designing cross-sectional surveys.
Multiplicative risks are more complicated to handle, as the link between
the covariates and the outcome variable(s) is non-linear. In this thesis be-
spoke R code was developed to fit such models. Covariates are still some-
what problematic, as the model code requires adapting for different covariate
structures. A “multirow” formulation of the data was developed, in which
the injecting duration and calendar time bands are split within each indi-
vidual, allowing an arbitrary matrix of covariate information to be included
easily. This has the downside of increasing the size of the dataset and number
of computations required, and therefore the time and computing resources
needed to fit models. It is likely that the routine could be made more ef-
ficient, or somehow “compiled” (as in computer programming) to minimise
the number of calculations performed, although this was not pursued.
Shared frailty models identify the degree of unobserved heterogeneity via
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the correlation between infections in bivariate data. Patterns of bivariate
association were therefore examined. These revealed that the association
between infections declined with injecting duration for all infection pairs,
although data on HIV were sparse. For HCV-HBV, there was evidence of
a potential change in correlation patterns according to survey year, with a
broadly constant association in more recent data, but a greater decline with
increasing injecting duration in earlier years. Some potential differences ac-
cording to age and reported risk behaviour were also noted, but of particular
interest are the patterns by gender, with a higher level of variability in males
compared to females. Females have a higher average risk, leading to the con-
clusion that females are generally at high risk of infection, whereas males are
a mixture of lower and higher risks.
The declining association between infections with time at risk indicates
that the gamma frailty model, which has constant relative frailty variance
(RFV), will not capture the patterns of correlation in the data. The inverse
Gaussian distribution induces a selection effect that results in a declining
RFV, and indeed this model provided a better fit to the data. A better fit
still was obtained under a time-varying frailty (TVF) model, which explicitly
models a decline in frailty variance. This may point to a homogenisation in
risk behaviour throughout injecting career, which appears plausible as PWID
may commence injecting under a variety of circumstances, but become more
homogeneous in their risk patterns as time passes (as well as being at gen-
erally lower risk). However, selection effects cannot be distinguished from
genuine reductions in underlying variability, and the TVF model may simply
fit better due to the additional model parameter. In particular, the TVF
model indicates a faster decline in RFV following initiation of injecting than
the inverse Gaussian model, although other frailty distributions that better
reflect variability in risk are of course possible, and need not necessarily be
time-varying to capture the observed correlation pattern.
Covariates were then added to the different bivariate frailty models, fo-
cussing on HCV-HBV, which have the most data. Interestingly, inclusion
of covariates resulted in substantially improved model fit, but only mod-
est reductions in estimates of frailty variances, which may be interpreted
as residual heterogeneity. Overall estimates of frailty variances were 1.94 in
the unadjusted and 1.44 for the fully adjusted inverse Gaussion model. To
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interpret these results the ratio between the 75th and 25th percentiles of the
frailty distribution can be considered: this is 4.5 for the unadjusted model,
and 3.9 for the adjusted model, indicating substantial differences in risk even
after accounting for a number of risk factors.
Also of note is that the estimated excess risk in first year injectors per-
sisted in frailty models. A well-known effect of frailty is that high-risk indi-
viduals tend to experience the event of interest earlier on, which may have
partly explained the observed high prevalence in 1st year injectors. Unless
the underlying frailty distribution has a very different form to the standard
distributions considered here, this appears not to be the case.
The final chapter investigated trivariate frailty models. Trivariate
(2x2x2) data have seven degrees of freedom at each time point; after es-
timating the three baseline hazards, this leaves four degrees of freedom to
estimate the correlation structure between infections, and hence components
of frailty. However, the same limitation exists as for bivariate data: informa-
tion on individual variability is only available at a single time point via the
correlation between infections, and frailty components relating to a single
infection cannot be identified. The “saturated” model therefore consists of
a component relating to all three infections, and three pairwise components.
There is some choice in the manner in which additive components can be
combined to form a single frailty that has unit mean, which broadly fall into
fixed weight and variable weight models; the latter has a similar form to the
correlated frailty model. Alternatively, the components may combine mul-
tiplicatively. Multiplicative models have attractive properties, but require
numerical integration and are more difficult to work with.
The information available to estimate differences in variances is very low,
and in practice simpler models had to be fitted to the data. This allowed
for the investigation of a specific hypothesis for blood-borne infections in
PWID, that HBV and HIV would have an additional frailty component
pertaining broadly to sexual risk, which is generally low for HCV. While
this was found to provide a better fit compared to a model with a single
overall frailty parameter, a better fit still was obtained when including an
HCV-HBV component rather than the HBV-HIV component. Including
more than one pairwise component resulted in model instability, with the
model estimating that the pairwise variability (in addition to the overall
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variability) was wholly attributable to HCV-HBV or HBV-HIV, depending
on the initial values used when starting the model. Ultimately, the HCV-
HBV and HBV-HIV correlations are the strongest, whereas the correlation
between HCV and HIV is weakest. This may point to sexual risk being
a greater component for HIV, and this risk is shared for HBV. However,
the majority of risk for HCV and HBV is through injecting, and hence the
correlation between these infections is strong.
8.2 Public health implications
The analyses presented here confirm the high excess risk in recent initiates to
injecting drug use, which persisted after accounting for individual variability
and indicated that the FOI for HCV in 1st year injectors has increased in
recent years (2010-2015). The implication is that harm reduction efforts need
to focus on recent initiates (in addition to discouraging individuals to begin
injecting in the first place). High rates of infection in 1st year injectors were
observed in Yorkshire and the Humber, London, and in particular the North
West. The latter two are well-known areas of high prevalence, although
these analyses suggest that minimising risk in new initiates is of utmost
importance, with generally comparable levels of risk across regions following
the first year of injecting.
Females appear to be particularly vulnerable to infection from HCV, with
a higher risk and less variability than men, some of whom appear to be at
relatively low risk. There is less of a gender difference for HBV and HIV.
It is not clear under what circumstances females tend to start injecting, but
efforts clearly need to be made for vulnerable risk groups. Those that initiate
injecting at an older age (25 or more) appear to be at particularly high risk of
HCV and HBV, although for HIV those initiating injecting at younger ages
(< 18) appeared to be at higher risk. Ever being in prison is a major risk
factor for HCV and HBV, and the majority of PWID in the survey (69%)
have been imprisoned at least once. Potential explanations are the lack of
sterile injecting equipment when in prison, the disruption of networks and
routines, and post-imprisonment binge use when released.
It is interesting to consider the hypothesis that risk of infection is gen-
erally low in those with established injecting patterns and access to needle
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exchanges, with infections occurring during periods of disruption. The high
initial risk might (in part) be due to all PWID being in a “disrupted” state
at initiation, rather than something intrinsic about initiation risks. If such a
hypothesis holds, this would indicate that harm reductions should minimise
the impact of disruptive states, such as homelessness and imprisonment.
This thesis has focussed on HCV, which has the highest prevalence in
PWID and comparatively high risks of developing severe disease. Results
for HBV are somewhat more difficult to interpret, due to a proportion of in-
dividuals being vaccinated. However, HBV prevalence has fallen consistently
throughout the survey. HIV infection has remained low, but shows no sign
of decreasing. It is quite possible that sexual transmission is a major route
of infection in this population, rather than injecting. Patterns of correlation
indicate that this may be the case, in addition to the markedly higher HIV
prevalence in men who have sex with men, who are a key risk group for
sexually acquired HIV.
Of particular interest at the current time is the potential impact that new
treatments for HCV will have on the prevalence and resulting transmission
of infection in PWID. Incident infections are difficult to observe or estimate
directly, requiring large cohort studies or relying on elusively small numbers
of individuals with markers of recent infection. FOI models can provide
estimates of infection rates through the differences in injecting duration-
specific prevalence from one year to the next, and have the potential to
detect changes in incidence that might be associated with the impact of
treatment.
The FOI model is also superior to examining trends in observed preva-
lence across survey years, which does not account for potential changes in
factors such as injecting duration, either through sampling variability or a
systematic shift. This has become increasingly important as the average age,
and injecting duration, of PWID sampled in the UAM has increased over
time.
8.3 Further work
The methodology in this thesis has focussed on piecewise constant FOI mod-
els and standard frailty distributions, fitted within a classical framework.
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Parametric models may lead to more efficient estimates, which could allow
for more complexity in other areas of the model, such as local-level estimates.
Flexible, non-parametric models such as splines and their multidimensional
extensions may also be used to investigate the relationship between calen-
dar time, injecting duration and risk of infection. However, these analyses
appeared to indicate that the only important differences in risk occur in the
first year of injecting, although there was evidence of temporal changes.
Current modelling of HCV in England aims to generate prevalence esti-
mates for the 22 geographic areas of Operational Delivery Networks (ODN)
for HCV treatment, using a FOI model to estimate HCV incidence and preva-
lence in PWID (Public Health England, 2018b). Due to the sparse data at
this level a relatively simple model is required, such as a constant FOI with
excess risk in the first year of injecting, and broad, piecewise constant time
intervals. The modelling conducted as part of this thesis is therefore a valu-
able input for this work, guiding the formulation of ODN-level modelling.
Further investigation of alternative frailty distributions could be under-
taken, in particular the positive stable distribution. Of interest would be
to use information on contact patterns, or numbers of equipment sharing
partners, in PWID to determine an appropriate distribution. However, such
information is likely to be very difficult to obtain.
Fitting models within a Bayesian framework would allow a number of
possible extensions. Variance components may be assigned semi-informative
priors, which may improve identifiability of parameters, in particular frailty
components. However, if there is insufficient information to reliably esti-
mate a parameter in the classical framework, estimates will likely be highly
sensitive to prior assumptions. More usefully, the marginal distribution of
the survivor function need not be explicitly defined: the frailty distribution
may be assigned a prior distribution with hyper-parameters, and frailties
for each individual simulated with a fully Bayesian Markov Chain Monte
Carlo framework. This would allow the use of frailty distributions that are
not analytically tractable, and obviate the need for numerical integration of
multivariate functions such as that of the multiplicative component model.
Other possibilities in a Bayesian framework are to incorporate exter-
nal information, such as data on mortality rates (which could incorporate
uncertainty, rather than being fixed) in order to account for differential mor-
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tality in infected individuals. Another question around the UAM data is
whether self-reported injecting duration is accurate. The misreporting pro-
cess could be modelled within a Bayesian framework, although this would
either require some assigned distribution, parametric model assumptions for
the injecting-duration specific FOI, or external information on this process to
be identifiable. Finally, Bayesian models are a natural environment for non-
parametric functions, which may be used for the baseline injecting duration-
and time-specific FOI as described above.
Markers of recent infection have been tested for in the UAM data since
2011, including those RNA positive and antibody negative, and avidity lev-
els, although the latter has been discontinued. In principle, such data could
be incorporated as part of a multi-state FOI model, in which susceptible
individuals move to a recently-infected state initially, then to established
infection. This would provide an assessment of the consistency of estimates
generated under a standard FOI model and the data on recent infections, and
how modelling assumptions need to be adjusted to incorporate the data on
recent infections. For instance, the assumed window period may be too long
or short for a marker of recent infection to be consistent with the injecting
duration-specific seroprevalence data, and some flexibility needs incorporat-
ing in order to accommodate this. This may again naturally be accomplished
in a Bayesian framework, in which the window period could be assigned an
informative, but flexible prior distribution.
The modelling and approaches developed in this thesis can be applied
to other datasets. In particular Scotland’s NESI programme is very similar
to the UAM, consisting of time at risk, serological status and questionnaire-
based risk factor information. Routine surveillance data may include little
in the way of covariate information, but geographic differences and tem-
poral changes may be considered, as has been here. Other seroprevalence
surveys that include questionnaire data may also make use of the methods
for analysing covariates in a FOI model. One potential area of application
is sexual health, which might also include testing for multiple sexually ac-
quired infections, which would allow the type of frailty models considered in
this thesis. Of particular interest would be further investigation of trivariate
models, which was hampered in this thesis by sparse data on HIV.
Trivariate frailty models are a novel development, and further investiga-
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tion may be worthwhile. In practice, the model is limited by the ability to
estimate only components that are shared by two or more infections, rather
than infection-specific effects. Further, even with large amounts of data there
are likely to be identifiability issues, although progress might be made by
combining data from different countries. Much of the interpretation of the
trivariate model amounts to the investigation of the correlation structure of
trivariate infection status, and it may be more worthwhile to pursue meth-
ods of association for trivariate data, extending the definition of Unkel and
Farrington (2012) beyond the bivariate case.
There is currently great interest in reducing the disease burden of viral
hepatitis and HIV, with new treatments for HCV, effective HBV vaccines and
high standards of HIV care making elimination of these infections as major
public health threats a real prospect in the UK and elsewhere. Injecting drug
use is the cause of a substantial proportion of blood-borne virus infections,
and nearly all HCV infections in England. Monitoring the population of
people who inject drugs, and understanding patterns of risk will be a crucial
part of developing policy to tackle blood-borne viruses. The methods and
analyses developed in this thesis may be used to this end. Force of infection
models can be traced right back to Daniel Bernoulli’s seminal 1766 paper on
smallpox (Dietz, 2002). More than 250 years later, these methods are still
proving useful. And they are far from being exhausted.
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Chapter 9
Appendices
9.1 Unlinked Anonymous Monitoring survey
of people who inject drugs: questionnaire
The Unlinked Anonymous Monitoring survey of people who inject drugs
questionnaire is displayed in full below (2015 version). The document is
printed double-sided on a single sheet of landscape A3 paper and folded in
half to produce a 4-page A4 leaflet. Hence reading of the questionnaire as
shown below begins on the right hand side of the first page, follows on the
left then right sides of the second page and ends on the left side of the first
page.
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                        Please turn over  
 If yes:  How old were you when you first used a Needle Exchange?  _____ 
 
Have you used a Needle Exchange in the last 12 months?   Yes 2    No 1     
 
If yes: How many individual needles (including ones attached to syringes) did  
you get from Needle Exchanges during the last month (28 days)? _____ 
 
How many of these needles were already attached to syringes (barrels)? _____ 
T
y
p
e
 1
5
 (
2
0
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15.  Which of these health services have you used in the last year (12 months)? (Tick all that apply) 
Sexual Health, GUM or STI Clinic 2   Family Planning Clinic 2   NHS Walk-in Clinic   2 
A&E or Casualty Department   2   GP or Family Doctor 2   None of these services 2 
 
16.  Have you ever had a blood test for HIV?       
Yes 2    No 1 
 
 
 
 
 
 
17.  Have you ever had a blood test for hepatitis C?  
Yes 2    No 1  
 
 
 
 
 
 
 
 
 
 
 
 
 
18.  Have you ever been in prison (or a young offenders institution)?       
 
Yes 2    No 1  
 
 
 
 
 
 
 
19.  Have you ever been homeless - that is living in a hostel, having no fixed abode, or living on the  
       streets? 
Yes 2    No 1  
 
 
 
 
 
 
20.  Were you born in the United Kingdom? (England, Scotland, Wales or Northern Ireland) 
 
Yes 2    No 1  
 
 
 
 
 
 
 
         CONFIDENTIAL   Centre: ________  
Survey of People Who Inject Drugs 
 
 
 
 
 
 
 
 
 
 
 
 
Please  the box or write in your answer. 
 
Please try to answer all the questions. 
 
1a. Have you ever injected any drug?    No 1    Yes 2 
 
1b. How old were you when you first injected?  _____ 
 
2.  How old are you now?  _____ 
 
3.  Are you?    Male 1    Female 2 
 
4.  Have you done this survey before?    No 1   Yes 2     
 
5.  Have you ever used a Needle Exchange (including a pharmacy exchange)? 
 
Yes 2    No 1 
 
 
 
 
 
 
 
 
 
 
 
 
6.  Have you ever been prescribed a detox or maintenance drug regime? 
Yes 2    No 1 
 
 
 
 
 
 
 
 
 
 
 
 If yes:  How old were you when you were first prescribed a detox or maintenance drug 
regime (script)?  _____ 
Are you currently being prescribed a detox or maintenance drug regime?   
Yes 2     No 1   
 
If yes, how long have you been on your current regime (script)? 
Less than a month 1    1 to 6 months 2     Over 6 months 3 
 If yes:  In which year did you last have a hepatitis C test?  _________ 
What was the result of your last test? 
Positive  1   Negative 2   Awaiting result 3 
 
     If tested positive, have you ever seen a specialist nurse or doctor            
    (e.g. a hepatologist) about your hepatitis C?    
No 1       Yes, but not given any medicine for hepatitis C  2 
Yes, and been given medicine for hepatitis C   3  
 
 
If yes, in which year did you 
last take part?  _________ 
 If yes:  In which year did you last have an HIV test?  _________ 
What was the result of your last test?  
Positive 1     Negative 2    Awaiting result 3  
 If yes:  Have you been homeless during the last 12 months?    
Yes, currently 3     Yes, but not currently 2       No 1 
 If no:  What country were you born in?  ___________________________________ 
 
Lab use barcode 
 
This questionnaire is completely anonymous: we do not wish to 
know your name or any other form of identification. 
 
The information from this study can help to develop better services for 
people who inject drugs. 
Thank you for completing this questionnaire. 
Please fold the questionnaire back up and then place it inside the brown envelope.  
DO NOT SEAL THE ENVELOPE. 
NOTE: Sample questionnaire below has been reduced to A4 size 
 
If yes:  How many times have you been in prison?  _____ 
How old were you when you first went to prison?  _____ 
Have you ever injected drugs whilst in prison?   Yes 2     No 1 
 
236
                        Please turn over  
 
7.  Have you injected drugs in the last year (12 months)?     
 
Yes 2      No 1     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8.  Have you injected drugs in the last month (28 days)?    
Yes 2     No 1       If you have not injected in the last month please go to Question 9. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9.   Have you ever received used needles or syringes from anyone?        
 
Yes 2    No 1 
 
10.  In the last month (28 days), have you? (Tick all that apply)  
  Snorted Cocaine          2     Drunk, snorted or swallowed Amphetamine (speed)  2 
  Smoked Crack            2      Smoked, chased or snorted Heroin          2 
  Smoked or swallowed Cannabis 2     Snorted, smoked or swallowed Mephedrone (m-cat) 2 
  Inhaled Solvents or Glue      2      Drunk, snorted or swallowed Ketamine        2   
  Taken Ecstasy/’E’ (MDMA)     2     Swallowed non-prescribed Benzodiazepines     2   
  Done none of these        2  
 
11.  In the last year (12 months), have you overdosed (OD-ed, gone-over, gone-under) to the point where 
  you have lost consciousness? 
 
Yes 2    No 1  
 
 
 
 
 
 
 
 
 
12.  Have you had sex (vaginal or anal) in the last year (12 months)?      
 
 
     Yes 2   
 
 
     No  1  
 
 
 
 
 
13.  Have you ever received money, goods or drugs in exchange for sex?   
 
Yes, in the last year 4   Yes, but not in the last year 3    Never 1 
 
14.  Have you ever been vaccinated for hepatitis B (hep B jab)?    
Yes 2    No 1     Not sure 3 
 
 
 
  If no:   In which year did you last inject drugs?  _________ 
How old were you when you last injected drugs?  _____ 
   Which drug were you injecting most often? _____________ 
  If you have not injected in the last year, please go to Question 9. 
If yes: 
In the last year, which of the following drugs have you injected? (Tick all that apply) 
Heroin   2     Crack   2      Amphetamine (speed) 2        Ketamine   2 
Methadone 2      Cocaine  2    Mephedrone (m-cat)   2        Other Drugs 2 
In the last year, have you had a swelling containing pus (abscess), sore, or open wound at an 
injection site?             Yes 2     No 1  
In the last year, did you inject with a needle or syringe that had already been used by someone else 
(including your partner)?     Yes 2     No 1 
If yes: 
In the last month (28 days), on how many days have you injected drugs?  _____ 
On the last full day that you injected, how many times did you inject drugs?  _____ 
In the last month (28 days), into which parts of your body did you inject drugs? (Tick all that apply)      
  Arms 2    Hands 2   Groin 2   Legs 2    Feet 2   Neck 2   Other 2  
In the last month (28 days), which drug have you injected most often? ________________ 
In the last month (28 days), which of these drugs have you injected? (Tick all that apply) 
Heroin   2     Crack   2      Amphetamine (speed) 2        Ketamine   2 
Methadone 2      Cocaine  2    Mephedrone (m-cat)   2        Other Drugs 2 
In the last month (28 days):  None   1 2 or more 
 To how many people have you passed on used needles or syringes 
(including your partner)? 
0 1      2 
 From how many people have you received used needles or syringes 
(including your partner)? 
0 1      2 
In the last month (28 days), did you use spoons or other containers for mixing which had previously  
been used by someone else (including your partner)?    Yes 2     No 1 
In the last month (28 days), did you use filters which had previously been used by  
someone else (including your partner)?            Yes 2     No 1 
In the last month (28 days), did you inject with a needle or syringe after it had been cleaned  
(e.g. with water, bleach or detergent)?             Yes 2     No 1 
 If yes:  With how many men in the last year?   
None 0  1 1    2-4 4  5-9 5   10 or more 3 
With how many women in the last year?  
None 0  1 1    2-4 4  5-9 5   10 or more 3 
Did you use a condom?  Always 1   Sometimes 2   Never 3 
 If yes:  How many times in the last 12 months have you overdosed? 
1 1   2-4 2   5-9 3  10 or more 4 
In the last 12 months, did you receive naloxone (the heroin overdose antidote) when 
you overdosed?  
Yes 2     No 1    Not Sure 3 
 If yes:  How many hep B jabs have you had?  
1 1     2 2     3+ 3    Not sure 4 
At which of the following services did you receive a hep B jab? (Tick all that apply)  
Needle Exchange          2      Drug Treatment Service 2 
Sexual Health, GUM or STI Clinic 2      In Prison         2 
Hostel or Homeless Service    2      GP or Family Doctor   2 
A&E or Casualty Department    2      Elsewhere        2 
Please go to top of the next page 
NOTE: Sample questionnaire below has been reduced to A4 size 
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9.2 R code
9.2.1 Univariate multiplicative model code
Shown below is the R code for a univariate, piecewise constant force of infec-
tion model. Injecting duration (“age”) and time combine multiplicatively,
and the model includes injecting duration X time interaction terms. The
model uses a dataset that includes the time at risk contributions to each
piecewise constant segment; for example, 2 years exposure in the 5-10 year
injecting duration category, 3 years exposure in the 1995-1999 time category
and so on, which contribute to the cumulative hazard. The code itself for
forming the cumulative hazard is not very concise: the sums of parameters
multiplied by time at risk contributions is written out term-by-term.
## y=outcome, n=denominator, s=sensitivity of test,
## data=exposure time contributions, inits=list of parameters
univarAT <- function(y,n,s,data,inits){
sumht <- array(0,c(1,length(y)))
llc <- rep(NA,length(y))
## 8 time periods: pre-1980 then 5 year
## first four have same injdur effect
## 7 injdur periods, baseline injdur is 3 (4-5 yrs)
## decompose init list
Bt <- array(0,8)
Ba <- array(0,7)
Bta <- array(0,c(8,7))
Bt <- inits[1:8]
Ba[1:2] <- inits[9:10]
Ba[4:7] <- inits[11:14]
for(i in 5:8){
Bta[i,1] <- inits[15+(i-5)*6]
Bta[i,2] <- inits[16+(i-5)*6]
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Bta[i,4] <- inits[17+(i-5)*6]
Bta[i,5] <- inits[18+(i-5)*6]
Bta[i,6] <- inits[19+(i-5)*6]
Bta[i,7] <- inits[20+(i-5)*6]
}
## hazards for each infection
## age and time parameters combine multiplicativel
ht <- array(0,c(8,7))
for(t in 1:8){
for(a in 1:7){
ht[t,a] <- exp(Bt[t] + Ba[a] + Bta[t,a])
}
}
## contributions to cumulative hazard
## could be written more efficiently!
sumht[] <- (
ht[1,1]*data$x1_1+ ht[1,2]*data$x1_2+ ht[1,3]*data$x1_3+
ht[1,4]*data$x1_4+ ht[1,5]*data$x1_5+ ht[1,6]*data$x1_6+
ht[1,7]*data$x1_7+
ht[2,1]*data$x2_1+ ht[2,2]*data$x2_2+ ht[2,3]*data$x2_3+
ht[2,4]*data$x2_4+ ht[2,5]*data$x2_5+ ht[2,6]*data$x2_6+
ht[2,7]*data$x2_7+
ht[3,1]*data$x3_1+ ht[3,2]*data$x3_2+ ht[3,3]*data$x3_3+
ht[3,4]*data$x3_4+ ht[3,5]*data$x3_5+ ht[3,6]*data$x3_6+
ht[3,7]*data$x3_7+
ht[4,1]*data$x4_1+ ht[4,2]*data$x4_2+ ht[4,3]*data$x4_3+
ht[4,4]*data$x4_4+ ht[4,5]*data$x4_5+ ht[4,6]*data$x4_6+
ht[4,7]*data$x4_7+
ht[5,1]*data$x5_1+ ht[5,2]*data$x5_2+ ht[5,3]*data$x5_3+
ht[5,4]*data$x5_4+ ht[5,5]*data$x5_5+ ht[5,6]*data$x5_6+
ht[5,7]*data$x5_7+
ht[6,1]*data$x6_1+ ht[6,2]*data$x6_2+ ht[6,3]*data$x6_3+
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ht[6,4]*data$x6_4+ ht[6,5]*data$x6_5+ ht[6,6]*data$x6_6+
ht[6,7]*data$x6_7+
ht[7,1]*data$x7_1+ ht[7,2]*data$x7_2+ ht[7,3]*data$x7_3+
ht[7,4]*data$x7_4+ ht[7,5]*data$x7_5+ ht[7,6]*data$x7_6+
ht[7,7]*data$x7_7+
ht[8,1]*data$x8_1+ ht[8,2]*data$x8_2+ ht[8,3]*data$x8_3+
ht[8,4]*data$x8_4+ ht[8,5]*data$x8_5+ ht[8,6]*data$x8_6+
ht[8,7]*data$x8_7)
################################
## probabilities and likelihood
pi_tru0 <- exp(-sumht[])
pi_tru1 <- 1 - pi_tru0
## relate true to observed via sensitivity
pi1 <- s*pi_tru1
pi0 <- 1-pi1
## likelihood - negative as optim minimises function
llc <- log(pi0)*(n-y) + log(pi1)*(y)
loglik <- -sum(llc)
return(loglik)
}
9.2.2 Bivariate shared frailty model code
Shown below is the R code used to fit bivariate frailty models. The code
is more general-purpose than the univariate model in section 9.2.1 and can
be used to fit bivariate models under independence, gamma and inverse
Gaussian frailty distributions, and also allows for different frailty variances
across subgroups (strata). The code also allows for an arbitrary covariate
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matrix, which can also be specified differently for each infection. In order
to achieve this flexibility a “multi-row” formulation of the data, in which
the time at risk for an individual is split according to changing covariate
combinations (described subsequently).
# fast tapply method
library("ecoreg",lib="C:/My programs/R library")
###############################################################
## multirow model
## - split age/time covariate levels into repeat observations
## y1, y2: infection status for 1 & 2
## s1, s2: sensitivity of tests for infection 1&2
## X1, X2: covariate matrix for infection risk
## frstr: frailty variance strata (constant for single frailty)
## inits: parameter list
## frdist: specified distribution
## (indep, gamma, inverse Gaussian)
## ret: log-likelihood for optim, or predictions/AIC
modelMR <- function(y1,y2,s1,s2,X1,X2,frstr,inits,frdist,ret){
llc <- rep(NA,length(y1))
## X - covar dataset consisting of ID, j (sub ID)
## , and T (time within band)
## subset inits - based on width of covar mat
clen1 <- dim(X1)[2]-3 ## width minus references and T
beta1 <- inits[1:clen1]
clen2 <- dim(X2)[2]-3 ## width minus references and T
beta2 <- inits[(clen1+1):(clen1+clen2)]
## remaining portion of inits are frailty variance(s)
theta <- inits[(clen1+clen2+1):length(inits)]
thstr <- theta[frstr]
table(thstr)
241
## exposure X beta coefs
betalist1 <- t(t(X1[,4:(clen1+3)])*beta1)
betalist2 <- t(t(X2[,4:(clen2+3)])*beta2)
## sum of beta coefs
betasum1<-rowSums(betalist1)
betasum2<-rowSums(betalist2)
## combine with ID var and exponentiate, multiply by T
htx1<-cbind(X1[,1],exp(betasum1)*X1[,3])
htx2<-cbind(X2[,1],exp(betasum2)*X2[,3])
## sum over IDs - aggregate and tapply both slow
## - this is a special version where groups are ordered
## - much faster
At1<-tapplysum.fast(htx1[,2],htx1[,1])
At2<-tapplysum.fast(htx2[,2],htx2[,1])
#######################################################
## multinomial probabilities with different frailties
## No frailty
if(frdist=="INDEP"){
pi_tru00 <- exp(-At1-At2)
pi_tru10 <- exp(-At2) - pi_tru00
pi_tru01 <- exp(-At1) - pi_tru00
pi_tru11 <- 1-pi_tru00-pi_tru10-pi_tru01
}
## GAMMA
if(frdist=="GAM"){
pi_tru00 <- (1+(At1+At2)/thstr)^-thstr
pi_tru10 <- (1+At2/thstr)^-thstr - pi_tru00
pi_tru01 <- (1+At1/thstr)^-thstr - pi_tru00
pi_tru11 <- 1-pi_tru00-pi_tru10-pi_tru01
}
## INVERSE GAUSSIAN
if(frdist=="INVG"){
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pi_tru00 <- exp(thstr*(1- sqrt(1+2*(At1+At2)/thstr) ))
pi_tru10 <- exp(thstr*(1- sqrt(1+2*(At2)/thstr) )) - pi_tru00
pi_tru01 <- exp(thstr*(1- sqrt(1+2*(At1)/thstr) )) - pi_tru00
pi_tru11 <- 1-pi_tru00-pi_tru10-pi_tru01
}
## Relate true proportions to observed through sensitivity of test
## Sutton BMC 2006, p3
pi00 <- pi_tru00 + (1-s1)*pi_tru10 + (1-s2)*pi_tru01
+ (1-s1)*(1-s2)*pi_tru11
pi10 <- pi_tru10*s1 + s1*(1-s2)*pi_tru11
pi01 <- pi_tru01*s2 + s2*(1-s1)*pi_tru11
pi11 <- pi_tru11*s1*s2
pi1_0 <- pi00+pi01
pi1_1 <- pi10+pi11
pi2_0 <- pi00+pi10
pi2_1 <- pi01+pi11
## full likelihood where both infections present
llc <- ifelse(is.na(y1) | is.na(y2), 0, log(pi00)*((1-y1)*(1-y2)) +
log(pi10)*(y1*(1-y2)) + log(pi01)*((1-y1)*y2) + log(pi11)*(y1*y2) )
## partial likelihood where one infection missing - y1 present only
llc <- ifelse(is.na(y2),
llc+log(pi1_0)*(1-y1) + log(pi1_1)*(y1), llc)
## y2 only
llc <- ifelse(is.na(y1),
llc+log(pi2_0)*(1-y2) + log(pi2_1)*(y2), llc)
loglik <- -sum(llc)
## Minus LL for optimisation
if(ret=="LL"){
return(loglik)
}
## return predicted probabilities at fixed parameters
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if(ret=="pred"){
return(cbind(pi00,pi10,pi01,pi11))
}
## or AIC
if(ret=="AIC"){
npar<-length(inits)
if(frdist=="INDEP"){
npar<-npar-1
}
AIC<- 2*loglik+2*npar
return(AIC)
}
}
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Shown below is an excerpt of the covariate data used for the “multi-row”
formulation. The first column, id, is an identifier for the individual. j is
a counter for the time interval, and t is the amount of time spent by the
individual in a particular covariate combination. The a and t are indicator
variables specifying which age (injecting duration) and calendar time effects
the individual was subjected to within the time interval; the time terms
governing the log baseline FOI and the age/injecting duration effects are log
hazard ratios compared to the baseline category, 3.
For example, id=1 is subjected to the baseline hazard for the time inter-
val 4 (t 4) with the change in hazard associated with a 1 for one year (j=1),
then spends 2 years in time interval 4 with hazard associated with a 2 (j=2).
At (j=3) the individual is in the baseline age/injecting duration category for
1 year, and at (j=4) the individual moves to the next time interval (t 5) for
one year.
Additional covariate effects are age at first use groups (fage1 and fage3,
vs. a baseline group 2) and female (vs. male). Parameters for the log FOI
and log hazard ratios are then multiplied by the indicators, and the sum of
the products is thus the log FOI for that covariate combination. The log FOI
is exponentiated for the multiplicative effects model. The resulting FOIs are
multiplied by the time at risk in that covariate combination (t) and the sum
of the FOI contributions across the individual is equal to the cumulative
hazard.
Additional covariates are easy to include, and in particular interaction
effects may be obtained by multiplying columns (for instance, an interaction
between female and the age at first use variables).
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id j t a_1 a_2 a_4 a_5 a_6 a_7 t_1 t_2 t_3 t_4 t_5 t_6 t_7 t_8 fage1 fage3 female
1 1 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0
1 2 2 0 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0
1 3 1 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0
1 4 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0
1 5 4 0 0 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0
2 1 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 1 0 1
2 2 1 0 1 0 0 0 0 0 0 0 1 0 0 0 0 1 0 1
2 3 1 0 1 0 0 0 0 0 0 0 0 1 0 0 0 1 0 1
2 4 2 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 0 1
2 5 2 0 0 1 0 0 0 0 0 0 0 1 0 0 0 1 0 1
3 1 1 1 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0
4 1 1 1 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0
5 1 1 1 0 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0
5 2 2 0 1 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0
5 3 2 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0
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9.2.3 Bivariate time-varying frailty code
Shown below is the R code for the time-varying frailty model. This has
some additional complications, as the calculation of the cumulative hazards
for each infection cannot be performed separately, as in the simpler bivariate
frailty model (section 9.2.2) and also involves the frailty parameters.
##############################################################
## takes additional argument frstrC for
## frailty strata within covariate data
modelMRTVF <- function(y1,y2,s1,s2,X1,X2,frstr,frstrC,inits,ret){
llc <- rep(NA,length(y1))
## X - covar dataset consisting of ID, j (sub ID)
##, and T (time within band)
clen1 <- dim(X1)[2]-5 ## width minus references and T
beta1 <- inits[1:clen1]
clen2 <- dim(X2)[2]-5 ## width minus references and T
beta2 <- inits[(clen1+1):(clen1+clen2)]
## remaining portion of inits assigned to frailty variance
## 3 parts: theta, rho, q
frlen <- length(inits)-clen1-clen2
frN <- frlen/3
theta <- inits[(clen1+clen2+1):(clen1+clen2+frN)]
rho <- inits[(clen1+clen2+frN+1):(clen1+clen2+frN*2)]
q <- inits[(clen1+clen2+frN*2+1):(length(inits))]
## theta is needed for both outcome and multirow form
thstr <- theta[frstr]
thstrC <- theta[frstrC]
## rho and q are at at the multirow level
rhostr <- rho[frstrC]
qstr <- q[frstrC]
## time and other vars - note that the covariate matrices
## must have matching time cutpoints
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id <- X1[,1]
t <- X1[,3]
c_i <- X1[,4]
v_i <- X1[,5]
## exposure X beta coefs
betalist1 <- t(t(X1[,6:(clen1+5)])*beta1)
betalist2 <- t(t(X2[,6:(clen2+5)])*beta2)
## sum of beta coefs
betasum1<-rowSums(betalist1)
betasum2<-rowSums(betalist2)
## ht vars - used alone with t in places
ht<-array(NA,dim=c(dim(X1)[1],3))
ht[,1]<-exp(betasum1)
ht[,2]<-exp(betasum2)
ht[,3]<-ht[,1]+ht[,2]
## Derive the other variables
eqq <- exp(qstr)/(1+exp(qstr))
epv <- exp(-rhostr*v_i)
epc <- exp(-rhostr*c_i)
## loop over FOIs for 1, 2, combined (3)
## setup arrays
S<-array(NA,dim=c(dim(X1)[1],3,4))
S.sum<-array(NA,dim=c(length(y1),3,4))
St<-array(NA,dim=c(length(y1),3))
for(i in 1:3){
S[,i,1] <- ht[,i]*t*(1-eqq)
S[,i,2] <- ht[,i]*(epv-epc)/(rhostr*(1+exp(qstr)))
S[,i,3] <- ht[,i]*(epc-epv)/(rhostr*thstrC*(1+exp(qstr)))
S[,i,4] <- ht[,i]*t*eqq/thstrC
## summations over multirow ID
S.sum[,i,1] <- tapplysum.fast(S[,i,1],id)
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S.sum[,i,2] <- tapplysum.fast(S[,i,2],id)
S.sum[,i,3] <- tapplysum.fast(S[,i,3],id)
S.sum[,i,4] <- tapplysum.fast(S[,i,4],id)
St[,i] <- exp(-S.sum[,i,1]-S.sum[,i,2])
* (1+S.sum[,i,3]+S.sum[,i,4])^(-thstr)
}
########################################################
## multinomial probabilities
pi_tru00 <- St[,3]
pi_tru10 <- St[,2] - pi_tru00
pi_tru01 <- St[,1] - pi_tru00
pi_tru11 <- 1-pi_tru00-pi_tru10-pi_tru01
## sensitivity - Sutton BMC 2006, p3
pi00 <- pi_tru00 + (1-s1)*pi_tru10 + (1-s2)*pi_tru01
+ (1-s1)*(1-s2)*pi_tru11
pi10 <- pi_tru10*s1 + s1*(1-s2)*pi_tru11
pi01 <- pi_tru01*s2 + s2*(1-s1)*pi_tru11
pi11 <- pi_tru11*s1*s2
pi1_0 <- pi00+pi01
pi1_1 <- pi10+pi11
pi2_0 <- pi00+pi10
pi2_1 <- pi01+pi11
## full likelihood where both infections present
llc <- ifelse(is.na(y1) | is.na(y2), 0, log(pi00)*((1-y1)*(1-y2)) +
log(pi10)*(y1*(1-y2)) + log(pi01)*((1-y1)*y2) + log(pi11)*(y1*y2) )
## partial likelihood where one infection missing - y1 present only
llc <- ifelse(is.na(y2),
llc+log(pi1_0)*(1-y1) + log(pi1_1)*(y1), llc )
## y2 only
llc <- ifelse(is.na(y1),
llc+log(pi2_0)*(1-y2) + log(pi2_1)*(y2), llc )
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loglik <- -sum(llc)
if(ret=="LL"){
return(loglik)
}
if(ret=="pred"){
return(cbind(pi00,pi10,pi01,pi11))
}
if(ret=="AIC"){
npar<-length(inits)
AIC<- 2*loglik+2*npar
return(AIC)
}
}
9.2.4 Trivariate frailty model code
Shown below is R code for the asymmetric trivariate frailty model, with mul-
tiplicative components for frailty specific to all infections, and a component
relating to HBV-HIV only (or other pair). The model requires numerical
integration of the survivor functions. Model fitting is computationally in-
tensive, due to numerical integration being carried out at each step of the
numerical optimisation routine. Data are aggregated by injecting duration
(age) only, unlike earlier models which examined individual level data in-
cluding time and other covariates.
## numerical integration package
library(cubature)
## survivor functions for numerical integration
## trivariate
St123 <- function(x, A1,A2,A3,k1,k2){
exp(-k2*x)*(k1^k1)*(k2^k2)*(x^(k2-1))
/ (gamma(k2)*(A1+A2*x+A3*x+k1)^k1)
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}## bivariate - same form for s13 and s23 (HBV & HIV)
## but spell out in case of any confusion
St12 <- function(x, A1,A2,k1,k2){
exp(-k2*x)*(k1^k1)*(k2^k2)*(x^(k2-1))
/ (gamma(k2)*(A1+A2*x+k1)^k1)
}
St13 <- function(x, A1,A3,k1,k2){
exp(-k2*x)*(k1^k1)*(k2^k2)*(x^(k2-1))
/ (gamma(k2)*(A1+A3*x+k1)^k1)
}
St23 <- function(x, A2,A3,k1,k2){
exp(-k2*x)*(k1^k1)*(k2^k2)*(x^(k2-1))
/ (gamma(k2)*((A2+A3)*x+k1)^k1)
}
## univariate - HCV does not require integration
St1 <- function(A1,k1){
(1+A1/k1)^(-k1)
}
St2 <- function(x, A2,k1,k2){
exp(-k2*x)*(k1^k1)*(k2^k2)*(x^(k2-1))
/ (gamma(k2)*(A2*x+k1)^k1)
}
St3 <- function(x, A3,k1,k2){
exp(-k2*x)*(k1^k1)*(k2^k2)*(x^(k2-1))
/ (gamma(k2)*(A3*x+k1)^k1)
}
## y is the dataset and includes time at risk, infection status
## (s000, s001, s010 etc.) and test sensitivities
trivarM4 <- function(y,inits,ret){
## inits and quantities for calculation
N <- dim(y)[1]
llc <- rep(NA,N)
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len<-(length(inits)-2)/3
ht <- matrix(data=NA, nrow=3, ncol=len)
ht[1,] <-exp(inits[1:len])
ht[2,] <-exp(inits[(len+1):(2*len)])
ht[3,] <-exp(inits[(2*len+1):(3*len)])
k1<-exp(inits[(3*len+1)]) ## exp. to ensure positive
k2<-exp(inits[(3*len+2)])
## cumulative hazard functions
At<-matrix(data=NA, nrow=N, ncol=3)
for(j in 1:3){
At[,j]<-ht[j,1]+ht[j,2]*(y$t2)+ht[j,3]*(y$t3)+ht[j,4]*(y$t4)
+ ht[j,5]*(y$t5)+ht[j,6]*(y$t6)+ht[j,7]*(y$t7)
+ ht[j,8]*(y$t8)+ht[j,9]*(y$t9)
}
## survivor functions
## upper limits of integrals are 1+ 10 times gamma variance
## or 5, whichever is greater
ilim <- 1+10/c(k1,k2)
ilim <- pmax(ilim,5)
S123<-rep(NA,N)
S12<-rep(NA,N)
S13<-rep(NA,N)
S23<-rep(NA,N)
S1<-rep(NA,N)
S2<-rep(NA,N)
S3<-rep(NA,N)
## numerical integration of survivor functions
for(i in 1:N){
S123[i] <-integrate(St123, 0,ilim[2],
At[i,1],At[i,2],At[i,3], k1,k2)$val
S12[i] <-integrate(St12, 0,ilim[2],
At[i,1],At[i,2], k1,k2)$val
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S13[i] <-integrate(St13, 0,ilim[2],
At[i,1],At[i,3], k1,k2)$val
S23[i] <-integrate(St23, 0,ilim[2],
At[i,2],At[i,3], k1,k2)$val
S1[i] <- St1(At[i,1], k1)
S2[i] <- integrate(St2, 0,ilim[2], At[i,2], k1,k2)$val
S3[i] <- integrate(St3, 0,ilim[2], At[i,3], k1,k2)$val
}
pi_tru000 <- pmax(S123,0.0000001)
pi_tru100 <- pmax((S23-pi_tru000) ,0.0000001)
pi_tru010 <- pmax((S13-pi_tru000) ,0.0000001)
pi_tru001 <- pmax((S12-pi_tru000) ,0.0000001)
pi_tru110 <- pmax((S3-pi_tru000-pi_tru100-pi_tru010) ,0.0000001)
pi_tru101 <- pmax((S2-pi_tru000-pi_tru100-pi_tru001) ,0.0000001)
pi_tru011 <- pmax((S1-pi_tru000-pi_tru001-pi_tru010) ,0.0000001)
pi_tru111 <- pmax((1-pi_tru000-pi_tru100-pi_tru010-pi_tru001
-pi_tru110-pi_tru101-pi_tru011) ,0.0000001)
## sensitivity of tests
pi000 <- pi_tru000 + (1-y$senshcv)*pi_tru100
+ (1-y$senshbv)*pi_tru010 + (1-y$senshiv)*pi_tru001
+ (1-y$senshcv)*(1-y$senshbv)*pi_tru110
+ (1-y$senshcv)*(1-y$senshiv)*pi_tru101
+ (1-y$senshbv)*(1-y$senshiv)*pi_tru011
+ (1-y$senshcv)*(1-y$senshbv)*(1-y$senshiv)*pi_tru111
pi100 <- pi_tru100*y$senshcv
+ y$senshcv*(1-y$senshbv)*pi_tru110
+ y$senshcv*(1-y$senshiv)*pi_tru101
+ y$senshcv*(1-y$senshbv)*(1-y$senshiv)*pi_tru111
pi010 <- pi_tru010*y$senshbv
+ y$senshbv*(1-y$senshcv)*pi_tru110
+ y$senshbv*(1-y$senshiv)*pi_tru011
+ y$senshbv*(1-y$senshcv)*(1-y$senshiv)*pi_tru111
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pi001 <- pi_tru001*y$senshiv
+ y$senshiv*(1-y$senshcv)*pi_tru101
+ y$senshiv*(1-y$senshbv)*pi_tru011
+ y$senshiv*(1-y$senshcv)*(1-y$senshbv)*pi_tru111
pi110 <- pi_tru110*y$senshcv*y$senshbv
+ y$senshcv*y$senshbv*(1-y$senshiv)*pi_tru111
pi101 <- pi_tru101*y$senshcv*y$senshiv
+ y$senshcv*y$senshiv*(1-y$senshbv)*pi_tru111
pi011 <- pi_tru011*y$senshbv*y$senshiv
+ y$senshbv*y$senshiv*(1-y$senshcv)*pi_tru111
pi111 <- pi_tru111*y$senshcv*y$senshbv*y$senshiv
if(ret=="pred"){
pred<-cbind(pi000,pi100,pi010,pi001,pi110,pi101,pi011,pi111)
return(pred)
}
if(ret=="LL"){
llc <- log(pi000)*y$s000 +log(pi001)*y$s001
+log(pi010)*y$s010 +log(pi100)*y$s100
+log(pi011)*y$s011 +log(pi101)*y$s101
+log(pi110)*y$s110 +log(pi111)*y$s111
loglik <- -sum(llc)
return(loglik)
}
}
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